=> file registry
FILE 'REGISTRY' ENTERED AT 10:20:59 ON 21 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9 DICTIONARY FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> file zcaplus FILE 'ZCAPLUS' ENTERED AT 10:21:01 ON 21 FEB 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 21 Feb 2008 VOL 148 ISS 8 FILE LAST UPDATED: 20 Feb 2008 (20080220/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L73 L68 96 SEA FILE=ZCAPLUS ABB=ON PLU=ON GARLICH J?/AU L69 49 SEA FILE=ZCAPLUS ABB=ON PLU=ON SUHR R?/AU L70 710 SEA FILE=ZCAPLUS ABB=ON PLU=ON PATTERSON M?/AU L71 5 SEA FILE=ZCAPLUS ABB=ON PLU=ON L68 AND (L69 OR L70) L72 4 SEA FILE=ZCAPLUS ABB=ON PLU=ON L69 AND L70 L73 5 SEA FILE=ZCAPLUS ABB=ON PLU=ON (L71 OR L72)

=> d stat que L74 L25 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation: Uploading L25.str



ring nodes:
1 2 3 4 5 6 7 8 9 10 11 12
ring/chain nodes:
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
ring/chain bonds:
9-25 10-21 11-17 12-13 13-14 14-16 14-15 17-18 18-20 18-19 21-22 22-24
22-23 25-26 26-28 26-27 28-29 29-30
ring bonds:
1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10
exact/norm bonds:
1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10 9-25 10-21 11-17
12-13 13-14 14-16 14-15 17-18 18-20 18-19 21-22 22-24 22-23 25-26 26-28
26-27 28-29
29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS

22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS

L29 2020 SEA FILE=REGISTRY SSS FUL L25
L68 96 SEA FILE=ZCAPLUS ABB=ON PLU=ON GARLICH J?/AU
L69 49 SEA FILE=ZCAPLUS ABB=ON PLU=ON SUHR R?/AU
L70 710 SEA FILE=ZCAPLUS ABB=ON PLU=ON PATTERSON M?/AU
L74 1 SEA FILE=ZCAPLUS ABB=ON PLU=ON L29 AND (L68 OR L69 OR L70)

=> s L73-L74

L75 5 (L73 OR L74)

=> file medline embase biosis FILE 'MEDLINE' ENTERED AT 10:21:26 ON 21 FEB 2008

FILE 'EMBASE' ENTERED AT 10:21:26 ON 21 FEB 2008 Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:21:26 ON 21 FEB 2008 Copyright (c) 2008 The Thomson Corporation

=> s L73 L76 1 L73

=> file wpix FILE 'WPIX' ENTERED AT 10:21:40 ON 21 FEB 2008 COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE LAST UPDATED: 20 FEB 2008 <20080220/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200812 <200812/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> IPC Reform backfile reclassification has been loaded to the end of
November 2007. No update date (UP) has been created for the
reclassified documents, but they can be identified by
20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC and
20071130/UPIC. <<</pre>

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://scientific.thomson.com/support/patents/coverage/latestupdates/

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0: http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0710.pdf

- >>> XML document distribution format now available See HELP XMLDOC <<<
- >>> ECLA Codes and Current US National Classifications have been added see NEWS and HELP CHANGE <<<
- >>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

10/573938 >>> Updated PDF files in the following links: http://www.stn-international.de/stndatabases/details/ico_0801.zip http://www.stn-international.de/stndatabases/details/epc_0801.zip <<< 'BIX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE => s L7334 GARLICH J?/AU 32 SUHR R?/AU 178 PATTERSON M?/AU 32 SUHR R?/AU 178 PATTERSON M?/AU L77 2 (L71 OR L72) => file stnquide FILE 'STNGUIDE' ENTERED AT 10:21:48 ON 21 FEB 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS) FILE CONTAINS CURRENT INFORMATION. LAST RELOADED: Feb 15, 2008 (20080215/UP). => dup rem L75 L76 L77 FILE 'ZCAPLUS' ENTERED AT 10:22:04 ON 21 FEB 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS) FILE 'EMBASE' ENTERED AT 10:22:04 ON 21 FEB 2008 Copyright (c) 2008 Elsevier B.V. All rights reserved. FILE 'WPIX' ENTERED AT 10:22:04 ON 21 FEB 2008 COPYRIGHT (C) 2008 THE THOMSON CORPORATION PROCESSING COMPLETED FOR L75 PROCESSING COMPLETED FOR L76 PROCESSING COMPLETED FOR L77 5 DUP REM L75 L76 L77 (3 DUPLICATES REMOVED) ANSWERS '1-5' FROM FILE ZCAPLUS => d ibib abs hitind hitstr L78 1-5 L78 ANSWER 1 OF 5 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1 ACCESSION NUMBER: 2005:324033 ZCAPLUS <u>Full-text</u> DOCUMENT NUMBER: 142:379479 TITLE: Chelate based scaffolds in tumor targeting INVENTOR(S): Garlich, Joseph R.; Suhr, Robert G.; Patterson, Mary PATENT ASSIGNEE(S): Semafore Pharmaceuticals Inc., USA SOURCE: PCT Int. Appl., 47 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATENT NO.				KIN	D	DATE			APPL	ICAT	DATE					
WO 2005032599				A1 20050414				WO 2	004-	20040930						
W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,
	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,

```
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     EP 1684809
                                20060802
                                           EP 2004-789423
                         Α1
                                                                   20040930
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     US 2007104645
                                20070510
                                            US 2006-573938
                         Α1
                                                                   20060725
PRIORITY APPLN. INFO.:
                                                                P 20030930
                                            US 2003-507427P
                                                                W 20040930
                                            WO 2004-US32289
     This invention relates to novel complexes that can be used to target tumor
AΒ
     cells. The complexes include a ligand including a tetraazacyclododecane
     macrocycle ring core that can bind metal ions including radioactive lanthanide
     ions. The complexes can mimic \alpha v \beta 3 integrin receptor antagonists and deliver
     the complexed radioactive metals to the tumor cells. For example, 24.4 mM of
     cyclen reacted with 24.4 mM of tert-Bu bromoacetate to give 5.72 g 1,4-DO2A
     bis-tert-Bu ester (82% of theory) as clear viscous oil. The oil was dissolved
     in MeOH, allowed to crystallize, the solid obtained was filtered, washed with
     water and then dried to give 4.3964 g of white solid.
IC
     ICM A61K051-00
CC
     63-8 (Pharmaceuticals)
     Section cross-reference(s): 1, 8, 24
ΙT
     849610-60-2P 849610-61-3P 849610-62-4P 849610-63-5P
     849610-64-6P 849610-65-7P 849610-66-8P
     849610-67-9P 849610-68-0P 849610-69-1P
     849610-70-4P 849610-71-5P 849610-72-6P
     849610-73-7P 849610-74-8P 849610-75-9P
     849610-76-0P 849610-77-1P 849610-78-2P
     849610-79-3P 849610-80-6P 849610-81-7P
     849610-82-8P 849610-83-9P 849610-84-0P
     849610-85-1P 849610-86-2P 849610-87-3P
     849610-88-4P 849610-89-5P 849610-90-8P
     849610-91-9P 849610-92-0P 849610-93-1P
     849610-94-2P 849610-95-3P 849610-96-4P
     849610-97-5P
                  849610-98-6P 849610-99-7P 849611-00-3P
     849680-88-2P
     RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
        (chelate-based scaffolds for tumor targeting)
     849610-60-2P 849610-65-7P 849610-66-8P
ΤТ
     849610-67-9P 849610-68-0P 849610-69-1P
     849610-70-4P 849610-71-5P 849610-72-6P
     849610-73-7P 849610-74-8P 849610-75-9P
     849610-76-0P 849610-77-1P 849610-78-2P
     849610-79-3P 849610-80-6P 849610-81-7P
     849610-82-8P 849610-83-9P 849610-84-0P
     849610-85-1P 849610-86-2P 849610-87-3P
     849610-88-4P 849610-89-5P 849610-90-8P
     849610-91-9P 849610-92-0P 849610-93-1P
     849610-94-2P 849610-95-3P 849610-96-4P
     849680-88-2P
     RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
        (chelate-based scaffolds for tumor targeting)
     849610-60-2 ZCAPLUS
RN
     1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, \alpha4-[[(4-
CN
     acetylphenyl)amino]carbonyl]-10-[2-[(3-aminopropyl)amino]-2-oxoethyl]-,
```

 α 4-ethyl ester (9CI) (CA INDEX NAME)

RN 849610-65-7 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(6-aminohexyl)amino]-2-oxoethyl]- α -[2-[(2-carboxybenzoyl)amino]ethyl]- (9CI) (CA INDEX NAME)

RN 849610-66-8 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(5-aminopentyl)amino]-2-oxoethyl]- α -[2-[(2-carboxybenzoyl)amino]ethyl]- (9CI) (CA INDEX NAME)

RN 849610-67-9 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(4-aminobutyl)amino]-2-oxoethyl]- α -[2-[(2-carboxybenzoyl)amino]ethyl]- (CA INDEX NAME)

RN 849610-68-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(3-aminopropyl)amino]-2-oxoethyl]- α -(carboxymethyl)- (9CI) (CA INDEX NAME)

$$HO_2C-CH_2$$
 N
 CH_2-CO_2H
 CH_2-CO_2H
 CH_2-CO_2H
 CH_2-CO_2H
 CH_2-CO_2H

RN 849610-69-1 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(4-aminobutyl)amino]-2-oxoethyl]- α -(carboxymethyl)- (9CI) (CA INDEX NAME)

$$HO_2C-CH_2$$
 N
 CH_2-CO_2H
 CH_2-CO_2H
 $CH_2-CH_2-CH_2$
 $CH_2-CH_2-CH_2$
 $CH_2-CH_2-CH_2$
 $CH_2-CH_2-CH_2$

RN 849610-70-4 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(5-aminopentyl)amino]-2-oxoethyl]- α -(carboxymethyl)- (9CI) (CA INDEX NAME)

RN 849610-71-5 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(6-aminohexyl)amino]-2-oxoethyl]- α -(carboxymethyl)- (9CI) (CA INDEX NAME)

RN 849610-72-6 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[(aminoiminomethyl)amino]propyl]amino]-2-oxoethyl]- α -(carboxymethyl)-(9CI) (CA INDEX NAME)

RN 849610-73-7 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, $10-[2-[[4-[(aminoiminomethyl)amino]butyl]amino]-2-oxoethyl]-<math>\alpha$ -(carboxymethyl)-(9CI) (CA INDEX NAME)

RN 849610-74-8 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[5-[(aminoiminomethyl)amino]pentyl]amino]-2-oxoethyl]- α -(carboxymethyl)-(9CI) (CA INDEX NAME)

$$HO_2C-CH_2$$
 $CH-CH_2-CO_2H$
 $CH-CH_2-CO_2H$
 NH
 NH
 NH
 CH_2-CO_2H
 CH_2-CO_2H

RN 849610-75-9 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[(aminoiminomethyl)amino]hexyl]amino]-2-oxoethyl]- α -(carboxymethyl)-(9CI) (CA INDEX NAME)

RN 849610-76-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]- α -(2-carboxyethyl)- (CA INDEX NAME)

RN 849610-77-1 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(3-aminopropyl)amino]-2-oxoethyl]- α -(2-carboxyethyl)- (9CI) (CA INDEX NAME)

RN 849610-78-2 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(4-aminobutyl)amino]-2-oxoethyl]- α -(2-carboxyethyl)- (9CI) (CA INDEX NAME)

RN 849610-79-3 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(5-aminopentyl)amino]-2-oxoethyl]- α -(2-carboxyethyl)- (9CI) (CA INDEX NAME)

$$CO_2H$$
 $CH_2CH_2CH_2CO_2H$
 $CH_2CH_2CH_2CO_2H$
 $CH_2CH_2CH_2CO_2H$
 $CH_2CH_2CH_2CO_2H$
 $CH_2CH_2CO_2H$

RN 849610-80-6 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(6-aminohexyl)amino]-2-oxoethyl]- α -(2-carboxyethyl)- (9CI) (CA INDEX NAME)

RN 849610-81-7 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]- α -(carboxymethyl)- (9CI) (CA INDEX NAME)

$$CO_{2}H$$
 $CH_{2}CH_{2}CH_{2}CO_{2}H$
 $CH_{2}CH$

RN 849610-82-8 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[(aminoiminomethyl)amino]ethyl]amino]-2-oxoethyl]- α -(2-carboxyethyl)-(CA INDEX NAME)

RN 849610-83-9 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[(aminoiminomethyl)amino]propyl]amino]-2-oxoethyl]- α -(2-carboxyethyl)- (CA INDEX NAME)

RN 849610-84-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[4-[(aminoiminomethyl)amino]butyl]amino]-2-oxoethyl]- α 1-(2-carboxyethyl)- (9CI) (CA INDEX NAME)

RN 849610-85-1 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[5-[(aminoiminomethyl)amino]pentyl]amino]-2-oxoethyl]- α 1-(2-carboxyethyl)- (9CI) (CA INDEX NAME)

RN 849610-86-2 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[(aminoiminomethyl)amino]hexyl]amino]-2-oxoethyl]- α 1-(2-carboxyethyl)- (9CI) (CA INDEX NAME)

RN 849610-87-3 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[(aminoiminomethyl)amino]ethyl]amino]-2-oxoethyl]- α 1-(carboxymethyl)-(9CI) (CA INDEX NAME)

$$HO_2C-CH_2$$
 $CH-CH_2-CO_2H$
 $CH-CH_2-CO_2H$
 NH
 NH
 CH_2-CO_2H
 CH_2-CH_2-NH
 CH_2-CH_2-NH

RN 849610-88-4 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]- α 1-(3-carboxypropyl)- (9CI) (CA INDEX NAME)

RN 849610-89-5 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(3-aminopropyl)amino]-2-oxoethyl]- α 1-(3-carboxypropyl)- (9CI) (CA INDEX NAME)

RN 849610-90-8 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(4-aminobutyl)amino]-2-oxoethyl]- α 1-(3-carboxypropyl)- (9CI) (CA INDEX NAME)

RN 849610-91-9 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(5-aminopentyl)amino]-2-oxoethyl]- α 1-(3-carboxypropyl)- (CA INDEX NAME)

RN 849610-92-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(6-aminohexyl)amino]-2-oxoethyl]- α 1-(3-carboxypropyl)- (9CI) (CA INDEX NAME)

RN 849610-93-1 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[(aminoiminomethyl)amino]propyl]amino]-2-oxoethyl]- α 1-(3-carboxypropyl)- (CA INDEX NAME)

RN 849610-94-2 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[4-[(aminoiminomethyl)amino]butyl]amino]-2-oxoethyl]- α 1-(3-carboxypropyl)- (CA INDEX NAME)

RN 849610-95-3 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[5-[(aminoiminomethyl)amino]pentyl]amino]-2-oxoethyl]- α 1-(3-carboxypropyl)- (9CI) (CA INDEX NAME)

RN 849610-96-4 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[(aminoiminomethyl)amino]hexyl]amino]-2-oxoethyl]- α 1-(3-carboxypropyl)- (9CI) (CA INDEX NAME)

$$HO_2C-CH_2$$
 CH_2
 C

RN 849680-88-2 ZCAPLUS

CN Yttrate(1-), $[10-[2-[[5-[(aminoiminomethyl)amino]pentyl]amino]-2-(oxo-\kappa0)ethyl]-\alpha1-(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(5-)-<math>\kappa$ N1, κ N4, κ N7, κ N10, κ O1,.kappa.O4, κ O7]-, hydrogen (9CI) (CA INDEX NAME)

● H+

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L78 ANSWER 2 OF 5 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2004:878386 ZCAPLUS Full-text

DOCUMENT NUMBER: 141:366126

TITLE: Preparation of quaternized derivatives of

(morpholinyl)phenylbenzopyranone as Pi-3 kinase

inhibitor prodrugs

Garlich, Joseph R.; Durden, Donald L.; Patterson, INVENTOR(S):

> Mary; Su, Jingdong; Suhr, Robert G. Semafore Pharmaceuticals, Inc., USA

PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 136 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.				KIND DATE				APPL	ICAT	ION 1		DATE						
WO	WO 2004089925					_	20041021		WO 2004-US10399 200								040403	
	W:	ΑE,	AG,	AL,	ΑM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,	
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NΙ,	
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	
		ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW	
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	
		BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	
		ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	ΙΤ,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	
		SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	${ m ML}$,	MR,	NE,	SN,	
		TD,	ΤG															
AU	2004	2286	68		A1 20041021					AU 2	004-	2286		20040403				
CA	2518	916			A1	A1 20041021				CA 2	004-	25189		20040403				
EΡ	1611	119			A1		2006	0104	EP 2004-758869						20040403			
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	NL,	SE,	MC,	PT,	
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	PL,	SK,	HR
BR	2004	0090	63		Α		2006	0328	BR 2004-9063						20040403			
CN	1826	331			А		2006	0830	(CN 2	004-	8000	9226		2	0040	403	

JP	2006523237	T	20061012	JP	2006-509693		20040403
US	2004242631	A1	20041202	US	2004-818145		20040405
US	6949537	B2	20050927				
US	2005203173	A1	20050915	US	2005-111201		20050420
MX	2005PA10471	A	20060525	MX	2005-PA10471		20050929
KR	2007087266	A	20070828	KR	2005-718781		20050930
IN	2005DN04597	A	20070817	IN	2005-DN4597		20051010
PRIORITY	APPLN. INFO.:			US	2003-460137P	Р	20030403
				WO	2004-US10399	Α	20040403
				US	2004-818145	Α1	20040405

OTHER SOURCE(S): MARPAT 141:366126

GΙ

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

The invention provides methods to prepare prodrugs I [Z and Z1-3 independently AΒ = O or S; R1 and R2 independently = H, (un)substituted-aliphatic, -aryl, OH, CN, halo, etc.; R3 = H, (un)substituted-aliphatic, -aryl; R4 and R5 = H, (un) substituted-aliphatic, -aryl, heterocyclyl, aryloxy, carboxy, or taken together form an (un) substituted heterocycle; R6 = H, (un) substitutedaliphatic, -aryl, etc.; R7 = -CH2-, -CH(CH3)-, -CH(Ph)-, -C(CH3)(CO2H)- or CH(CH(CH3)2)-; T is optional but when present = targeting agent], possessing a hydrolyzable quaternary nitrogen which can provide metabolites II capable of inhibiting PI-3 kinase. Thus, e.g., III was prepared via N-alkylation of IV with chloromethyl-t-butylsuccinate followed by hydrolysis and chlorination to the acid chloride which was reacted with resin bound peptide (arg-gly-asp-ser) after which cleavage from the resin provided III. III was evaluated for in vivo efficacy against non-small cell lung cancer and after 17 days a 35% reduction in tumor volume was observed (at 25mg/kg/day dosage). The novel compds. are IV and analogs thereof comprising a reversibly quaternized amine.

IC ICM C07D311-22

AUTHOR(S):

ICS C07D407-12; C07D475-04; A61K031-5377; A61P025-00

CC 27-14 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 34, 63

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L78 ANSWER 3 OF 5 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2004:891169 ZCAPLUS Full-text

DOCUMENT NUMBER: 142:322489

TITLE: Nanoparticles for delivery of pifithrins to combat

cell death due to chemotherapy and radiation Brannon-Peppas, L.; Soehl, K.; Monaco, M. D.;

Garlich, J.; Patterson, M.; Smith, T. C.

CORPORATE SOURCE: Department of Biomedical Engineering and Division of

Pharmaceutics, The University of Texas at Austin,

Austin, TX, 78712-0231, USA

SOURCE: Journal of Drug Delivery Science and Technology

(2004), 14(4), 257-264

CODEN: JDDSAL

PUBLISHER: Editions de Sante

DOCUMENT TYPE: Journal LANGUAGE: English

AB This work describes the first stage of our research efforts to develop targetable nanoparticles to deliver agents to help healthy bone marrow cells survive radiation and chemotherapy. Administering pifithrin, a small mol. inhibitor of the protein p53, could prevent p53 initiated cell death. The p53

protein imparts sensitivity to normal tissue subjected to genotoxic stress such as radiation therapy or chemotherapy. We describe the conversion of pifithrin- α to pifithrin- β in buffer and serum and even while frozen and the implications in developing successful formulations. Encapsulation of pifithrin- β in biodegradable nanoparticles of poly(lactic-co-glycolic) acid showed encapsulation of up to 13% pifithrin and release in vitro of at least 28 days. Particle sizes ranged from 240 to 3250 nm, depending on the preparation methods used including variation of organic solvent type and amount

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 8

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L78 ANSWER 4 OF 5 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:435190 ZCAPLUS <u>Full-text</u>

TITLE: Targeted Delivery of p53 Inhibitors

AUTHOR(S): Smith, Tim C.; Garlich, Joseph R.; Patterson, Mary

L.; Suhr, Robert G.

CORPORATE SOURCE: Semafore Pharmaceuticals, Indianapolis, IN, 46268, USA

SOURCE: Abstracts, 36th Central Regional Meeting of the American Chemical Society, Indianapolis, IN, United

States, June 2-4 (2004), GEN-452. American Chemical

Society: Washington, D. C.

CODEN: 69FMAU

DOCUMENT TYPE: Conference; Meeting Abstract

AB The protein p53 is a tumor suppressor, which often is triggered during chemoand radiation therapy, causing unwanted side effects by inducing apoptosis of
healthy tissue such as the hematopoietic system. Thus suppression of p53 in
healthy tissues during therapy should decrease the damage. Pifithrin- and
pifithrin- have been shown to act as small mol. inhibitors of p53. We have
embarked on a program to target pifithrin- and to bone, thus offering
selective protection to bone marrow and the immune system during therapy.
This presentation will focus on the synthetic chemical of linking bone-seeking
moieties to pifithrin- and as well as promising preliminary in vitro studies.

L78 ANSWER 5 OF 5 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:435232 ZCAPLUS Full-text

TITLE: Novel Purification Techniques and the Solid Phase

Synthesis of Macrocyclic Ligands

AUTHOR(S): Garlich, Joseph R.; Patterson, Mary; Smith, Tim

C.; Suhr, Robert G.; Georgiadis, Taxiarchis M.

CORPORATE SOURCE: Semafore Pharmaceuticals, Indianapolis, IN, 46268, USA

SOURCE: Abstracts, 36th Central Regional Meeting of the American Chemical Society, Indianapolis, IN, United

American Chemical Society, Indianapolis, IN, United States, June 2-4 (2004), INV-033. American Chemical

Society: Washington, D. C.

CODEN: 69FMAU

DOCUMENT TYPE: Conference; Meeting Abstract

One highly useful procedure in parallel or combinatorial synthesis is the clean-up of reaction mixts. using facilitated liquid-liquid extraction Researchers have previously described the use of large mesh sized diatomaceous earth beads coated with an aqueous phase for simultaneous extraction workup of an array of compds. simply by exposure of the reaction mix dissolved in an organic phase to the beads. We have taken this concept beyond simple liquid-liquid extns. by employing diatomaceous earth beads coated with various aqueous based scavenging, catalytic and reactive solns. This supported aqueous film exposure can be utilized during a reaction to introduce catalysts or reactive reagents which react at the films water-organic interface. Post-

reaction workup is thus reduced to simple filtration or decanting. Novel phys. formats for this technique have also been explored. This work and the solid-phase synthesis of macrocyclic ligands will be discussed.

=> file registry
FILE 'REGISTRY' ENTERED AT 10:22:51 ON 21 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9 DICTIONARY FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9


New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html




ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 ring/chain nodes:
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 ring/chain bonds:
9-25 10-21 11-17 12-13 13-14 14-16 14-15 17-18 18-20 18-19 21-22 22-24 22-23 25-26 26-28 26-27 28-29 29-30 ring bonds:
1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10 exact/norm bonds:
1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10 9-25 10-21 11-

17 12-13 13-14 14-16 14-15 17-18 18-20 18-19 21-22 22-24 22-23 25-26 26-28 26-27 28-29 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS



ring nodes:
1 2 3 4 5 6 7 8 9 10 11 12
ring/chain nodes:
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 33 34 35

ring/chain bonds:
9-25 10-21 11-17 12-13 13-14 14-16 14-15 17-18 18-20 18-19 21-22 22-24
22-23 25-26 26-28 26-27 28-29 29-30 30-33 33-34 33-35

ring bonds:
1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10
exact/norm bonds:
1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10 9-25 10-21 11-17
12-13 13-14 14-16 14-15 17-18 18-20 18-19 21-22 22-24 22-23 25-26 26-28
26-27 28-29
29-30 30-33 33-34 33-35

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:CLASS 35:CLASS

ring nodes:
1 2 3 4 5 6 7 8 9 10 11 12
ring/chain nodes:
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 33 34 35
36
ring/chain bonds:
9-25 10-21 11-17 12-13 13-14 14-16 14-15 17-18 18-20 18-19 21-22 21-33

22-24 22-23 25-26 26-28 26-27 28-29 29-30 33-34 34-35 34-36 ring bonds:
1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10 exact/norm bonds:
1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10 9-25 10-21 11-17
12-13 13-14 14-16 14-15 17-18 18-20 18-19 21-22 21-33 22-24 22-23 25-26 26-28 26-27 28-29 29-30 33-34 34-35 34-36

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 34:CLASS 35:CLASS 36:CLASS 36:CLASS



chain nodes :
31 32
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
ring/chain nodes :
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
chain bonds :
29-31 29-32

ring/chain bonds : $9-25 \quad 10-21 \quad 11-17 \quad 12-13 \quad 13-14 \quad 14-16 \quad 14-15 \quad 17-18 \quad 18-20 \quad 18-19 \quad 21-22 \quad 22-24$ 22-23 25-26 26-28 26-27 28-29 29-30 ring bonds : 1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10exact/norm bonds : 1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10 9-25 10-21 11-17 $12-13 \quad 13-14 \quad 14-16 \quad 14-15 \quad 17-18 \quad 18-20 \quad 18-19 \quad 21-22 \quad 22-24 \quad 22-23 \quad 25-26 \quad 26-28 \quad 26-2$ 26-27 28-29 29-30 29-31 29-32

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS

=> file zcaplus FILE 'ZCAPLUS' ENTERED AT 10:22:54 ON 21 FEB 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 21 Feb 2008 VOL 148 ISS 8 FILE LAST UPDATED: 20 Feb 2008 (20080220/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification. 'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L32 L25 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation. L27 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

2020 SEA FILE=REGISTRY SSS FUL L25

L31 62 SEA FILE=REGISTRY SUB=L29 SSS FUL L27 L32 9 SEA FILE=ZCAPLUS ABB=ON PLU=ON L31

=> d stat que L37 L25

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

2020 SEA FILE=REGISTRY SSS FUL L25 L29

L34 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

12 SEA FILE=REGISTRY SUB=L29 SSS FUL L34 L37 1 SEA FILE=ZCAPLUS ABB=ON PLU=ON L36

=> d stat que L45

L2 65 SEA FILE=REGISTRY ABB=ON PLU=ON (118726-52-6/BI OR 17137-11-0 /BI OR 294-90-6/BI OR 507475-91-4/BI OR 5292-43-3/BI OR 7429-91-6/BI OR 7439-91-0/BI OR 7439-94-3/BI OR 7440-00-8/BI OR 7440-10-0/BI OR 7440-12-2/BI OR 7440-19-9/BI OR 7440-20-2/BI OR 7440-27-9/BI OR 7440-30-4/BI OR 7440-45-1/BI OR 7440-52-0/B I OR 7440-53-1/BI OR 7440-54-2/BI OR 7440-60-0/BI OR 7440-64-4/ BI OR 7440-65-5/BI OR 849610-60-2/BI OR 849610-61-3/BI OR 849610-62-4/BI OR 849610-63-5/BI OR 849610-64-6/BI OR 849610-65 -7/BI OR 849610-66-8/BI OR 849610-67-9/BI OR 849610-68-0/BI OR 849610-69-1/BI OR 849610-70-4/BI OR 849610-71-5/BI OR 849610-72 -6/BI OR 849610-73-7/BI OR 849610-74-8/BI OR 849610-75-9/BI OR 849610-76-0/BI OR 849610-77-1/BI OR 849610-78-2/BI OR 849610-79 -3/BI OR 849610-80-6/BI OR 849610-81-7/BI OR 849610-82-8/BI OR 849610-83-9/BI OR 849610-84-0/BI OR 849610-85-1/BI OR 849610-86 -2/BI OR 849610-87-3/BI OR 849610-88-4/BI OR 849610-89-5/BI OR 849610-90-8/BI OR 849610-91-9/BI OR 849610-92-0/BI OR 849610-93 -1/BI OR 849610-94-2/BI OR 849610-95-3/BI OR 849610-96-4/BI OR 849610-97-5/BI OR 849610-98-6/BI OR 849610-99-7/BI OR 849611-00 -3/BI OR 849680-88-2/BI OR 95196-95-5/BI) L25 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation. L27 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

2020 SEA FILE=REGISTRY SSS FUL L25 L29

L31 62 SEA FILE=REGISTRY SUB=L29 SSS FUL L27

L32 9 SEA FILE=ZCAPLUS ABB=ON PLU=ON L31

L34 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

```
L36
            12 SEA FILE=REGISTRY SUB=L29 SSS FUL L34
L37
             1 SEA FILE=ZCAPLUS ABB=ON PLU=ON L36
L38
             9 SEA FILE=ZCAPLUS ABB=ON PLU=ON L37 OR L32
L40
           273 SEA FILE=REGISTRY ABB=ON PLU=ON (934183-16-1/BI OR 111119-28-
               9/BI OR 137076-54-1/BI OR 14265-75-9/BI OR 15750-15-9/BI OR
                15757-14-9/BI OR 317809-26-0/BI OR 33507-63-0/BI OR 705283-66-5
                /BI OR 901439-51-8/BI OR 901439-89-2/BI OR 901442-07-7/BI OR
               901443-47-8/BI OR 91037-65-9/BI OR 934183-14-9/BI OR 934183-15-
                0/BI OR 934350-78-4/BI OR 934350-82-0/BI OR 934350-86-4/BI OR
               934350-87-5/BI OR 10098-91-6/BI OR 110880-55-2/BI OR 110880-57-
                4/BI OR 111844-19-0/BI OR 112188-16-6/BI OR 115608-61-2/BI OR
                118726-52-6/BI OR 128009-23-4/BI OR 135702-31-7/BI OR 137184-55
                -5/BI OR 137813-35-5/BI OR 13967-64-1/BI OR 13967-65-2/BI OR
               13981-25-4/BI OR 13981-56-1/BI OR 14119-08-5/BI OR 14119-09-6/B
               I OR 14133-76-7/BI OR 141743-95-5/BI OR 14191-64-1/BI OR
               14265-85-1/BI OR 14687-25-3/BI OR 14809-53-1/BI OR 14834-85-6/B
               I OR 14885-78-0/BI OR 148893-10-1/BI OR 14913-49-6/BI OR
               14981-79-4/BI OR 15065-93-7/BI OR 15757-86-5/BI OR 15765-31-8/B
                I OR 15776-20-2/BI OR 161552-03-0/BI OR 17137-11-0/BI OR
               174267-75-5/BI OR 188982-12-9/BI OR 22541-18-0/BI OR 22541-19-1
                /BI OR 267410-13-9/BI OR 29022-11-5/BI OR 294-90-6/BI OR
               36849-05-5/BI OR 41444-88-6/BI OR 415706-07-9/BI OR 507475-91-4
                /BI OR 5292-43-3/BI OR 585531-74-4/BI OR 6066-82-6/BI OR
               623575-85-9/BI OR 676544-84-6/BI OR 676544-85-7/BI OR 676553-18
                -7/BI OR 676553-19-8/BI OR 7087-68-5/BI OR 713520-27-5/BI OR
               728914-72-5/BI OR 728914-74-7/BI OR 7429-91-6/BI OR 7439-91-0/B
               I OR 7439-94-3/BI OR 7440-00-8/BI OR 7440-10-0/BI OR 7440-12-2/
               BI OR 7440-19-9/BI OR 7440-20-2/BI OR 7440-27-9/BI OR 7440-30-4
               /BI OR 7440-45-1/BI OR 7440-52-0/BI OR 7440-53-1/BI OR
               7440-54-2/BI OR 7440-60-0/BI OR 7440-64-4/BI OR 7440-65-5/BI
               OR 766529-14-0/BI OR 766529-15-1/BI OR 766529-16-2/BI OR
               766529-18-4/BI OR 766529-19-5/BI OR 766529-20-8/BI OR 766529-22
                -0/BI OR 766529-24-2/BI OR 766529-25-3/BI OR 76652
L41
            65 SEA FILE=REGISTRY ABB=ON PLU=ON L40 AND L2
L42
            75 SEA FILE=REGISTRY ABB=ON PLU=ON L40 AND M/ELS
             8 SEA FILE=ZCAPLUS ABB=ON PLU=ON (L41 OR L42) AND L38
L45
```

=> d stat que L55 L25 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L29 2020 SEA FILE=REGISTRY SSS FUL L25

L47 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

345 SEA FILE=REGISTRY SUB=L29 SSS FUL L47

L50 142 SEA FILE=REGISTRY ABB=ON PLU=ON L49 AND M/ELS L54 9 SEA FILE=REGISTRY ABB=ON PLU=ON L50 AND Y/ELS

L55 10 SEA FILE=ZCAPLUS ABB=ON PLU=ON L54

=> d stat que L67

65 SEA FILE=REGISTRY ABB=ON PLU=ON (118726-52-6/BI OR 17137-11-0 /BI OR 294-90-6/BI OR 507475-91-4/BI OR 5292-43-3/BI OR 7429-91-6/BI OR 7439-91-0/BI OR 7439-94-3/BI OR 7440-00-8/BI

OR 7440-10-0/BI OR 7440-12-2/BI OR 7440-19-9/BI OR 7440-20-2/BI OR 7440-27-9/BI OR 7440-30-4/BI OR 7440-45-1/BI OR 7440-52-0/B I OR 7440-53-1/BI OR 7440-54-2/BI OR 7440-60-0/BI OR 7440-64-4/ BI OR 7440-65-5/BI OR 849610-60-2/BI OR 849610-61-3/BI OR 849610-62-4/BI OR 849610-63-5/BI OR 849610-64-6/BI OR 849610-65 -7/BI OR 849610-66-8/BI OR 849610-67-9/BI OR 849610-68-0/BI OR 849610-69-1/BI OR 849610-70-4/BI OR 849610-71-5/BI OR 849610-72 -6/BI OR 849610-73-7/BI OR 849610-74-8/BI OR 849610-75-9/BI OR 849610-76-0/BI OR 849610-77-1/BI OR 849610-78-2/BI OR 849610-79 -3/BI OR 849610-80-6/BI OR 849610-81-7/BI OR 849610-82-8/BI OR 849610-83-9/BI OR 849610-84-0/BI OR 849610-85-1/BI OR 849610-86 -2/BI OR 849610-87-3/BI OR 849610-88-4/BI OR 849610-89-5/BI OR 849610-90-8/BI OR 849610-91-9/BI OR 849610-92-0/BI OR 849610-93 -1/BI OR 849610-94-2/BI OR 849610-95-3/BI OR 849610-96-4/BI OR 849610-97-5/BI OR 849610-98-6/BI OR 849610-99-7/BI OR 849611-00 -3/BI OR 849680-88-2/BI OR 95196-95-5/BI)

L25 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation. L27 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

2020 SEA FILE=REGISTRY SSS FUL L25 L29

L31 62 SEA FILE=REGISTRY SUB=L29 SSS FUL L27

9 SEA FILE=ZCAPLUS ABB=ON PLU=ON L31 L32

L34 STR

L40

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

12 SEA FILE=REGISTRY SUB=L29 SSS FUL L34 L36

L37 1 SEA FILE=ZCAPLUS ABB=ON PLU=ON L36

L38 9 SEA FILE=ZCAPLUS ABB=ON PLU=ON L37 OR L32

273 SEA FILE=REGISTRY ABB=ON PLU=ON (934183-16-1/BI OR 111119-28-9/BI OR 137076-54-1/BI OR 14265-75-9/BI OR 15750-15-9/BI OR 15757-14-9/BI OR 317809-26-0/BI OR 33507-63-0/BI OR 705283-66-5 /BI OR 901439-51-8/BI OR 901439-89-2/BI OR 901442-07-7/BI OR 901443-47-8/BI OR 91037-65-9/BI OR 934183-14-9/BI OR 934183-15-0/BI OR 934350-78-4/BI OR 934350-82-0/BI OR 934350-86-4/BI OR 934350-87-5/BI OR 10098-91-6/BI OR 110880-55-2/BI OR 110880-57-4/BI OR 111844-19-0/BI OR 112188-16-6/BI OR 115608-61-2/BI OR 118726-52-6/BI OR 128009-23-4/BI OR 135702-31-7/BI OR 137184-55 -5/BI OR 137813-35-5/BI OR 13967-64-1/BI OR 13967-65-2/BI OR 13981-25-4/BI OR 13981-56-1/BI OR 14119-08-5/BI OR 14119-09-6/B I OR 14133-76-7/BI OR 141743-95-5/BI OR 14191-64-1/BI OR 14265-85-1/BI OR 14687-25-3/BI OR 14809-53-1/BI OR 14834-85-6/B I OR 14885-78-0/BI OR 148893-10-1/BI OR 14913-49-6/BI OR 14981-79-4/BI OR 15065-93-7/BI OR 15757-86-5/BI OR 15765-31-8/B I OR 15776-20-2/BI OR 161552-03-0/BI OR 17137-11-0/BI OR 174267-75-5/BI OR 188982-12-9/BI OR 22541-18-0/BI OR 22541-19-1 /BI OR 267410-13-9/BI OR 29022-11-5/BI OR 294-90-6/BI OR 36849-05-5/BI OR 41444-88-6/BI OR 415706-07-9/BI OR 507475-91-4 /BI OR 5292-43-3/BI OR 585531-74-4/BI OR 6066-82-6/BI OR 623575-85-9/BI OR 676544-84-6/BI OR 676544-85-7/BI OR 676553-18 -7/BI OR 676553-19-8/BI OR 7087-68-5/BI OR 713520-27-5/BI OR 728914-72-5/BI OR 728914-74-7/BI OR 7429-91-6/BI OR 7439-91-0/B

```
I OR 7439-94-3/BI OR 7440-00-8/BI OR 7440-10-0/BI OR 7440-12-2/
               BI OR 7440-19-9/BI OR 7440-20-2/BI OR 7440-27-9/BI OR 7440-30-4
               /BI OR 7440-45-1/BI OR 7440-52-0/BI OR 7440-53-1/BI OR
               7440-54-2/BI OR 7440-60-0/BI OR 7440-64-4/BI OR 7440-65-5/BI
               OR 766529-14-0/BI OR 766529-15-1/BI OR 766529-16-2/BI OR
               766529-18-4/BI OR 766529-19-5/BI OR 766529-20-8/BI OR 766529-22
               -0/BI OR 766529-24-2/BI OR 766529-25-3/BI OR 76652
            65 SEA FILE=REGISTRY ABB=ON PLU=ON L40 AND L2
L41
            75 SEA FILE=REGISTRY ABB=ON PLU=ON L40 AND M/ELS
L42
             8 SEA FILE=ZCAPLUS ABB=ON PLU=ON (L41 OR L42) AND L38
L45
L47
               STR
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.
           345 SEA FILE=REGISTRY SUB=L29 SSS FUL L47
           142 SEA FILE=REGISTRY ABB=ON PLU=ON L49 AND M/ELS
L50
L51
           203 SEA FILE=REGISTRY ABB=ON PLU=ON L49 NOT L50
            9 SEA FILE=REGISTRY ABB=ON PLU=ON L50 AND Y/ELS
L54
            10 SEA FILE=ZCAPLUS ABB=ON PLU=ON L54
L55
           112 SEA FILE=REGISTRY ABB=ON PLU=ON L50 AND LNTH/PG
L56
            18 SEA FILE=ZCAPLUS ABB=ON PLU=ON L32 OR L37 OR L45 OR L55
L58
       641196 SEA FILE=ZCAPLUS ABB=ON PLU=ON ?TUMOUR?/BI OR ?TUMOR?/BI
        25232 SEA FILE=ZCAPLUS ABB=ON PLU=ON ?SCAFFOLD?/BI
L62
             2 SEA FILE=ZCAPLUS ABB=ON PLU=ON (L51 OR L56) AND L62
L64
            40 SEA FILE=ZCAPLUS ABB=ON PLU=ON (L51 OR L56) AND L60
8 SEA FILE=ZCAPLUS ABB=ON PLU=ON (L64 OR L65) AND L58
L65
L67
=> s (132 or L37 or L45 or L55 or L67) not L73-L74
           17 (L32 OR L37 OR L45 OR L55 OR L67) NOT (L73 OR L74)
=> d ibib abs hitind hitstr L79 1-17
L79 ANSWER 1 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1302637 ZCAPLUS Full-text
DOCUMENT NUMBER:
                        147:522590
TITLE:
                        Preparation of peptides containing the
                        D-Phe-D-Phe-D-Val-D-Leu-D-Lys sequence as imaging
                        agents
                        Austen, Brian
INVENTOR(S):
PATENT ASSIGNEE(S):
                       St. George's Hospital Medical School, UK
SOURCE:
                        PCT Int. Appl., 36pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
     PATENT NO.
                   KIND DATE APPLICATION NO. DATE
                       ____
                                          _____
    WO 2007129077
WO 2007129077
                        A2 20071115
                                         WO 2007-GB1669 20070504
                        A3 20080103
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
            CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
            GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
            KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,
```

MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,

TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

```
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.:
                                            GB 2006-8960
                                                                 A 20060505
     The invention relates to synthetic peptides capable of recognizing and binding
     to \beta-amyloid and to the use of the peptides in the diagnosis, monitoring and
     therapy of Alzheimer's disease (AD). Peptides containing the sequence D-Phe-
     D-Phe-D-Val-D-Leu-D-Lys (ffvlk) and an amine or quanidine substituent are
     claimed for this purpose. Thus, acetyl-rGffvlkr-NH2 and DOTA-rGffvlkGrG-
     pentadiamine (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
     acid) Gd complex were prepared by the solid-phase method and assayed for
     inhibition of \beta-amyloid oligomer formation.
     34-3 (Amino Acids, Peptides, and Proteins)
CC
     Section cross-reference(s): 1, 78
     956489-86-4P 956599-09-0P 956599-10-3P
ΙT
     RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic
     use); BIOL (Biological study); PREP (Preparation); USES (Uses)
        (preparation of peptides containing D-configurated
phenylalanylphenylalanylvalyl
        leucylleucine sequence as imaging agents)
     956489-89-7P 956489-91-1P 956489-93-3P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of peptides containing D-configurated
phenylalanylphenylalanylvalyl
        leucylleucine sequence as imaging agents)
     956599-09-0P 956599-10-3P
ΙT
     RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic
     use); BIOL (Biological study); PREP (Preparation); USES (Uses)
        (preparation of peptides containing D-configurated
phenylalanylphenylalanylvalyl
        leucylleucine sequence as imaging agents)
     956599-09-0 ZCAPLUS
RN
CN
     Gadolinium, [N-[2-[4,7,10-tris[(carboxy-\kappa0)methyl]-1,4,7,10-tris]
     tetrazacyclododec-1-yl-KN1, KN4, KN7, KN10]acetyl-
     κ0]-D-arginylglycyl-D-phenylalanyl-D-phenylalanyl-D-valyl-D-leucyl-D-
     lysylglycyl-D-arginyl-N-(5-aminopentyl)glycinamidato(3-)]- (CA INDEX
     NAME)
```

PAGE 2-A

RN 956599-10-3 ZCAPLUS

Ŋ

CN Gadolinium, [N-[2-[4,7,10-tris[(carboxy- κ 0)methyl]-1,4,7,10-tetrazadodec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl- κ O]-D-arginylglycyl-D-phenylalanyl-D-phenylalanyl-D-valyl-D-leucyl-D-lysylglycyl-D-argin

PAGE 1-C

PAGE 2-A

IT 956489-91-1P 956489-93-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of peptides containing D-configurated phenylalanylphenylalanylvalyl

leucylleucine sequence as imaging agents)

RN 956489-91-1 ZCAPLUS

CN Glycinamide, N2-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-arginylglycyl-D-phenylalanyl-D-phenylalanyl-D-valyl-D-leucyl-D-lysylglycyl-D-arginyl-N-(5-aminopentyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A
$$H_{2}N \xrightarrow{(CH_{2})} 5 \xrightarrow{H} \xrightarrow{(CH_{2})} 3 \xrightarrow{R} \xrightarrow{H} \xrightarrow{H} \xrightarrow{(CH_{2})} 4 \xrightarrow{R} \xrightarrow{(CH_{2})} 4 \xrightarrow{R} \xrightarrow{(CH_{2})} 4 \xrightarrow{R} \xrightarrow{H} \xrightarrow{(CH_{2})} 4 \xrightarrow{R} \xrightarrow{(CH_{2})} 4 \xrightarrow{(CH_{2})} 4$$

PAGE 1-B

PAGE 1-A

Ph
$$H_{2N}$$
 H_{2N} H_{NH} $H_{O_{2}C}$ $H_{$

RN 956489-93-3 ZCAPLUS

CN D-Argininamide, N2-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-arginylglycyl-D-phenylalanyl-D-phenylalanyl-D-argi

Absolute stereochemistry.

$$H_{2N}$$
 H_{2N}
 H_{2N}

PAGE 1-B

PAGE 2-A

PAGE 2-B

PAGE 3-A

L79 ANSWER 2 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:410019 ZCAPLUS Full-text

DOCUMENT NUMBER: 146:415599

TITLE: Neuropeptide Y analogs for treating and diagnosing Y1

receptor-expressing breast cancer

INVENTOR(S):
Srinivasan, Ananth

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 83pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA:	PATENT NO.					KIND DATE			,	APPL	ICAT		DATE				
	2007039318 2007039318			A2 A3		20070412			WO 2	006-		20061005					
WO	W:	AE,	AG,		AM,	AT,	AU, DE,	AZ,	•				,	,	,	•	•
		GE,	GH,	GM,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KN,	KP,
		•	,	•	•	•	LR, NG,	•	•	•	•	•	•	•	•		•
			- '		•	- '	SK, VN,	•	•		SY,	TJ,	TM,	TN,	TR,	TT,	TZ,
	RW:	AT,	BE,	ВG,	CH,	CY,	CZ,	DE,	DK,	EE,	•						
		•	,	•	•	•	MC, GN,	•	•	•	•	•	•	•	•		•
		•		•			NA, TM,		•	•	•	UG,	ZM,	ZW,	AM,	AZ,	BY,
PRIORIT	Y APP	LN.	INFO	.:	·	,		·	•	US 2	005-	7239	09P		P 2	0051	006

The neuropeptide Y(NPY)-receptor-subtype Y1 is expressed differentially from breast tumor cells and is therefore an advantageous target mol. for the mol. imaging of breast cancer. Peptide analogs were synthesized, whose sequence is reduced to the receptor-binding sections of the natural ligand NPY. These Y1 receptor-selective peptide analogs contain unnatural amino acids that increase the receptor affinity and are to ensure the stability of the greatly shortened peptide. New NPY analogs, which are to be used as radioligands, were tested for their binding affinity and selectivity for the Y1 receptor. To this end, in-vitro binding tests with Y1- or Y2 receptor-expressing cell lines were established and optimized. Then, the binding affinities of the NPY analogs were determined. In this case, a peptide (P2489) was identified, whose highest

binding affinity was determined with a Ki of 42.8 nmol of Y1 receptor-

CC

ΙT

ΙT

ΙT

ΙT

RN CN

RN

CN

expressing SK-N-MC cells and whose selectivity for the Y1 receptor could be detected by the fact that there is no binding to Y2 receptor-expressing MHH-NB-11 cells. As an addnl. NPY analog, peptide fW7 contained the unnatural amino acid β -aminocyclopropanecarboxylic acid on positions 32 and 34, by which the binding to the Y1 receptor was influenced in a pos. manner. A direct coupling of the chelating agent DOTA, which is necessary for the radiometal labeling of the peptides, to the N-terminal end of the peptides resulted in the loss of the binding affinity. By indirect coupling of the DOTA to the peptide fW7 via a spacer, this loss could be reduced, and fW7(DOTA) had a high binding affinity (Ki = 62.8 nmol) similar to P2489. 2-10 (Mammalian Hormones) 13981-56-1D, 18 F, complexes with neuropeptide Y analogs, biological studies 14133-76-7D, 99Tc, metastable, complexes with neuropeptide Y analogs, biological studies 14265-75-9D, complexes with neuropeptide Y analogs, biological studies 15750-15-9D, 111In, complexes with neuropeptide Y analogs, biological studies 15757-14-9D, complexes with neuropeptide Y analogs, biological studies 82785-45-3D, Neuropeptide Y, analogs 705283-66-5D, labeled 934183-14-9D, labeled 934183-15-0D, labeled 934183-16-1D, labeled 934350-78-4D, labeled 934350-82-0D, 934350-86-4D, labeled 934350-87-5D, labeled RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses) (neuropeptide Y analogs for treating and diagnosing Y receptor-expressing breast cancer) 705283-66-5 934183-14-9 934183-15-0 934183-16-1 934350-78-4 934350-82-0 934350-86-4 934350-87-5 RL: DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (neuropeptide Y analogs for treating and diagnosing Y receptor-expressing breast cancer) 934183-16-1D, 177-Lu-DOTA complexes 934350-88-6 RL: DGN (Diagnostic use); PKT (Pharmacokinetics); BIOL (Biological study); USES (Uses) (neuropeptide Y analogs for treating and diagnosing Y receptor-expressing breast cancer) 14133-76-7D, 99Tc, metastable, complexes with neuropeptide Y analogs, biological studies 14265-75-9D, complexes with neuropeptide Y analogs, biological studies 15750-15-9D, 111In, complexes with neuropeptide Y analogs, biological studies 15757-14-9D, complexes with neuropeptide Y analogs, biological studies 934183-15-0D, labeled RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses) (neuropeptide Y analogs for treating and diagnosing Y receptor-expressing breast cancer) 14133-76-7 ZCAPLUS Technetium, isotope of mass 99 (CA INDEX NAME) 99Tc 14265-75-9 ZCAPLUS Lutetium, isotope of mass 177 (CA INDEX NAME)

 177_{Lu}

RN 15750-15-9 ZCAPLUS

CN Indium, isotope of mass 111 (CA INDEX NAME)

111_{In}

RN 15757-14-9 ZCAPLUS

CN Gallium, isotope of mass 68 (CA INDEX NAME)

68_{Ga}

RN 934183-15-0 ZCAPLUS

CN L-Tyrosinamide, N2-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginyl-L-histidyl-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-(1S,2S,3S)-2-amino-3-(methoxycarbonyl)cyclopropanecarbonyl-L-arginyl-(1S,2S,3S)-2-amino-3-(methoxycarbonyl)cyclopropanecarbonyl-L-arginyl- (CA INDEX NAME)

PAGE 1-C

PAGE 1-C

IT 934350-88-6
 RL: DGN (Diagnostic use); PKT (Pharmacokinetics); BIOL (Biological study);
 USES (Uses)
 (neuropeptide Y analogs for treating and diagnosing Y
 receptor-expressing breast cancer)
RN 934350-88-6 ZCAPLUS
CN Lutetium-177Lu, [N-[2-[4,7,10-tris[(carboxy-κ0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl-κ0]glycyl-L-arginyl-L-histidyl-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-L-threonyl-L-arginyl-2-aminocyclohexanecarbonyl-L-arginyl-L-tyrosinamidato(3-)]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

PAGE 3-A

PAGE 3-B

L79 ANSWER 3 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:1274397 ZCAPLUS Full-text

DOCUMENT NUMBER: 147:183765

TITLE: Evaluation of a new biotin-DOTA conjugate for

pretargeted antibody-guided radioimmunotherapy

(PAGRIT)

AUTHOR(S): Urbano, Nicoletta; Papi, Stefano; Ginanneschi, Mauro;

Santis, Rita; Pace, Silvia; Lindstedt, Ragnar; Ferrari, Liliana; Choi, SunJu; Paganelli, Giovanni;

Chinol, Marco

CORPORATE SOURCE: Division of Nuclear Medicine, European Institute of

Oncology, Milan, 20141, Italy

SOURCE: European Journal of Nuclear Medicine and Molecular

Imaging (2007), 34(1), 68-77
CODEN: EJNMA6; ISSN: 1619-7070

PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

Purpose: A novel biotin-DOTA conjugate (r-BHD: reduced biotinamidohexylamine-AΒ DOTA) was investigated in order to provide an efficient pretargeted antibodyguided radioimmunotherapy (PAGRIT) application. Preclin. and clin. results are described. Methods: 90Y and 177Lu were used to label r-BHD. The effect of pH and a wide range of specific activities were studied. Radiolabeled r-BHD was tested for affinity towards avidin and for stability in saline or in human serum with and without ascorbic acid. Pharmacokinetic data were collected and organ biodistribution evaluated in a tumor-bearing pretargeted animal model. A pilot study was performed in a metastatic melanoma patient and dosimetry was estimated Results: High radiochem. purity (>99%) was routinely achieved with 90Y or 177Lu in sodium acetate buffer (1.0 M, pH 5.0) at a specific activity of 2.6 MBq/nmol. Both 90Y- and 177Lu-r-BHD were also prepared at higher specific activities. Radiolabeled r-BHD was stable up to 96 h in human serum and saline with the addition of ascorbic acid. The structural modifications proposed for the r-BHD stabilized it against enzymic degradation while retaining high binding affinity for avidin. Renal clearance appeared to be the main route of excretion in animals, and high tumor uptake was observed in the pretargeted animals. The patient study showed a total body clearance of .apprx.85% in 24 h, with a kidney absorbed dose of 1.5 mGy/MBq. Tumor uptake was rapid and the calculated dose to a 10-mm tumor lesion was .apprx.12 mGy/MBq. Conclusion: These results indicate that the new biotin-DOTA conjugate may be a suitable candidate for pretargeting trials.

CC 8-9 (Radiation Biochemistry)

IT 58-85-5D, DOTA conjugates, Lu-177 complexes 14265-75-9D, 177Lu, complexes with DOTA-biotin, biological studies 60239-18-1D, DOTA, biotin

conjugates, Lu-177 complexes 586962-90-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(evaluation of new biotin-DOTA conjugate for pretargeted

antibody-guided radioimmunotherapy)

IT 586962-90-5

 ${\tt RL:}$ PAC (Pharmacological activity); THU (Therapeutic use); ${\tt BIOL}$

(Biological study); USES (Uses)

(evaluation of new biotin-DOTA conjugate for pretargeted


antibody-guided radioimmunotherapy)

RN 586962-90-5 ZCAPLUS

CN Yttrium-90Y, [10-[2-[[6-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]imidazol-4-(hexahydro-2-oxo-1H-thieno[4,4-d]

yl)pentyl]amino]hexyl]amino]-2-(oxo- κ O)ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)- κ N1, κ N4, κ N7,.

kappa.N10, κ 01, κ 04, κ 07]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L79 ANSWER 4 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:734439 ZCAPLUS Full-text

DOCUMENT NUMBER: 145:195598

TITLE: Compounds having RD targeting motifs

INVENTOR(S): Achilefu, Samuel

PATENT ASSIGNEE(S): Washington University, USA SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.					D	DATE			APPL	ICAT	DATE					
					_											
WO 2006078914				A1 20060727				•	WO 2	006-		20060120				
W	AE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KN,	KP,	KR,
	KΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,
	MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,
	SG,	SK,	SL,	SM,	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,
	VN,	YU,	ZA,	ZM,	ZW											

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2005-645816P P 20050121

OTHER SOURCE(S):

MARPAT 145:195598

- AB The present invention provides compds. that have motifs that target the compds. to cells that express integrins. In particular, the compds. have peptides with one or more RD motifs conjugated to an agent selected from an imaging agent and a targeting agent. The compds. may be used to detect, monitor and treat a variety of disorders mediated by integrins.
- CC 63-5 (Pharmaceuticals)
- 91037-65-9D, conjugates with cypate and glucosamine 111119-28-9D, DTPA ΤТ 111844-19-0D, conjugates with cypate and octreotate conjugates 317809-26-0, Cypate 317809-26-0D, Cypate, conjugates with peptides 901439-51-8D, DTPA conjugates 901442-07-7D, conjugates with cypate and 901442-87-3 glucosamine 901442-72-6 901442-80-6 901442-94-2 901443-47-8D, conjugates with peptides 901443-01-4 901443-47-8 901443-61-6 901443-68-3 901443-74-1 901443-82-1 901443-89-8 901443-96-7 901444-04-0 901444-12-0 901444-20-0D, DTPA conjugates 901444-27-7D, DTPA conjugates 901444-34-6D, DTPA conjugates 901444-41-5D, DTPA conjugates 901444-63-1 901444-71-1 901445-41-8 901444-86-8 901445-34-9 901444-79-9 901445-48-5 RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(diagnostic and therapeutic peptide conjugates targeted to integrin-pos. cells)

IT 901444-63-1 901444-71-1

RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

RN 901444-63-1 ZCAPLUS

CN L-Lysine, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginylglycyl-L- α -aspartyl-L-seryl-L-prolyl- (9CI) (CA INDEX NAME)

PAGE 1-B

RN 901444-71-1 ZCAPLUS

CN L-Lysinamide, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginylglycyl-L- α -aspartyl-L-seryl-L-prolyl-N6-[3-[2-[7-[3-(2-carboxyethyl)-1,3-dihydro-1,1-dimethyl-2H-benz[e]indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-1H-benz[e]indolio]-1-oxopropyl]-, bromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

● Br-

PAGE 2-B

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L79 ANSWER 5 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:625378 ZCAPLUS Full-text

DOCUMENT NUMBER: 145:243952

TITLE: Magnetic resonance imaging of tumox cells by

targeting the amino acid transport system

AUTHOR(S): Lattuada, Luciano; Demattio, Silvia; Vincenzi,

Veronica; Cabella, Claudia; Visigalli, Massimo; Aime, Silvio; Crich, Simonetta Geninatti; Gianolio, Eliana CRM Chemistry, Bracco Imaging SpA, Milan, 20134, Italy

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006),

16(15), 4111-4114

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:243952

- AB An early diagnosis of cancer is crucial in the battle against this disease and the in vivo visualization of tumors at cellular level is still the most challenging goal. In order to target tumor cells, we took into account their increased metabolism and amino acid nutrients or pseudo-nutrients, which are actively transported through the cell membrane, have been chosen as vectors for new MRI contrast agents. For this reason new gadolinium complexes conjugated to agmatine, arginine, and glutamine have been synthesized and studied.
- CC 8-9 (Radiation Biochemistry)
- ST MRI tumor aminoacid transport prepn gadolinium complex conjugate; agmatine arginine glutamine conjugate gadolinium MRI contrast agent
- IT Neoplasm

CORPORATE SOURCE:

(MRI of tumor by targeting amino acid transport: preparation of gadolinium complexes conjugated to agmatine, arginine, and glutamine)

IT Imaging agents

(NMR contrast; MRI of tumor by targeting amino acid transport: preparation of gadolinium complexes conjugated to agmatine, arginine, and glutamine)

IT Imaging

(NMR; MRI of tumor by targeting amino acid transport: preparation

ΙT

ΙT

ΙT

RN

of gadolinium complexes conjugated to agmatine, arginine, and glutamine)

IT Imaging

(tumor; MRI of tumor by targeting amino acid transport: preparation of gadolinium complexes conjugated to agmatine, arginine, and glutamine)

IT 906078-01-1P 906078-02-2P 906078-03-3P 906078-04-4P 906078-05-5P 906078-06-6P 906078-07-7P

RL: DGN (Diagnostic use); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MRI of tumor by targeting amino acid transport: preparation of gadolinium complexes conjugated to agmatine, arginine, and glutamine) 79-04-9, Chloroacetylchloride 6066-82-6, N-Hydroxysuccinimide 41444-88-6 115608-61-2 128009-23-4 174267-75-5 585531-74-4 805233-27-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(MRI of tumor by targeting amino acid transport: preparation of gadolinium complexes conjugated to agmatine, arginine, and glutamine) 905985-29-7P 905985-30-0P 905985-31-1P 905985-32-2P 905985-34-4P

905985-29-7P 905985-30-0P 905985-31-1P 905985-32-2P 905985-34-4P 905985-35-5P 905985-36-6P 905985-37-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(MRI of tumor by targeting amino acid transport: preparation of gadolinium complexes conjugated to agmatine, arginine, and glutamine) 906078-01-1P 906078-02-2P 906078-03-3P

906078-04-4P 906078-05-5P 906078-06-6P 906078-07-7P

RL: DGN (Diagnostic use); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MRI of tumor by targeting amino acid transport: preparation of gadolinium complexes conjugated to agmatine, arginine, and glutamine) 906078-01-1 ZCAPLUS

CN Gadolinate(3-), [N,N-bis[2-[bis[(carboxy- κ 0)methyl]amino- κ N]ethyl]-L- γ -glutamyl- κ N, κ 01-L-glutaminato(6-)]-, trisodium (9CI) (CA INDEX NAME)

PAGE 1-A

O

O

O

O

O

CH2-CH2-C-NH-CH-CH2-CH2

CO2-

PAGE 1-B

PAGE 1-A

●3 Na+


RN 906078-02-2 ZCAPLUS

CN Gadolinate(2-), [1-amino-12-[2-[bis[(carboxy- κ O)methyl]amino- κ N]ethyl]-11-(carboxy- κ O)-15-[(carboxy- κ O)methyl]-1-imino-8-oxo-2,7,12,15-tetraazaheptadecan-17-oato(5-)- κ N12, κ N15, κ O17]-, disodium (9CI) (CA INDEX NAME)

-3+Gd O-CH2-CH2-C-NH-(CH2)4-NH-C-NH ●2 Na+

RN 906078-03-3 ZCAPLUS


CN Gadolinate(3-), [N,N-bis[2-[bis[(carboxy- κ 0)methyl]amino- κ N]ethyl]-L- γ -glutamyl- κ N, κ 01-L-argininato(6-)]-, trisodium (9CI) (CA INDEX NAME)



●3 Na+

RN 906078-04-4 ZCAPLUS

CN Gadolinate(3-), [N,N-bis[2-[bis[(carboxy- κ 0)methyl]amino- κ N]ethyl]-L-glutamato(6-)- κ N2, κ 01]-, trisodium (9CI) (CA INDEX NAME)



PAGE 2-A

●3 Na+

RN 906078-05-5 ZCAPLUS

CN Gadolinate(1-), $[10-[2-[(4-amino-1-carboxy-4-oxobutyl)amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(4-)- <math>\kappa$ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]-, hydrogen (9CI) (CA INDEX NAME)

● H+

RN 906078-06-6 ZCAPLUS
CN Gadolinium, [10-[2-[[4-[(aminoiminomethyl)amino]butyl]amino]-2-oxoethyl]1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(7-)KN1,KN4,KN7,KN10,KO1,KO4,KO7](9CI) (CA INDEX NAME)

RN 906078-07-7 ZCAPLUS
CN Gadolinate(1-), [10-[2-[[4-[(aminoiminomethyl)amino]-1-carboxybutyl]amino]2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(4-)κN1,κN4,κN7,κN10,κΟ1,κΟ4,κΟ7]-,
hydrogen (9CI) (CA INDEX NAME)

● H +

IT 905985-35-5P 905985-37-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(MRI of tumor by targeting amino acid transport: preparation of gadolinium complexes conjugated to agmatine, arginine, and glutamine)

RN 905985-35-5 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[4-[(aminoiminomethyl)amino]butyl]amino]-2-oxoethyl]- (CA INDEX NAME)

RN 905985-37-7 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[(1S)-4-[(aminoiminomethyl)amino]-1-carboxybutyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L79 ANSWER 6 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2005:1289862 ZCAPLUS Full-text

DOCUMENT NUMBER: 144:31701

TITLE: Preparation of metal complexes of trimeric

DOTA-macrocyclic substituted aminoisophthalate

trihalophenyl derivatives

INVENTOR(S): Harto, Juan R.; Martin, Jose L.; Platzek, Johannes;

Schirmer, Heiko; Weinmann, Hanns-Joachim; Carretero,

Jose

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

TENT	NO.																
2005	 1159	97		A1											0050	422	
W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
	CN,	CO,	CR,	CU,	CZ,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,	GE,	
	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KP,	KR,	KΖ,	LC,	
	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NΙ,	
	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	
	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	
	ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	
	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IS,	ΙT,	LT,	LU,	MC,	NL,	PL,	PT,	
	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	$\mathrm{ML}_{m{\prime}}$	
	MR,	NE,	SN,	TD,	ΤG												
E 102004026103				A1 20051222					DE 2	004-	1020	6103					
EP 1748992				A1		2007	0207		EP 2	005-	7410		20050422				
R:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	
IS, IT, LI,																	
2008	5002	93		Τ		2008	0110		JP 2007-513721						20050422		
US 2006120965						2006	0608		US 2005-274895						20051116		
US 2006120965									DE 2	004-	1020	0402	6103.	A 2	0040	525	
									US 2	004-	5754	17P		P 2	0040	601	
EE, ES, FI, RO, SE, SI, MR, NE, SN, DE 102004026103 EP 1748992 R: AT, BE, BG, IS, IT, LI, JP 2008500293									WO 2	005-	EP44	93	•	W 2	0050	422	
									US 2	005-	1356		A1 20050524				
	2005 W: RW: 1020 1748 R: 2008 2006	20051159 W: AE, CN, GH, LK, NO, SY, RW: BW, AZ, EE, RO, MR, 10200402 1748992 R: AT, IS, 20085002 20061209	2005115997 W: AE, AG, CN, CO, GH, GM, LK, LR, NO, NZ, SY, TJ, RW: BW, GH, AZ, BY, EE, ES, RO, SE, MR, NE, 102004026103 1748992 R: AT, BE, IS, IT, 2008500293 2006120965	2005115997 W: AE, AG, AL, CN, CO, CR, GH, GM, HR, LK, LR, LS, NO, NZ, OM, SY, TJ, TM, RW: BW, GH, GM, AZ, BY, KG, EE, ES, FI, RO, SE, SI, MR, NE, SN, 102004026103 1748992 R: AT, BE, BG, IS, IT, LI, 2008500293 2006120965	2005115997 A1 W: AE, AG, AL, AM, CN, CO, CR, CU, GH, GM, HR, HU, LK, LR, LS, LT, NO, NZ, OM, PG, SY, TJ, TM, TN, RW: BW, GH, GM, KE, AZ, BY, KG, KZ, EE, ES, FI, FR, RO, SE, SI, SK, MR, NE, SN, TD, 102004026103 A1 1748992 A1 R: AT, BE, BG, CH, IS, IT, LI, LT, 2008500293 T 2006120965 A1	2005115997 A1 W: AE, AG, AL, AM, AT, CN, CO, CR, CU, CZ, GH, GM, HR, HU, ID, LK, LR, LS, LT, LU, NO, NZ, OM, PG, PH, SY, TJ, TM, TN, TR, RW: BW, GH, GM, KE, LS, AZ, BY, KG, KZ, MD, EE, ES, FI, FR, GB, RO, SE, SI, SK, TR, MR, NE, SN, TD, TG 102004026103 A1 1748992 A1 R: AT, BE, BG, CH, CY, IS, IT, LI, LT, LU, 2008500293 T 2006120965 A1	2005115997 A1 2005 W: AE, AG, AL, AM, AT, AU, CN, CO, CR, CU, CZ, DK, GH, GM, HR, HU, ID, IL, LK, LR, LS, LT, LU, LV, NO, NZ, OM, PG, PH, PL, SY, TJ, TM, TN, TR, TT, RW: BW, GH, GM, KE, LS, MW, AZ, BY, KG, KZ, MD, RU, EE, ES, FI, FR, GB, GR, RO, SE, SI, SK, TR, BF, MR, NE, SN, TD, TG 102004026103 A1 2005 1748992 A1 2007 R: AT, BE, BG, CH, CY, CZ, IS, IT, LI, LT, LU, MC, 2008500293 T 2008 2006120965 A1 2006	2005115997 A1 20051208 W: AE, AG, AL, AM, AT, AU, AZ, CN, CO, CR, CU, CZ, DK, DM, GH, GM, HR, HU, ID, IL, IN, LK, LR, LS, LT, LU, LV, MA, NO, NZ, OM, PG, PH, PL, PT, SY, TJ, TM, TN, TR, TT, TZ, RW: BW, GH, GM, KE, LS, MW, MZ, AZ, BY, KG, KZ, MD, RU, TJ, EE, ES, FI, FR, GB, GR, HU, RO, SE, SI, SK, TR, BF, BJ, MR, NE, SN, TD, TG 102004026103 A1 20051222 R: AT, BE, BG, CH, CY, CZ, DE, IS, IT, LI, LT, LU, MC, NL, 2008500293 T 20080110	2005115997 A1 20051208 W: AE, AG, AL, AM, AT, AU, AZ, BA,	2005115997 A1 20051208 W0 2 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB,	2005115997 A1 20051208 W0 2005- W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, MR, NE, SN, TD, TG 102004026103 A1 20051222 DE 2004- R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, 2008500293 T 20080110 JP 2007- 2006120965 A1 20060608 US 2005- Y APPLN. INFO:: DE 2004- WO 2005-	2005115997 A1 20051208 WO 2005-EP44 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR,	2005115997 A1 20051208 W0 2005-EP4493 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, MR, NE, SN, TD, TG 102004026103 A1 20051222 DE 2004-10200402 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, 2008500293 T 20080110 JP 2007-513721 2006120965 A1 20060608 US 2005-274895 Y APPLN. INFO:: DE 2004-10200402 US 2004-575417P WO 2005-EP4493	2005115997 A1 20051208 WO 2005-EP4493 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, MR, NE, SN, TD, TG 102004026103 A1 20051222 DE 2004-102004026103 1748992 A1 20070207 EP 2005-741025 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, 2008500293 T 20080110 JP 2007-513721 2006120965 A1 20060608 US 2005-274895 Y APPLN. INFO:: DE 2004-102004026103 US 2004-575417P WO 2005-EP4493	2005115997 A1 20051208 W0 2005-EP4493 2 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, MR, NE, SN, TD, TG 102004026103 A1 20051222 DE 2004-102004026103 2 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR 2008500293 T 20080110 JP 2007-513721 2 2006120965 A1 20060608 US 2005-274895 2 Y APPLN. INFO.: DE 2004-102004026103A 2 US 2004-575417P P 2 WO 2005-EP4493 W 2	2005115997 A1 20051208 W0 2005-EP4493 20050 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, MR, NE, SN, TD, TG 102004026103 A1 20051222 DE 2004-102004026103 20040 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR 2008500293 T 20080110 JP 2007-513721 20050 Y APPLN. INFO:: DE 2004-102004026103A 20040 US 2005-274895 20051 Y APPLN. INFO:: DE 2004-102004026103A 20040	2005115997 A1 20051208 W0 2005-EP4493 20050422 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG 102004026103 A1 20051222 DE 2004-102004026103 20040525 1748992 A1 20070207 EP 2005-741025 20050422 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR 2008500293 T 20080110 JP 2007-513721 20050422 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR 2008500293 T 20080110 JP 2007-513721 20050422 R: APPLN. INFO:: DE 2004-102004026103A 20040525 US 2004-575417P P 20040601 WO 2005-EP4493 W 20050422

OTHER SOURCE(S): MARPAT 144:31701

GΙ

- AB The preparation is described for metal complexes of trihalobenzene functionalized with three DOTA-like chelating groups (I), where X = bromo or iodo. These complexes are suitable as contrast agents. Thus, the ligand I (X = iodo) was prepared in a multistep procedure and was used to prepare Gd, Dy, Yb and Y complexes.
- IC ICM C07D257-02
 - ICS A61K049-04; A61K051-04; A61K049-08; C07K005-023; C07K005-02
- CC 78-7 (Inorganic Chemicals and Reactions) Section cross-reference(s): 8, 28
- TT 7429-91-6P, Dysprosium, preparation 7439-89-6P, Iron, preparation 7439-96-5P, Manganese, preparation 7440-53-1P, Europium, preparation 7440-54-2P, Gadolinium, preparation 870475-42-6P 870475-43-7P 870475-44-8P 870475-45-9P 870475-48-2DP, metal complexes RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (preparation of metal complexes with trihalobenzene functionalized with three DOTA-like chelating groups for use as contrast agents)
- IT 870475-45-9P
 - RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (preparation of metal complexes with trihalobenzene functionalized with three DOTA-like chelating groups for use as contrast agents)
- RN 870475-45-9 ZCAPLUS
- CN Yttrium, $[\mu 3-[[10,10'-[[2,4,6-triiodo-5-[methyl[[[1-(oxo-κ0)-2-[4,7,10-tris[(carboxy-κ0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]propyl]amino]acetyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino[1-methyl-2-(oxo-κ0)-2,1-ethanediyl]]]bis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato-κN1,κN4,κN7,κN10,κ01,κ04,κ07]](9-)]tri-(9CI) (CA INDEX NAME)$

PAGE 1-A

PAGE 1-B

PAGE 2-A

0==

PAGE 2-B

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L79 ANSWER 7 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2005:1220695 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 143:471966

TITLE: Macrocycle-substituted trimer halogen-benzene

derivatives

INVENTOR(S): Harto, Juan R.; Martin, Jose L.; Platzek, Johannes;

Schirmer, Heiko; Weinmann, Hanns-Joachim; Carretero,

Jose

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA:	CENT :	NO.			KIND DATE					ICAT			D.					
WO	2005	1083	 79	A1 20051117								2						
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	GE,	
		GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KP,	KR,	KΖ,	LC,	
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,	
		NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	
		SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	
		AΖ,	BY,	KG,	KΖ,	MD,	RU,	ΤJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	IT,	LT,	LU,	MC,	NL,	PL,	PT,	
		RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	
		MR,	ΝE,	SN,	TD,	ΤG												
DE	DE 102004023093				В3		2006	0302		DE 2	004-	1020	3093	20040505				
EP	EP 1742926				A1		2007	0117		EP 2	005-	7428		20050419				
EP	1742	926			В1		2007	8080										
	R:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	
		IS,	ΙT,	LI,	LT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR			
ΑT	AT 369347					T 20070815				AT 2	005-	7428		20050419				
JP	JP 2007536295					Γ 20071213								20050419				
ES	2289	711			Т3		2008	0201		ES 2	005-	7428		20050419				

```
US 2006154989 A1 20060713 US 2005-272008 20051114
PRIORITY APPLN. INFO.:

DE 2004-102004023093A 20040505
US 2004-574713P P 20040527
WO 2005-EP4319 W 20050419
US 2005-122248 A1 20050505
OTHER SOURCE(S):

MARPAT 143:471966
GI
```

- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- The invention relates to rare earth, Fe and Mn complexes of I (X = Br or I' Al = CONR1(CH2)nNR2(COCHZ1NH)mCOCHZ2K, A2 = NR1COCHZ2K (R1 and R1 = H, C1-2 alkyl group of monohydroxy C1-2 alkyl group; Z1 and Z2 = H or Me; n = 2-4; m = 0-1; K = 1,4,7,11-tetraazacyclotetradecane-1,4,7-triacetic acid group)) and said complexes are suitable as contrast agents. For example, II (H3L) was prepared in a multi step process starting from 2,4,6-triiodo-5- (methylamino)isophthaloyl dichloride and ethylenediamine, with subsequent reaction with 2-bromopropanoyl bromide, 1,4,7-tris(benzylcarbonyl)-1,4,7,11-tetraazacyclotetradecane with deprotection and reaction with chloroacetic acid. GdL in 58 % yield was prepared from II and Gd2O3.
- IC ICM C07D257-02 ICS A61K051-04; A61K049-08
- CC 78-7 (Inorganic Chemicals and Reactions) Section cross-reference(s): 9, 28, 77
- TT 7429-91-6DP, Dysprosium, complexes with tetraazacyclotetradecanetriacetic acid, isophthalic acid amide derivs. 7439-89-6DP, Iron, complexes with tetraazacyclotetradecanetriacetic acid, isophthalic acid amide derivs. 7439-96-5DP, Manganese, complexes with tetraazacyclotetradecanetriacetic acid, isophthalic acid amide derivs. 7440-53-1DP, Europium, complexes with tetraazacyclotetradecanetriacetic acid, isophthalic acid amide derivs. 7440-54-2DP, Gadolinium, complexes with tetraazacyclotetradecanetriacetic acid, isophthalic acid amide derivs. 869339-24-2P 869339-25-3P 869339-26-4P 869339-28-6P 869339-51-5DP, isophthalic acid amide derivs., transition metal complexes RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (USES)

(preparation as contrast agents)

IT 869339-26-4P

RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as contrast agents)

RN 869339-26-4 ZCAPLUS

CN Yttrium, $[\mu 3-[[10,10'-[[2,4,6-triiodo-5-[methyl[1-(oxo-κ0)-2-[4,7,10-tris[(carboxy-κ0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]propyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino[1-methyl-2-(oxo-κ0)-2,1-ethanediyl]]]bis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato-κN1,κN4,κN7,κN10,κO1,κO4,κO7]](9-)]tri-(9CI) (CA INDEX NAME)$

PAGE 1-A

PAGE 1-B

PAGE 2-A

O==

PAGE 2-B

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L79 ANSWER 8 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2004:799481 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 141:320007

TITLE: Radiopharmaceuticals for cancer diagnosis and

treatment

INVENTOR(S): Merlo, Adrian; Maecke, Helmut; Reubi, Jean-Claude;

Good, Stephan

PATENT ASSIGNEE(S): Kantonsspital Basel, Switz.; Universitaet Bern

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. K						KIND DATE				APPL	ICAT	DATE							
	2004 2004				A2 A3		20040930 20050106			WO 2	004-		20040318						
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,		
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,		
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,		
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NΙ,		
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,		
		ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW		
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑM,	ΑZ,		
		BY,	KG,	KΖ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,		
		ES,	FI,	FR,	GB,	GR,	HU,	IE,	ΙΤ,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,		
		SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	$\mathrm{ML}_{{}_{\!{}^{\prime}}}$	MR,	NE,	SN,		
		TD,	ΤG																
ΕP	P 1459769				A1		2004	0922		EP 2003-6061					20030319				
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,		
		ΙE,	SI,	LT,	LV,	FΙ,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK			
ΑU	2004	2225	31		A1		2004	0930		AU 2	004-		2	0040	318				
CA	CA 2519315				A1	A1 20040930				CA 2	004-		20040318						
EΡ	1603598				A2		20051214			EP 2004-721547						20040318			
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	NL,	SE,	MC,	PT,		
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	PL,	SK		

```
JP 2007527366
                         Τ
                               20070927
                                           JP 2006-505475
                                                                  20040318
    US 2007053837
                        A1
                               20070308
                                           US 2005-549665
                                                                  20050919
PRIORITY APPLN. INFO.:
                                           EP 2003-6061
                                                               A 20030319
                                           WO 2004-EP50329
                                                              W 20040318
                       MARPAT 141:320007
OTHER SOURCE(S):
AΒ
     The invention relates to radiopharmaceutical carriers consisting of a
     radiolabeled substance P analog conjugated to a chelating agent such as
     DOTAGA, DOTASA or DOTA, which are useful for targeting and treatment of brain
     tumors, especially gliomas.
IC
    ICM A61K051-00
CC
    63-5 (Pharmaceuticals)
    Section cross-reference(s): 8
    10098-91-6D, Yttrium 90, substance P-conjugated complexes,
ΙT
    biological studies 13967-64-10, Dysprosium 165, substance
    P-conjugated complexes, biological studies 13967-65-20, Holmium
    166, substance P-conjugated complexes, biological studies
    13981-25-4D, Copper 64, substance P-conjugated complexes,
    biological studies 14119-08-5D, Gallium 66, substance
    P-conjugated complexes, biological studies 14119-09-6D, Gallium
    67, substance P-conjugated complexes, biological studies
    14191-64-1D, Praseodymium 142, substance P-conjugated complexes,
    biological studies 14265-75-9D, Lutetium 177, substance
    P-conjugated complexes, biological studies 14265-85-1D, Actinium
    225, substance P-conjugated complexes, biological studies
    14687-25-3D, Lead 203, substance P-conjugated complexes,
    biological studies 14809-53-1D, Yttrium 86, substance
    P-conjugated complexes, biological studies 14834-85-60,
    Dysprosium 162, substance P-conjugated complexes, biological studies
    14885-78-00, Indium 113, substance P-conjugated complexes,
    biological studies 14913-49-6D, Bismuth 212, substance
    P-conjugated complexes, biological studies 14981-79-4D,
    Praseodymium 143, substance P-conjugated complexes, biological studies
    15065-93-7D, Terbium 149, substance P-conjugated complexes,
    biological studies 15750-15-9D, Indium 111, substance
    P-conjugated complexes, biological studies 15757-14-9D, Gallium
    68, substance P-conjugated complexes, biological studies
    15757-86-5D, Copper 67, substance P-conjugated complexes,
    biological studies 15765-31-8D, Promethium 149, substance
    P-conjugated complexes, biological studies 15776-20-2D, Bismuth
    213, substance P-conjugated complexes, biological studies
                                                                33507-63-0D,
    Substance P, conjugates of radionuclide complexes 36849-05-5D,
    Dysprosium 167, substance P-conjugated complexes, biological studies
    77128-75-7D, conjugates of radionuclide complexes 110880-55-2D,
    conjugates of radionuclide complexes 110880-57-4D, conjugates of
    radionuclide complexes 766529-14-0D, conjugates of radionuclide
    complexes 766529-15-1D, conjugates of radionuclide complexes
    766529-16-2D, conjugates of radionuclide complexes 766529-18-4D,
    conjugates of radionuclide complexes 766529-19-5D, conjugates of
    radionuclide complexes
                            766529-20-8D, conjugates of radionuclide
    complexes
               766529-22-0D, conjugates of radionuclide complexes
    766529-24-2D, conjugates of radionuclide complexes
                                                        766529-25-3D,
    conjugates of radionuclide complexes 766529-28-6D, conjugates of
    radionuclide complexes 766529-29-7D, conjugates of radionuclide
    complexes
    RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study);
    USES (Uses)
        (radiolabeled substance P conjugates for cancer diagnosis and
       treatment)
ΙT
    767340-53-4P
```

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

```
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (radiolabeled substance P conjugates for cancer diagnosis and
        treatment)
     766529-30-0P 766529-31-1P 766529-32-2P
ΙT
     766529-33-3P 766529-34-4P 766529-35-5P
     766529-36-6P 766529-37-7P 766529-38-8P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (radiolabeled substance P conjugates for cancer diagnosis and
        treatment)
     767340-54-5P 767340-55-6P 767340-56-7P
ΙT
     767340-57-8P 767340-58-9P 767340-59-0P
     767340-60-3P 767340-61-4P 767340-62-5P
     RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
        (radiolabeled substance P conjugates for cancer diagnosis and
        treatment)
     10098-91-6D, Yttrium 90, substance P-conjugated complexes,
ΙT
     biological studies 13967-64-1D, Dysprosium 165, substance
     P-conjugated complexes, biological studies 13967-65-2D, Holmium
     166, substance P-conjugated complexes, biological studies
     13981-25-4D, Copper 64, substance P-conjugated complexes,
     biological studies 14119-08-5D, Gallium 66, substance
     P-conjugated complexes, biological studies 14119-09-6D, Gallium
     67, substance P-conjugated complexes, biological studies
     14191-64-1D, Praseodymium 142, substance P-conjugated complexes,
     biological studies 14265-75-9D, Lutetium 177, substance
     P-conjugated complexes, biological studies 14265-85-1D, Actinium
     225, substance P-conjugated complexes, biological studies
     14687-25-3D, Lead 203, substance P-conjugated complexes,
     biological studies 14809-53-1D, Yttrium 86, substance
     P-conjugated complexes, biological studies 14834-85-6D,
     Dysprosium 162, substance P-conjugated complexes, biological studies
     14885-78-0D, Indium 113, substance P-conjugated complexes,
     biological studies 14913-49-6D, Bismuth 212, substance
     P-conjugated complexes, biological studies 14981-79-40,
     Praseodymium 143, substance P-conjugated complexes, biological studies
     15065-93-7D, Terbium 149, substance P-conjugated complexes,
     biological studies 15750-15-9D, Indium 111, substance
     P-conjugated complexes, biological studies 15757-14-9D, Gallium
     68, substance P-conjugated complexes, biological studies
     15757-86-5D, Copper 67, substance P-conjugated complexes,
     biological studies 15765-31-8D, Promethium 149, substance
     P-conjugated complexes, biological studies 15776-20-20, Bismuth
     213, substance P-conjugated complexes, biological studies
     36849-05-5D, Dysprosium 167, substance P-conjugated complexes,
     biological studies
     RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study);
        (radiolabeled substance P conjugates for cancer diagnosis and
        treatment)
RN
     10098-91-6 ZCAPLUS
CN
     Yttrium, isotope of mass 90 (CA INDEX NAME)
```

90_Y

```
RN
     13967-64-1 ZCAPLUS
CN
     Dysprosium, isotope of mass 165 (CA INDEX NAME)
165<sub>Dy</sub>
     13967-65-2 ZCAPLUS
RN
CN
     Holmium, isotope of mass 166 (CA INDEX NAME)
166<sub>HO</sub>
RN
     13981-25-4 ZCAPLUS
CN
     Copper, isotope of mass 64 (CA INDEX NAME)
64cu
     14119-08-5 ZCAPLUS
RN
     Gallium, isotope of mass 66 (CA INDEX NAME)
CN
66Ga
RN
    14119-09-6 ZCAPLUS
CN
     Gallium, isotope of mass 67 (CA INDEX NAME)
67<sub>Ga</sub>
     14191-64-1 ZCAPLUS
RN
CN
     Praseodymium, isotope of mass 142 (CA INDEX NAME)
142<sub>Pr</sub>
RN
    14265-75-9 ZCAPLUS
     Lutetium, isotope of mass 177 (CA INDEX NAME)
CN
```

```
177_{\mathrm{Lu}}
```

212_{Bi}

```
14265-85-1 ZCAPLUS
RN
    Actinium, isotope of mass 225 (CA INDEX NAME)
CN
225Ac
   14687-25-3 ZCAPLUS
RN
CN
    Lead, isotope of mass 203 (CA INDEX NAME)
203<sub>Pb</sub>
    14809-53-1 ZCAPLUS
RN
CN Yttrium, isotope of mass 86 (CA INDEX NAME)
 86Y
     14834-85-6 ZCAPLUS
RN
CN
     Dysprosium, isotope of mass 162 (CA INDEX NAME)
162<sub>Dy</sub>
RN
   14885-78-0 ZCAPLUS
CN
     Indium, isotope of mass 113 (CA INDEX NAME)
113<sub>In</sub>
     14913-49-6 ZCAPLUS
RN
CN
     Bismuth, isotope of mass 212 (CA INDEX NAME)
```

```
RN
     14981-79-4 ZCAPLUS
CN
   Praseodymium, isotope of mass 143 (CA INDEX NAME)
143_{
m Pr}
     15065-93-7 ZCAPLUS
RN
     Terbium, isotope of mass 149 (CA INDEX NAME)
CN
149\,\mathrm{Tb}
    15750-15-9 ZCAPLUS
RN
     Indium, isotope of mass 111 (CA INDEX NAME)
111<sub>In</sub>
    15757-14-9 ZCAPLUS
RN
     Gallium, isotope of mass 68 (CA INDEX NAME)
 68<sub>Ga</sub>
RN
    15757-86-5 ZCAPLUS
     Copper, isotope of mass 67 (CA INDEX NAME)
 67<sub>Cu</sub>
     15765-31-8 ZCAPLUS
RN
CN
     Promethium, isotope of mass 149 (CA INDEX NAME)
149<sub>Pm</sub>
RN
     15776-20-2 ZCAPLUS
CN
     Bismuth, isotope of mass 213 (CA INDEX NAME)
```

213_{Bi}

RN 36849-05-5 ZCAPLUS

CN Dysprosium, isotope of mass 167 (CA INDEX NAME)

167_{Dy}


IT 767340-53-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(radiolabeled substance P conjugates for cancer diagnosis and treatment)

RN 767340-53-4 ZCAPLUS

CN Indate(1-)-111In, [N2-[4-(carboxy- κ O)-1-oxo-4-[4,7,10-tris[(carboxy- κ O)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]butyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl-L-methioninamidato(4-)]- (9CI) (CA INDEX NAME)



PAGE 1-B

PAGE 2-A

PAGE 2-B

766529-31-1P 766529-32-2P 766529-33-3P ΙT 766529-34-4P 766529-35-5P 766529-36-6P

766529-37-7P 766529-38-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(radiolabeled substance P conjugates for cancer diagnosis and

treatment)

RN 766529-31-1 ZCAPLUS

CN Substance P, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-11-[(2S)-2-amino-4-(methylsulfonyl)butanamide]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

RN 766529-32-2 ZCAPLUS

CN L-Methioninamide, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-phenylalanyl-L-phenylalanyl-N-methylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-B

RN 766529-33-3 ZCAPLUS

CN L-Methioninamide, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-phenylalanyl-3-(2-thienyl)-L-alanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

RN 766529-34-4 ZCAPLUS

CN L-Methioninamide, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-3-(2-thienyl)-L-alanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

RN 766529-35-5 ZCAPLUS

CN Substance P, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-9-(N-methylglycine)-11-[(2S)-2-amino-4-(methylsulfonyl)butanamide]- (9CI) (CA INDEX NAME)

PAGE 1-B

RN 766529-36-6 ZCAPLUS

CN Butanamide, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-phenylalanyl-3-(2-thienyl)-L-alanylglycyl-L-leucyl-2-amino-4-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

RN 766529-37-7 ZCAPLUS

CN L-Methioninamide, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-phenylalanyl-3-(2-thienyl)-L-alanyl-N-methylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

RN 766529-38-8 ZCAPLUS
CN L-Methioninamide, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-3-(2-thienyl)-L-alanyl-3-(2-thienyl)-L-alanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

767340-54-5P 767340-55-6P 767340-56-7P ΙT 767340-57-8P 767340-58-9P 767340-59-0P 767340-60-3P 767340-61-4P 767340-62-5P RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (radiolabeled substance P conjugates for cancer diagnosis and treatment) RN 767340-54-5 ZCAPLUS CN Yttrate(1-)-90Y, $[N2-[4-(carboxy-\kappa 0)-1-oxo-4-[4,7,10-tris](carboxy-\kappa 0)]$ κ O)methyl]-1,4,7,10-tetraazacyclododec-1-ylκΝ1,κΝ4,κΝ7,κΝ10]butyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-L-phenylalanylglycyl-Lleucyl-L-methioninamidato(4-)]- (9CI) (CA INDEX NAME)

PAGE 1-A


PAGE 1-B

PAGE 2-A

RN 767340-55-6 ZCAPLUS

CN Indium-111In, [N2-[[4,7,10-tris[(carboxy- κ 0)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl- κ 0]-11-[(2S)-2-amino-4-(methylsulfonyl)butanamide]substance P-ato(3-)]- (9CI) (CA INDEX NAME)

PAGE 1-A



RN 767340-56-7 ZCAPLUS

CN Indium-111In, [N2-[[4,7,10-tris[(carboxy-k0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-kN1,kN4,kN7,kN10]acetyl- kO]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-N-methylglycyl-L-leucyl-L-methioninamidato(3-)]- (9CI) (CA INDEX NAME)


PAGE 1-A

PAGE 1-B

RN 767340-57-8 ZCAPLUS

CN Indium-111In, [N2-[[4,7,10-tris[(carboxy-κ0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl-κ0]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-3-(2-thienyl)-L-alanylglycyl-L-leucyl-L-methioninamidato(3-)]-(9CI) (CA INDEX NAME)

PAGE 1-A



RN 767340-58-9 ZCAPLUS

CN Indium-111In, [N2-[[4,7,10-tris[(carboxy-κ0)methyl]-1,4,7,10 tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl κO]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-3 (2-thienyl)-L-alanyl-L-phenylalanylglycyl-L-leucyl-L-methioninamidato(3-)] (9CI) (CA INDEX NAME)

PAGE 2-A

RN 767340-59-0 ZCAPLUS

CN Indium-111In, [N2-[[4,7,10-tris[(carboxy- κ 0)methy1]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl- κ O]-9-(N-methylglycine)-11-[(2S)-2-amino-4-(methylsulfonyl)butanamide]substance P-ato(3-)]- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

RN 767340-60-3 ZCAPLUS

CN Indium-111In, [N2-[[4,7,10-tris[(carboxy- κ 0)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl- κ 0]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-phenylalanyl-3-(2-thienyl)-L-alanylglycyl-L-leucyl-(2S)-2-amino-4-(methylsulfonyl)butanamidato(3-)]- (9CI) (CA INDEX NAME)

PAGE 1-A



RN 767340-61-4 ZCAPLUS

CN Indium-111In, [N2-[[4,7,10-tris[(carboxy- κ O)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl- κ O]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-3-(2-thienyl)-L-alanyl-N-methylglycyl-L-leucyl-(2S)-2-amino-4-(methylsulfonyl)butanamidato(3-)]- (9CI) (CA INDEX NAME)

PAGE 2-A

RN 767340-62-5 ZCAPLUS

CN Indium-111In, [N2-[[4,7,10-tris[(carboxy- κ 0)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl- κ 0]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-3-(2-thienyl)-L-alanyl-3-(2-thienyl)-L-alanylglycyl-L-leucyl-L-methioninamidato(3-)]- (9CI) (CA INDEX NAME)


PAGE 1-A

PAGE 1-B

PAGE 2-A

o<u>==</u>

PAGE 2-B



L79 ANSWER 9 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2004:718526 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 141:243575

TITLE: Preparation of 1,3,5-trihalo-2,4,6-

benzenetricarboxamide N,N,N-tristetraazacyclododecane metal complexes and related compounds as contrast

media.

INVENTOR(S): Platzek, Johannes; Weinmann, Hanns-Joachim; Schirmer,

Heiko; Martin, Jose Luis; Harto, Juan R.; Riefke,

Bjoern

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.				KIND		DATE		APPLICATION NO.						DATE		
					_											
WO 2004074267			A1	20040902			WO 2003-EP14149						20031212			
W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
	CO,	CR,	CU,	CZ,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	GE,	GH,
	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,
	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NΙ,	NO,	NΖ,	OM,
	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ΤJ,	TM,	TN,
	TR,	TT,	TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW				
RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,

```
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     DE 10307759
                                 20041118
                                             DE 2003-10307759
                                                                     20030219
                          ВЗ
     CA 2516467
                                 20040902
                                             CA 2003-2516467
                                                                     20031212
                          Α1
     AU 2003290032
                          A1
                                 20040909
                                             AU 2003-290032
                                                                     20031212
     EP 1594851
                          Α1
                                 20051116
                                             EP 2003-782386
                                                                     20031212
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                                             BR 2003-18125
     BR 2003018125
                          Α
                                 20060207
                                                                     20031212
     CN 1753878
                                             CN 2003-80109870
                                                                     20031212
                                 20060329
                          Α
                                             JP 2004-568408
     JP 2006514664
                                                                     20031212
                          Τ
                                 20060511
     US 2004265236
                          Α1
                                 20041230
                                             US 2004-780887
                                                                     20040219
     US 7208140
                          В2
                                 20070424
     IN 2005DN03633
                                20070824
                                             IN 2005-DN3633
                                                                     20050817
                          Α
     MX 2005PA08781
                          Α
                                 20060310
                                             MX 2005-PA8781
                                                                     20050818
     NO 2005004291
                          Α
                                 20051117
                                             NO 2005-4291
                                                                     20050916
PRIORITY APPLN. INFO.:
                                             DE 2003-10307759
                                                                     20030219
                                                                 Α
                                             US 2003-452053P
                                                                 Ρ
                                                                     20030306
                                             WO 2003-EP14149
                                                                 W
                                                                     20031212
```

OTHER SOURCE(S):

GΙ

- AΒ Title compds. [I; Hal = Br, iodo; A1 = CONR1(CH2)nNR2(COCHZ1NH)mCOCHZ2K, CONR1(CH2)p(CONR2CH2)mCH(OH)CH2K, CH2O(CH2)pCH(OH)CH2K, CH2O(CH2) nNR1(COCHZ1NH) mCOCHZ2K, CH2NR1CO(CHZ1NHCO) mCHZ2K; A2 = A1, NR1CO(NR1)m(CH2)pNR2(COCHZ1NH)mCOCHZ1K; R1, R2 = H, alkyl, hydroxyalkyl; Z1, Z2 = H, Me; n = 2-4; m = 0, 1; p = 1-4; K = Q1; X = H, metal ion of element nos. 20-29, 39, 42, 44, 57-83; ≥ 2 X = metal ions], were prepared Thus, 2,4,6triiodo-1,3,5-benzenetricarbonyl trichloride in THF was added to ethylenediamine in THF over 1 h followed by stirring for 14 h to give 70% 2,4,6-triiodo-1,3,5-benzenetricarboxylic acid tris(2-aminoethyl)amide. This was added to a mixture prepared from the Gd complex of 10-[4-carboxy-1-methyl-2-oxo-3-azabutyl]-1,4,7,10- tetraazacyclododecane-1,4,7-triacetic acid, DCC, and N-hydroxysuccinimide in Me2SO to give 73% 2,4,6-triiodo-1,3,5benzenetricarboxylic acid N,N,N-tris-[3,6-diaza-4,7-dioxo-8-methyloctan-1,8diyl-[10-[1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, Gdcomplex]]]amide. The latter was used for CT imaging of rat blood vessels and kidnevs.
- IC ICM C07D257-02
 - ICS A61K049-04; A61K049-06; A61K051-04; A61K049-08
- 28-23 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 63, 78
- Musculoskeletal diseases ΙT

(tumor imaging; preparation of trihalobenzenetricarboxamide tristetraazacyclododecane metal complexes and related compds. as

```
contrast media)
ΙT
    7429-91-6DP, Dysprosium, complexes 7439-89-6DP, Iron, complexes
    7439-96-5DP, Manganese, complexes 7440-53-1DP, Europium, complexes
    7440-54-2DP, Gadolinium, complexes 753020-30-3P 753020-31-4P
    753020-32-5P 753020-33-6P 753020-34-7P 753020-35-8P
    753020-36-9P
                  753020-37-0P 753020-39-2P 753020-40-5P 753020-42-7P
                 753020-44-9P 753020-45-0P 753020-46-1P
    753020-43-8P
    753020-49-4P 753020-51-8P 753020-53-0P
    753020-56-3P 753020-59-6P 753020-61-0P
    753020-63-2P
                  753020-65-4P
    RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological
    study); PREP (Preparation); USES (Uses)
        (preparation of trihalobenzenetricarboxamide tristetraazacyclododecane
metal
       complexes and related compds. as contrast media)
ΙT
    14321-26-7P 88285-82-9P 138884-10-3P 138884-11-4P
                                                             400894-66-8P
                                 425367-60-8P
                                               752252-78-1P
    425367-31-3P 425367-47-1P
                                                               752252-79-2P
    752252-80-5P 752252-81-6P 752252-82-7P 752252-83-8P
    752252-84-9P 752252-85-0P 752252-86-1P
                                              752252-87-2P
    752252-88-3P
                  752252-89-4P
                                 752252-90-7P
                                                752252-91-8P
                                                              752252-92-9P
    752252-93-0P 752252-94-1P 752252-95-2P 752252-96-3P
                                                              752252-97-4P
    752252-98-5P 752252-99-6P 752253-00-2P 752253-01-3P
                                                              752253-02-4P
    752253-03-5P 752253-04-6P 752253-05-7P 752253-06-8P
                                                              752253-07-9P
    752253-08-0P 752253-09-1P 752253-10-4P 752253-11-5P
                                                              752253-12-6P
    752253-13-7P 752253-14-8P 752253-15-9P 752253-16-0P
                                                              752253-17-1P
    752253-18-2P 752253-19-3P 752253-20-6P 752253-21-7P
                                                               752253-22-8P
    752253-23-9P 752253-24-0P 752253-25-1P 752253-26-2P
    752253-27-3P 752253-28-4P 752253-29-5P
                                               752253-30-8P
    752253-31-9P 752253-32-0P 752253-33-1P 752253-34-2P
    752253-35-3P 752253-36-4P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of trihalobenzenetricarboxamide tristetraazacyclododecane
metal
       complexes and related compds. as contrast media)
    753020-32-5P 753020-33-6P 753020-49-4P
ΙT
    753020-51-8P 753020-53-0P 753020-56-3P
    753020-59-6P 753020-61-0P
    RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological
    study); PREP (Preparation); USES (Uses)
        (preparation of trihalobenzenetricarboxamide tristetraazacyclododecane
metal
       complexes and related compds. as contrast media)
RN
    753020-32-5 ZCAPLUS
    Yttrium, [\mu 3-[[10,10],10]]-[(2,4,6-triiodo-1,3,5-
CN
    benzenetriyl)tris[carbonylimino-2,1-ethanediylimino[2-(\infty-\kappa0)-2,1-
    ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato-
    κΝ1, κΝ4, κΝ7, κΝ10, κΟ1, κΟ4, κΟ7]](9-
    )]]tri- (9CI) (CA INDEX NAME)
```

PAGE 1-A


PAGE 1-B

PAGE 2-A

0==

RN 753020-33-6 ZCAPLUS

CN Gadolinium, [μ 3-[[10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[carbonylimino-2,1-ethanediylimino[1-methyl-2-(oxo- κ 0)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4,. κ 0 appa.07]](9-)]]tri- (9CI) (CA INDEX NAME)



PAGE 1-B

PAGE 2-A

 $\circ ==$

PAGE 2-B

RN 753020-49-4 ZCAPLUS

Gadolinium, $[\mu 3-[[10,10'-[[2,4,6-triiodo-5-[[[[[4,7,10-tris[(carboxy-\kappa0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-kN1,kN4,kN7,kN10]acetyl-kO]amino]acetyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino[2-(oxo-kO)-2,1-ethanediyl]]]bis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato-kN1,kN4,kN7,.kapp a.N10,kO1,kO4,kO7]](9-)]]tri-(9CI) (CA INDEX NAME)$


PAGE 2-A

 $\circ ==$

RN 753020-51-8 ZCAPLUS

CN Gadolinium, $[\mu 3-[[10,10'-[[2,4,6-triiodo-5-[[[[1-(oxo-κ0)-2-[4,7,10-tris[(carboxy-κ0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]propyl]amino]acetyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino[1-methyl-2-(oxo-κ0)-2,1-ethanediyl]]]bis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato-κN1,κN4,κN7,κN10,κ01,κ04,κ07]](9-)]]tri-(9CI) (CA INDEX NAME)$






PAGE 2-A

O===

RN 753020-53-0 ZCAPLUS

CN Gadolinium, $[\mu 3-[[10,10]-[[2,4,6-triiodo-5-[methyl][[[4,7,10-tris[(carboxy-<math>\kappa$ O)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl- κ O]amino]acetyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino[2-(oxo- κ O)-2,1-ethanediyl]]]bis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7,.kapp a.N10, κ O1, κ O4, κ O7]](9-)]]tri- (9CI) (CA INDEX NAME)



PAGE 1-B

PAGE 2-A

0===

NH ON NH ON


PAGE 2-B

RN 753020-56-3 ZCAPLUS

CN Gadolinium, [μ3-[[10,10'-[[2,4,6-triiodo-5-[[[[2-[[[4,7,10-tris[(carboxy-κ0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl]amino]ethyl]amino]carbonyl
]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino[2-(oxo-κ0)-2,1-ethanediyl]]]bis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato-κN1,κN4,κN7,κN10,κO1,κO4,.k
appa.07]][9-)]]tri- (9CI) (CA INDEX NAME)


$$\begin{array}{c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

PAGE 1-B



RN 753020-59-6 ZCAPLUS

CN Gadolinium, [μ 3-[[10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[carbonylimino-2,1-ethanediylimino[2-(∞ - κ 0)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ 01, κ 04, κ 07]](9-)]]tri- (9CI) (CA INDEX NAME)



PAGE 2-A

 $\circ =$

PAGE 2-B

RN 753020-61-0 ZCAPLUS

CN Dysprosium, $[\mu 3-[[10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[carbonylimino-2,1-ethanediylimino[2-(oxo-<math>\kappa$ 0)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ 01, κ 04, κ 07]](9-)]]tri- (9CI) (CA INDEX NAME)

PAGE 2-A

 $\circ ==$

PAGE 2-B

IT 752252-82-7P 752252-85-0P 752253-24-0P 752253-27-3P 752253-32-0P 752253-36-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

 $(preparation\ of\ trihalobenzenetricarboxamide\ tristetraazacyclododecane\ metal$

complexes and related compds. as contrast media)

RN 752252-82-7 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]tris- (9CI) (CA INDEX NAME)

PAGE 1-B
$$- \text{NH-CH}_2 - \text{CH}_2 - \text{NH-CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{CH}_2 - \text{CO}_2 H$$

PAGE 2-B

-CH2-CO2H

RN 752252-85-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[carbonylimino-2,1-ethanediylimino(1-methyl-2-oxo-2,1-ethanediyl)]]tris- (9CI) (CA INDEX NAME)

--- CH2-CO2H

RN 752253-24-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[(2,4,6-triiodo-5-[[[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]acetyl]amino]-1,3-phenylene)bis[carbonylimino-2,1-ethanediyl)]]bis- (9CI) (CA INDEX NAME)

PAGE 1-B

-CH2-CO2H

RN 752253-27-3 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[(2,4,6-triiodo-5-[[[1-oxo-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]propyl]amino]acetyl]amino]-1,3-phenylene)bis[carbonylimino-2,1-ethanediylimino(1-methyl-2-oxo-2,1-ethanediyl)]]bis- (9CI) (CA INDEX NAME)

$$-\text{CH}_2-\text{CH}_2-\text{NH}-\text{C}-\text{CH}-\text{N}-\text{N}-\text{C}-\text{CH}_2-\text{CO}_2\text{H}$$

PAGE 2-B

____содн

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[(2,4,6-triiodo-5-[methyl[[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]acetyl]amino]-1,3-phenylene)bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]bis-(9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{PAGE 1-A} \\ \text{HO}_2\text{C}-\text{CH}_2 \\ \text{HO}_2\text{C}-\text{CH}_2 \end{array} \\ \text{N} \\ \text{HO}_2\text{C}-\text{CH}_2 \\ \end{array}$$

$$CH_2-NH$$
 CCH_2-NH
 CH_2-CO_2H
 CH_2-CO_2H
 CH_2-CO_2H

RN 752253-36-4 ZCAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[(2,4,6-triiodo-5-[[[[2-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]amino]carbonyl]amino]-1,3-phenylene)bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]bis-(9CI) (CA INDEX NAME)

PAGE 2-B

-CH2-CO2H

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L79 ANSWER 10 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2004:432097 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 141:153123

TITLE: In Vitro and in Vivo Comparison of Human Escherichia

coli Heat-Stable Peptide Analogues Incorporating the

111In-DOTA Group and Distinct Linker Moieties

AUTHOR(S): Giblin, Michael F.; Gali, Hariprasad; Sieckman, Gary

L.; Owen, Nellie K.; Hoffman, Timothy J.; Forte,

Leonard R.; Volkert, Wynn A.

CORPORATE SOURCE: Research Service, Harry S. Truman Memorial Veterans'

Administration Hospital, Columbia, MO, 65201, USA

SOURCE: Bioconjugate Chemistry (2004), 15(4), 872-880

CODEN: BCCHES; ISSN: 1043-1802

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

Three human Escherichia coli heat-stable peptide (STh) analogs, each AΒ containing a DOTA chelating group, were synthesized by SPPS and oxidative refolding and compared in in vitro and in vivo systems. One analog, DOTA-F19-STh(1-19), contains an N-terminal DOTA group attached via an amide bond linkage to an STh moiety which is essentially wild-type except for a Tyr to Phe alteration at position 19 of the mol. A second analog, DOTA-R1,4,F19-STh(1-19), differs from the first in that asparagine residues in positions 1 and 4 have been altered to arginine residues in order to examine the effect of pos. charged groups in the linker domain. A third analog, DOTA-11AUN-F19-STh(1-19), differs from the first in that it incorporates an 11aminoundecanoic acid spacer group between the DOTA group and the first asparagine residue. In vitro competitive binding assays utilizing T-84 human colon cancer cells demonstrated that significant alterations to the N-terminal region of the STh mol. were well tolerated and did not significantly affect binding affinity of STh for the guanylyl cyclase C (GC-C) receptor.

ΙT

Internalization and efflux studies of the indium-labeled species demonstrated that inclusion of pos. charge in the linker moiety inhibits internalization of the compound within tumor cells. The characteristics of the three analogs were compared in an in vivo model utilizing T-84 human colon cancer cell xenografts in SCID mice. Clearance of all analogs was rapid, primarily via renal excretion into the urine, with >89% ID excreted into the urine at 1 h pi for all analogs. The 111In-DOTA-R1,4,F19-STh(1-19) and 111In-DOTA-11AUN-F19-STh(1-19) analogs both had longer residence times in the blood than did the 111In-DOTA-F19-STh(1-19) analog, probably accounting for increased %ID/g values for tumors and nontarget tissues at 1 h pi. At 4 h pi, significant differences between analogs were only seen with respect to metabolic routes of excretion, indicating that increased blood residence time did not result in increased tumor residualization. Reduction of hepatic uptake of these compds., however, could have significance in the development of agents for the imaging of hepatic metastases. The ability to manipulate in vivo pharmacodynamics and tumor uptake of radiolabeled STh peptides through modification of linker moieties is under continuing investigation in order to produce optimal imaging and therapeutic radiopharmaceuticals.

CC 8-9 (Radiation Biochemistry)

IT 415706-07-9P 728914-72-5P 728914-74-7P

RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (in vitro and in vivo comparison of human E. coli heat-stable peptide analogs incorporating 111In-DOTA group and distinct linker moieties) 415706-07-9P 728914-72-5P 728914-74-7P

RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (in vitro and in vivo comparison of human E. coli heat-stable peptide analogs incorporating 111In-DOTA group and distinct linker moieties)

RN 415706-07-9 ZCAPLUS CN Indate(2-)-111In, [N2-[2-[4,7,10-tris[(carboxy- κ 0)methyl]-1,4,7,10-

tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl]-L-asparaginyl-L-seryl-L-asparaginyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-cysteinyl-L-asparaginyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-L-phenylalanine cyclic (6 \rightarrow 11),(7 \rightarrow 15),(10 \rightarrow 18)-tris(disulfidato)(5-)]-, hydrogen (1:2) (CA INDEX NAME)

PAGE 1-B

PAGE 3-B

PAGE 4-B

PAGE 5-A

Ph—CH2—


●2 H+

RN 728914-72-5 ZCAPLUS

CN Indate(2-)-111In, [N2-[[4,7,10-tris[(carboxy- κ 0)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl-

$$\begin{split} &\kappa \text{O}]-\text{L-arginyl-L-seryl-L-seryl-L-arginyl-L-tyrosyl-L-cysteinyl-L-} \\ &\text{cysteinyl-L-}\alpha-\text{glutamyl-L-leucyl-L-cysteinyl-L-cysteinyl-L-} \\ &\text{asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-L-} \\ &\text{phenylalanine cyclic } (6 \rightarrow 11), (7 \rightarrow 15), (10 \rightarrow 18)-\\ &\text{tris}(\text{disulfidato})(5-)]-, &\text{dihydrogen } (9\text{CI}) &\text{(CA INDEX NAME)} \end{split}$$

PAGE 1-A



PAGE 1-B

PAGE 2-A

$$\bigvee^{\text{OM}}_{\text{Me}} - \bigvee^{\text{OH}}_{\text{CH}} \bigvee^{\text{O}}_{\text{N}} \bigvee^{\text{H}}_{\text{N}}$$

PAGE 3-B

RN 728914-74-7 ZCAPLUS

CN Indate(2-)-111In, [N2-[1-oxo-11-[[[4,7,10-tris[(carboxy- κ 0)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]

2 H+

acetyl- κ O]amino]undecyl]-L-asparaginyl-L-seryl-L-seryl-L-asparaginyl-L-tyrosyl-L-cysteinyl-L- α -glutamyl-L-leucyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-L-phenylalanine cyclic (6 \rightarrow 11),(7 \rightarrow 15),(10 \rightarrow 18)-tris(disulfidato)(5-)]-, dihydrogen (9CI) (CA INDEX NAME)

PAGE 1-B

PAGE 4-B

PAGE 5-A

H +

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L79 ANSWER 11 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN 2004:261461 ZCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER: 142:70820

TITLE: Cellular Delivery of MRI Contrast Agents AUTHOR(S): Allen, Matthew J.; MacRenaris, Keith W.;

Venkatasubramanian, P. N.; Meade, Thomas J. CORPORATE SOURCE: Dep. Chem., Biochem. and Mol. and Cell Biol.,

Neurobiol. and Physiol., and Radiol., Northwestern

Univ., Evanston, IL, 60208, USA

SOURCE: Chemistry & Biology (2004), 11(3), 301-307

CODEN: CBOLE2; ISSN: 1074-5521

PUBLISHER: Cell Press DOCUMENT TYPE: Journal LANGUAGE: English

Magnetic resonance imaging (MRI) is a powerful tool for acquiring images of opaque living animals with the benefit of tracking events over extended periods of time on the same specimen. Contrast agents are used to enhance regions, tissues, and cells that are magnetically similar but histol. distinct. A principal barrier to the development of MRI contrast agents for investigating biol. questions is the delivery of agents across cellular membranes. Here, we describe the synthesis and in vitro testing of Gd(III)based MRI contrast agents containing varying length polyarginine oligomers capable of permeating cell membranes. We examine the effect of the length of oligomer on T1 enhancement and cellular uptake. Furthermore, the effect of incubation time, concentration, and cell type on uptake is explored. Toxicity and washout studies are performed in addition to MRI phantom studies. CC

8-9 (Radiation Biochemistry)

ΤТ

ΙT 22541-18-0DP, Europium III, complexes with DOTA-polyarginine, biological studies 22541-19-1DP, Gadolinium(III), complexes with DOTA-polyarginine, biological studies 812644-18-1P 812644-19-2P 812644-20-5P 812644-21-6P

RL: DGN (Diagnostic use); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Gd(III)-based MRI contrast agents preparation and cellular uptake) 811804-40-7P 811804-47-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(Gd(III)-based MRI contrast agents preparation and cellular uptake) ΙT 22541-18-0DP, Europium III, complexes with DOTA-polyarginine, biological studies 22541-19-10P, Gadolinium(III), complexes with DOTA-polyarginine, biological studies 812644-18-1P 812644-19-2P 812644-20-5P 812644-21-6P RL: DGN (Diagnostic use); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (Gd(III)-based MRI contrast agents preparation and cellular uptake) RN 22541-18-0 ZCAPLUS CN Europium, ion (Eu3+) (CA INDEX NAME) Eu3+ 22541-19-1 ZCAPLUS RN Gadolinium, ion (Gd3+) (CA INDEX NAME) CN Gd 3+ RN 812644-18-1 ZCAPLUS Gadolinate(1-), $[N2-[[4,7,10-tris[(carboxy-\kappa0)methyl]-1,4,7,10-tris[(carboxy-k0)methyl]]$ CN tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl- κ O]-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-Larginyl-L-argininato(4-)]-, hydrogen (9CI) (CA INDEX NAME)

PAGE 1-A

0

PAGE 1-B

PAGE 2-A



● H+

- RN 812644-19-2 ZCAPLUS
- CN Gadolinate(1-), [N2-[[4,7,10-tris[(carboxy-κ0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl-κ0]-L-arginyl-L-argin

PAGE 1-B

PAGE 2-B


RN 812644-20-5 ZCAPLUS

CN Europate(1-), [N2-[[4,7,10-tris[(carboxy- κ 0)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl- κ O]-L-arginyl-L-argin

PAGE 1-A

PAGE 1-B

PAGE 2-A



● H+

- RN 812644-21-6 ZCAPLUS
- CN Europate(1-), [N2-[[4,7,10-tris[(carboxy-κ0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl-κ0]-L-arginyl

PAGE 1-B

PAGE 2-B

IT 811804-40-7P 811804-47-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Gd(III)-based MRI contrast agents preparation and cellular uptake)

RN 811804-40-7 ZCAPLUS

CN L-Arginine, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginyl-L-arginy

Absolute stereochemistry.

PAGE 2-A

RN 811804-47-4 ZCAPLUS

CN L-Arginine, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginyl-L-arginy

Absolute stereochemistry.

PAGE 2-A

$$H_{2N}$$
 H_{2N}
 H

PAGE 3-A

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L79 ANSWER 12 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2003:750102 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 139:214227

AUTHOR(S):

TITLE: A New Biotin Derivative-DOTA Conjugate as a Candidate

for Pretargeted Diagnosis and Therapy of Tumors Sabatino, Giuseppina; Chinol, Marco; Paganelli, Giovanni; Papi, Stefano; Chelli, Mario; Leone, Giuseppe; Papini, Anna Maria; De Luca, Angelo;

Ginanneschi, Mauro

CORPORATE SOURCE: Dep. of Org. Chem. "Ugo Schiff", CNR-ICCOM, Polo

Scientifico, Univ. of Florence, Sesto Fiorentino,

I-50019, Italy

SOURCE: Journal of Medicinal Chemistry (2003), 46(14),

3170-3173

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:214227

- AB The synthesis of a new biotin derivative, the (CO) reduced N-aminohexyl biotinamido derivative, designed to be serum biotinidase resistant, and its conjugation to the chelator DOTA through an amide bond at one of the four carboxymethyl chains are described. The 90Y-labeled conjugate was able to bind avidin at different Av/conjugate molar ratios with good results. The preclin. The preclin. results indicate that this new biotin-DOTA conjugate is a good candidate for pretargeted diagnosis and therapy of tumors.
- CC 26-8 (Biomolecules and Their Synthetic Analogs)
 Section cross-reference(s): 1
- ST aminohexyl biotinamido biotin deriv prepn; biotin DOTA conjugate prepn; stability avidin binding biotin DOTA conjugate; pretargeted diagnosis tamor therapy biotin DOTA conjugate prepn
- IT Antitumor agents

Diagnostic agents

(preparation of a biotin-DOTA conjugate and evaluation of its serum stability and avidin binding properties as a candidate for pretargeted diagnosis and potential tumor therapy)

IT Avidins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of a biotin-DOTA conjugate and evaluation of its serum stability and avidin binding properties as a candidate for pretargeted diagnosis and potential tumor therapy)

IT 451478-45-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of a biotin-DOTA conjugate and evaluation of its serum stability and avidin binding properties as a candidate for pretargeted diagnosis and potential tumor therapy)

IT 586962-90-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of a biotin-DOTA conjugate and evaluation of its serum stability and avidin binding properties as a candidate for pretargeted diagnosis and potential tumor therapy)

IT 58-85-5 51857-17-1 60239-18-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of a biotin-DOTA conjugate and evaluation of its serum stability and avidin binding properties as a candidate for pretargeted diagnosis and potential tumor therapy)

IT 65953-56-2P 153162-70-0P 451478-44-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of a biotin-DOTA conjugate and evaluation of its serum stability and avidin binding properties as a candidate for pretargeted diagnosis and potential tumor therapy)

IT 451478-45-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of a biotin-DOTA conjugate and evaluation of its serum stability and avidin binding properties as a candidate for pretargeted diagnosis and potential tumor therapy)

RN 451478-45-8 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]pentyl]amino]hexyl]amino]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

__СО2Н

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L79 ANSWER 13 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2003:726127 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 140:299530

TITLE: Synthesis and visualization of a membrane-permeable

MRI contrast agent

AUTHOR(S): Allen, Matthew J.; Meade, Thomas J.

CORPORATE SOURCE: Division of Biology and the Beckman Institute,

California Institute of Technology, Pasadena, CA,

91125, USA

SOURCE: JBIC, Journal of Biological Inorganic Chemistry

(2003), 8(7), 746-750

CODEN: JJBCFA; ISSN: 0949-8257

PUBLISHER: Springer-Verlag

DOCUMENT TYPE: Journal LANGUAGE: English

AB The study of in vivo developmental events has undergone significant advances with the advent of biol. mol. imaging techniques such as computer enhanced light microscopy imaging, positron emission tomog. (PET), micro-CT, and magnetic resonance imaging (MRI). MRI has proven to be a particularly powerful tool in clin. and biol. settings. Images can be acquired of opaque living animals, with the benefit of tracking events of extended periods of time on the same specimen. Contrast agents are routinely used to enhance regions, tissues, and cells that are magnetically similar but histol. distinct. A principal barrier to the development of MR contrast agents for investigating developmental biol. questions is the ability to deliver the agent across cellular membranes. As part of our research, we are investigating a number of small mols. that facilitate transport of charged and uncharged species across cell membranes. Here we describe the synthesis and testing of a Gd(III)-based MR contrast agent conjugated to polyarginine that is able to permeate cell membranes. We confirmed cellular uptake of the agent using twophoton laser microscopy to visualize a Eu(III) derivative of the contrast agent in cell culture, and verified this uptake by T1 anal. of the Gd(III) agent in cells.

CC 8-9 (Radiation Biochemistry)

IT 112188-16-6P 137184-55-5P


RL: PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of Gd(III)-based membrane-permeable MRI contrast agent)


IT 676553-18-7P 676553-19-8P

RL: PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic

use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of Gd(III)-based membrane-permeable MRI contrast agent) ΙT RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of Gd(III)-based membrane-permeable MRI contrast agent) ΙT 7087-68-5, Diisopropylethylamine 91000-69-0D, L-Arginine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-, resin-bound 137076-54-1, DOTA tri(tert-butyl) ester 148893-10-1, HATU 676544-85-7 RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of Gd(III)-based membrane-permeable MRI contrast agent) 112188-16-6P 137184-55-5P ΙT RL: PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of Gd(III)-based membrane-permeable MRI contrast agent) RN 112188-16-6 ZCAPLUS CN Gadolinium, [1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)κΝ1, κΝ4, κΝ7, κΝ10, κΟ1, κΟ4, κΟ7]-(9CI) (CA INDEX NAME)



RN 137184-55-5 ZCAPLUS
CN Europium, [1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)κN1,κN4,κN7,κN10,κΟ1,κΟ4,κΟ7](9CI) (CA INDEX NAME)



IT 676553-18-7P 676553-19-8P

RL: PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Gd(III)-based membrane-permeable MRI contrast agent)

RN 676553-18-7 ZCAPLUS

CN Gadolinate(1-), [N2-[[4,7,10-tris[(carboxy- κ 0)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl]-L-arginyl-

PAGE 1-A

PAGE 1-B

PAGE 2-A

PAGE 3-B

RN 676553-19-8 ZCAPLUS

CN Europate(1-), [N2-[[4,7,10-tris[(carboxy-κ0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl]-L-arginyl-L-

PAGE 1-A

PAGE 1-B

PAGE 2-A

PAGE 3-B

RN

IT 676544-84-6P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of Gd(III)-based membrane-permeable MRI contrast agent) 676544-84-6 ZCAPLUS

CN L-Arginine, N2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-arginyl-L-arginy

Absolute stereochemistry.

IT 676544-85-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of Gd(III)-based membrane-permeable MRI contrast agent)

RN 676544-85-7 ZCAPLUS

CN Europium hydroxide (Eu(OH)3), pentahydrate (9CI) (CA INDEX NAME)

●5 H₂O

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L79 ANSWER 14 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2003:71732 ZCAPLUS Full-text

DOCUMENT NUMBER: 138:122864

TITLE: Preparation of vitronectin receptor antagonist

pharmaceuticals for use in the diagnosis and treatment

of cancer

INVENTOR(S): Harris, Thomas D.; Barrett, John A.; Carpenter, Alan

P., Jr.; Rajopadhye, Milind

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 146 pp., Cont.-in-part of U.S. Ser. No. 465,300.

CODEN: USXXAM

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
US 6511649	В1	20030128	US 2000-599364	20000621		

US 6	6322770	B1	20011127	US	1999-281207		19990330
US 2	2002015680	A1	20020207	US	1999-281209		19990330
US (6524553	В2	20030225				
US (6548663	B1	20030415	US	1999-281050		19990330
US 2	2002182147	A1	20021205	US	1999-465300		19991217
US (6511648	В2	20030128				
US 2	2002041878	A1	20020411	US	2001-948807		20010907
US 6	6683163	В2	20040127				
US 2	2002061909	A1	20020523	US	2001-948390		20010907
US 6	6689337	В2	20040210				
US 2	2003232053	A1	20031218	US	2001-947783		20010907
US 6	6743412	В2	20040601				
US 2	2003124120	A1	20030703	US	2002-269252		20021011
US 2	2003113336	A1	20030619	US	2002-281015		20021026
US '	7018611	В2	20060328				
US 2	2003149262	A1	20030807	US	2002-306054		20021126
PRIORITY	APPLN. INFO.:			US	1998-112732P	Ρ	19981218
				US	1999-465300	A2	19991217
				US	1998-80150P	Ρ	19980331
				US	1998-112715P	Ρ	19981218
				US	1998-112829P	Ρ	19981218
				US	1998-112831P	Р	19981218
				US	1999-281050	А3	19990330
					1999-281209	A3	19990330
					2000-599364	A3	20000621
					 -		

OTHER SOURCE(S): MARPAT 138:122864

AB Compds. (Q)d-Ln-Ch and (Q)d-Ln-(Ch)d' [Q is a residue having a quinolone-type moiety; Ln is a linking group; Ch is a metal-bonding unit; d = 1-10; d' = 1-100] and pharmaceutical compns. containing them were prepared for the treatment of cancer in combination therapy. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent. Thus, 2-[[[4-[4-[[[3-[2-[2-[3-[[6-[[1-aza-2-(2-sulfophenyl)vinyl]amino]-3-

 $\label{lem:pyridyl} $$ pyridyl] = 1-methyl-3-[[7-[(imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-hydroquinolyl] $$ arbonylamino] = 1-methyl-2-ylamino) = 1-methyl-4-oxo-3-hydroquinolyl] $$ arbonylamino] $$ propanoic acid (claimed compound) $$ was prepared $$ propanoic acid (claimed compound) $$ arbonylamino] $$ arbonylamino] $$ propanoic acid (claimed compound) $$ arbonylamino] $$ arbonylamino] $$ propanoic acid (claimed compound) $$ arbonylamino] $$ arbonylamino] $$ propanoic acid (claimed compound) $$ arbonylamino] $$ arbonylamino$

IC ICM A61K051-00

ICS A61M036-14

INCL 424001690; 424001110; 424001650; 424009100; 424009400; 424009500; 530331000

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 8, 27, 28, 63, 78

IT Angiogenesis

Antirheumatic agents

Antitumor agents

Human

Imaging agents

Radiopharmaceuticals

 $\hbox{(preparation of peptide- and tetraazadodecane-containing quinolones and their}\\$

radioactive metal complexes for diagnosis and treatment of cancer)

5704-04-1DP, Tricine, technetium-99 complexes 10098-91-6DP, complexes with vitronectin receptor binding conjugates, preparation 14133-76-7DP, complexes with vitronectin receptor binding conjugates, preparation 14265-75-9DP, complexes with vitronectin receptor binding conjugates, preparation 15750-15-9DP, complexes with vitronectin receptor binding

277315-51-2P

```
277315-57-8P
                   277315-58-9P
                                  277315-59-0P
                                                 277315-60-3P
                                                                277315-61-4P
                                                 277315-65-8P
    277315-62-5P
                   277315-63-6P
                                  277315-64-7P
                                                                277315-67-0P
    277315-68-1P
                   277315-69-2P
                                  277315-70-5P
                                                 277315-72-7P
    277315-74-9P 277315-75-0P
                                277315-76-1P
                                               277315-77-2P
    277315-78-3P
                   277315-79-4P
                                  277315-80-7P
                                                 277315-81-8DP, technetium-99
    complexes 277316-60-6P 277316-61-7P 277316-62-8P 277316-63-9P
    277316-64-0P
                   277316-65-1P
                                  277316-66-2P
                                                 277316-67-3P
                                                                277316-68-4P
    277316-69-5P
                   278172-91-1P
                                  278172-92-2P
                                                 278172-93-3P
                                                                278172-94-4P
                                                 278172-98-8P
                                                                278172-99-9P
    278172-95-5P
                   278172-96-6P
                                  278172-97-7P
    278173-00-5P
                   278173-01-6P
                                  278173-02-7P
                                                 278173-03-8P
    278173-04-9P
                   278173-05-0P
                                  278173-06-1P
                                                 278173-07-2P
    278173-08-3P
    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of peptide- and tetraazadodecane-containing quinolones and
their
       radioactive metal complexes for diagnosis and treatment of cancer)
                 57932-18-0P
                                137076-54-1P 192635-89-5P
                                                             220156-99-0P
TТ
    40324-66-1P
    250612-31-8P
                   277315-82-9P
                                  277315-83-0P
                                                 277315-84-1P
                                                                277315-85-2P
    277315-86-3P
                   277315-88-5P
                                  277315-89-6P
                                                 277315-90-9P
                                                                277315-91-0P
    277315-92-1P
                   277315-93-2P
                                  277315-94-3P
                                                 277315-95-4P
                                                                277315-96-5P
    277315-97-6P
                   277315-98-7P
                                  277315-99-8P
                                                 277316-00-4P
                                                                277316-01-5P
    277316-02-6P
                   277316-04-8P
                                  277316-06-0P
                                                 277316-08-2P
                                                                277316-09-3P
    277316-10-6P
                   277316-12-8P
                                  277316-13-9P
                                                 277316-15-1P
                                                                277316-16-2P
    277316-17-3P
                   277316-18-4P
                                  277316-19-5P
                                                 277316-20-8P
                                                                277316-24-2P
    277316-27-5P
                   277316-28-6P
                                  277316-29-7P
                                                 277316-30-0P
                                                                277316-31-1P
    277316-32-2P
                   277316-33-3P
                                  277316-34-4P
                                                 277316-36-6P
                                                                277316-37-7P
    277316-39-9P
                   277316-40-2P
                                  277316-41-3P
                                                 277316-42-4P
                                                                277316-43-5P
    277316-44-6P
                   277316-45-7P 277316-47-9P
                                               277316-48-0P
    277316-50-4P
                   277316-52-6P
                                  277316-53-7P 277316-54-8P
                                                                277316-56-0P
    277316-58-2P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of peptide- and tetraazadodecane-containing quinolones and
their
        radioactive metal complexes for diagnosis and treatment of cancer)
    277315-74-9P 277315-75-0P 278173-04-9P
ΤT
    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of peptide- and tetraazadodecane-containing quinolones and
their
       radioactive metal complexes for diagnosis and treatment of cancer)
RN
    277315-74-9 ZCAPLUS
CN
    1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[3-[[(2S)-
    2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-
    7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-
    oxoethyl] - (CA INDEX NAME)
```

conjugates, preparation 63995-70-0DP, TPPTS, technetium-99 complexes

277315-53-4P 277315-55-6P

277315-56-7P

277315-52-3P

Absolute stereochemistry.

PAGE 1-A

RN 277315-75-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[3-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-oxoethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 277315-74-9 CMF C45 H61 N11 O13 S

Absolute stereochemistry.

PAGE 1-A

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 278173-04-9 ZCAPLUS
CN Yttrate(1-)-90Y, [10-[2-[[3-[3-[[((2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-(oxo-κO)ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(4-)-κN1,κN4,κN7,κN10,κO1,κO4,κO7]-,hydrogen (9CI) (CA INDEX NAME)

PAGE 2-A

● H +

IT 277316-47-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

 $\hbox{(preparation of peptide- and tetraazadodecane-containing quinolones and their}\\$

radioactive metal complexes for diagnosis and treatment of cancer)

RN 277316-47-9 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, $10-[2-[[3-[3-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-oxoethyl]-, <math>\alpha,\alpha',\alpha''$ -tris(1,1-dimethylethyl) ester, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 277316-46-8

CMF C57 H85 N11 O13 S

Absolute stereochemistry.

PAGE 1-A

CM 2

CRN 76-05-1 CMF C2 H F3 O2

REFERENCE COUNT: 143 THERE ARE 143 CITED REFERENCES AVAILABLE FOR

THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L79 ANSWER 15 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2001:935440 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 136:70082

TITLE: Vitronectin receptor antagonist pharmaceuticals for

use in combination therapy

INVENTOR(S): Harris, Thomas D.; Barrett, John A.; Carpenter, Alan

P., Jr.; Rajopadhye, Milind

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA; Bristol-Myers

Squibb Pharma. Company

SOURCE: PCT Int. Appl., 542 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

P	PATENT NO.							APPLICATION NO.						DATE					
M(WO 2001-US19793					20010621				
Mo	О.	2001	0978	48		А3		20030313											
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB	, BG,	BR,	BY,	BΖ,	CA,	CH,	CN,	
			CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES.	, FI,	GB,	GD,	GE,	GH,	GM,	HR,	
			HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP	, KR,	KΖ,	LC,	LK,	LR,	LS,	LT,	
			LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX	, MZ,	NO,	NZ,	PL,	PT,	RO,	RU,	
			SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR	, TT,	TZ,	UA,	UG,	UZ,	VN,	YU,	
			ZA,	ZW															
		RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ	, TZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,	
			DE,	DK,	ES,	FΙ,	FR,	GB,	GR,	IE,	ΙT	, LU,	MC,	NL,	PT,	SE,	TR,	BF,	
			ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GW,	ML	, MR,	NE,	SN,	TD,	TG			
C	Α.	2412	854			A1		20011227			CA 2001-2412854					20010621			
E	Ρ	1307	226			A2	2 20030507			EP 2001-952180						20010621			
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR	, IT,	LI,	LU,	NL,	SE,	MC,	PT,	
			IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL	, TR							
J1	Ρ.	2004521066			Τ	20040715			JP 2002-503332						20010621				
										CN 2001-814430						20010621			
Bl	R.	2001	01011880			Α	20060425				BR 2001-11880					20010621			
N:	Ζ.	5229:	25			Α		20060831			NZ 2001-522925					20010621			
M	Χ.	20021	PA12	750	A			20040730			MX 2002-PA12750					20021218			
Il					20070427 IN 2007-DN1157			57	20070213										
PRIORI'	ΤY	APP:	LN.	INFO	.:						US :	2000-	2132	10P		P 2	0000	621	
											WO :	2001-	US19	793	,	W 2	0010	621	
											IN :	2002-	DN11	68		A3 2	0021	128	
OBUED COUDOR (C)						1 (7 D)	m	100	7000	`									

OTHER SOURCE(S): MARPAT 136:70082

- AB Anticancer agents of the formulas (Q)d-Ln-Ch or (Q)d-Ln-(Ch)d (I) [Q is a residue having a quinolone-type moiety; Ln is a linking group; Ch is a metal-bonding unit; d = 1-10; d' = 1-100] and kits containing I are prepared for the treatment of cancer in combination therapy in a patient. I are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. I may be used with radioisotopes; in addition, I may be used in conjunction with radio- and photosensitizers, ligands such as TPPTS or tricine, and reducing agents such as tin(II). The present invention provides novel compds. useful for the treatment of rheumatoid arthritis (no data).
- IC ICM A61K041-00

ICS A61K051-04

- CC 34-3 (Amino Acids, Peptides, and Proteins) Section cross-reference(s): 8, 27, 28, 63, 78
- IT Antitumor agents

 $\hbox{(preparation of peptide- and tetraazadodecane-containing quinolones and their}\\$

radioactive metal complexes as anticancer agents)

IT 5704-04-1DP, Tricine, technetium-99 complexes 10098-91-6DP, complexes with vitronectin receptor binding conjugates, preparation 14133-76-7DP,

ΙT

ΙT

RN

CN

```
complexes with vitronectin receptor binding conjugates, preparation
    14265-75-9DP, complexes with vitronectin receptor binding conjugates,
    preparation 15750-15-9DP, complexes with vitronectin receptor binding
    conjugates, preparation 63995-70-0DP, TPPTS, technetium-99 complexes
    277315-51-2P
                   277315-52-3P
                                 277315-53-4P
                                              277315-55-6P
                                                             277315-56-7P
    277315-57-8P
                   277315-58-9P
                                 277315-59-0P
                                                277315-60-3P
                                                              277315-61-4P
    277315-62-5P
                   277315-63-6P
                                277315-64-7P
                                                277315-65-8P
                                                              277315-67-0P
    277315-68-1P
                   277315-69-2P
                                 277315-70-5P
                                                277315-72-7P
    277315-74-9P 277315-75-0P 277315-76-1P 277315-77-2P
                 277315-79-4P
                                 277315-80-7P
                                                277315-81-8DP, technetium-99
    277315-78-3P
    complexes 277316-60-6P 277316-61-7P 277316-62-8P 277316-63-9P
    277316-64-0P
                                 277316-66-2P 277316-67-3P
                                                              277316-68-4P
                   277316-65-1P
                   278172-91-1P
    277316-69-5P
                                 278172-92-2P
                                                278172-93-3P
                                                              278172-94-4P
    278172-95-5P
                   278172-96-6P
                                 278172-97-7P
                                                278172-98-8P
                                                              278172-99-9P
    278173-00-5P 278173-01-6P
                                 278173-02-7P
                                                278173-03-8P
    278173-04-9P 278173-05-0P 278173-06-1P 278173-07-2P
    278173-08-3P
    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
       (preparation of peptide- and tetraazadodecane-containing quinolones and
their
       radioactive metal complexes as anticancer agents)
    40324-66-1P
                  57932-18-0P
                              137076-54-1P 192635-89-5P
                                                            220156-99-0P
    250612-31-8P
                   277315-82-9P
                                 277315-83-0P
                                                277315-84-1P
                                                              277315-85-2P
    277315-86-3P
                   277315-88-5P
                                 277315-89-6P
                                                277315-90-9P
                                                              277315-91-0P
    277315-92-1P
                                                277315-95-4P
                   277315-93-2P
                                 277315-94-3P
                                                              277315-96-5P
    277315-97-6P 277315-98-7P
                                 277315-99-8P 277316-00-4P
                                                              277316-01-5P
    277316-02-6P 277316-04-8P 277316-06-0P 277316-08-2P
                                                              277316-09-3P
    277316-10-6P 277316-12-8P 277316-13-9P 277316-15-1P
                                                              277316-16-2P
    277316-17-3P 277316-18-4P 277316-19-5P 277316-20-8P
                                                              277316-24-2P
                                 277316-29-7P
    277316-27-5P 277316-28-6P
                                                277316-30-0P
                                                              277316-31-1P
    277316-32-2P
                   277316-33-3P
                                 277316-34-4P
                                                277316-36-6P
                                                              277316-37-7P
    277316-39-9P
                   277316-40-2P
                                 277316-41-3P
                                                277316-42-4P
                                                              277316-43-5P
    277316-44-6P 277316-45-7P 277316-47-9P 277316-48-0P
                                 277316-53-7P 277316-54-8P
    277316-50-4P
                 277316-52-6P
                                                              277316-56-0P
    277316-58-2P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
       (preparation of peptide- and tetraazadodecane-containing quinolones and
their
       radioactive metal complexes as anticancer agents)
    277315-74-9P 277315-75-0P 278173-04-9P
    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
       (preparation of peptide- and tetraazadodecane-containing quinolones and
their
       radioactive metal complexes as anticancer agents)
    277315-74-9 ZCAPLUS
    1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[3-[[(2S)-
    2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-
    7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-
```

Absolute stereochemistry.

oxoethyl]- (CA INDEX NAME)

PAGE 1-A

RN 277315-75-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[3-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-oxoethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 277315-74-9 CMF C45 H61 N11 O13 S

PAGE 1-A

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 278173-04-9 ZCAPLUS
CN Yttrate(1-)-90Y, [10-[2-[[3-[3-[[((2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-(oxo-κ0)ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(4-)-κN1,κN4,κN7,κN10,κO1,κO4,κO7]-, hydrogen (9CI) (CA INDEX NAME)

PAGE 2-A

● H +

IT 277316-47-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

 $\hbox{ (preparation of peptide- and tetraazadodecane-containing quinolones and their}\\$

radioactive metal complexes as anticancer agents)

RN 277316-47-9 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, $10-[2-[[3-[3-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-oxoethyl]-, <math>\alpha,\alpha',\alpha''$ -tris(1,1-dimethylethyl) ester, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 277316-46-8

CMF C57 H85 N11 O13 S

PAGE 1-A

CM 2

CRN 76-05-1 CMF C2 H F3 O2

L79 ANSWER 16 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2000:661180 ZCAPLUS $\underline{\text{Full-text}}$

DOCUMENT NUMBER: 133:249059

TITLE: Radionuclide conjugates with DOTA-biotin derivatives

for diagnosis and therapy

INVENTOR(S): Griffiths, Gary L.; Hansen, Hans; Govindan, Serengulam

V.

PATENT ASSIGNEE(S): Immunomedics, Inc., USA

SOURCE: U.S., 10 pp., Cont.-in-part of U.S. Ser. No. 486,166,

abandoned. CODEN: USXXAM

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 19

PATENT INFORMATION:

	TENT				KIN	D	DATE				ICAT					ATE		
	6120				A	_	2000				 997-					9971		
US	US 5736119				А	. 19980407				US 1	995-	4099	19950323					
US	US 5922302				A		19990713			US 1	4406	19950515						
WO	WO 9930745			A2		19990624			WO 1998-US26579					19981215				
WO	9930	745			А3	20000113												
	W:	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,	
							GE,											
		KΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,	MX,	NO,	NZ,	
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	TM,	TR,	TT,	UA,	UG,	
		US,	UΖ,	VN,	YU,	ZW.	ŕ	·	·	·	·	·	·	·	·	·	•	
	RW:	GH,	GM,	KE,	LS,	MW.	SD,	SZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,	ES,	
		•				•	IT,		•	•		•	•	•	•	•		
		•	•		•	•	MR,	•	•	•	•	,	,	,	,	,	,	
AU	9918	258	·	·	A	·	1999	0705	·	AU 1	999-	1825	8		1	9981	215	
PRIORITY APPLN. INFO.:							US 1993-62662				B1 19930517							
								US 1995-409960					A2 19950323					
											995-				B2 1	9950	607	
										US 1996-688781								
											997-				A1 1			
											998-				W 1			

- AB A radionuclide-chelator conjugate composition for detecting and/or treating lesions in a patient comprises pre-targeting the cell, tissue, or pathogen with a substrate, using a targeting protein that specifically binds a marker substance on the target cell, tissue, or pathogen and to which the substrate is directly or indirectly bound. Parenteral injection comprises a chelate conjugate of biotin, a chelator, and a chelatable detection or therapeutic agent, and allows the composition to accrete at the targeted cell, tissue, or pathogen. The chelate conjugate is purified by liquid chromatog. after chelate formation, or further comprises a blood transit-modifying linker or addend that is covalently bound within the chelate conjugate, or both. The detection or therapeutic agent of the invention are used to detect or treat cancer, infectious diseases, or cardiovascular diseases. Preparation of biotin-D-Phe-D-Lys-DOTA is presented.
- IC ICM A61K039-395
- INCL 424178100
- CC 8-9 (Radiation Biochemistry)

Section cross-reference(s): 1, 15, 28, 34

- ST DOTA biotin deriv chelator radionuclide conjugate; diagnosis therapy DOTA biotin deriv radionuclide; antitumor antiinfective cardiovascular agent radionuclide conjugate
- IT Antitumor agents

- IT Antitumor agents
 - (glioma; radionuclide conjugates with DOTA-biotin derivs. for diagnosis and therapy)
- IT Antitumor agents

(leukemia; radionuclide conjugates with DOTA-biotin derivs. for diagnosis and therapy) $\,$

IT Antitumor agents

(lymphoma; radionuclide conjugates with DOTA-biotin derivs. for diagnosis and therapy)

IT Antitumor agents

(melanoma; radionuclide conjugates with DOTA-biotin derivs. for diagnosis and therapy)

IT Antitumor agents

(myeloma; radionuclide conjugates with DOTA-biotin derivs. for diagnosis and therapy)

IT Antitumor agents

(neuroblastoma; radionuclide conjugates with DOTA-biotin derivs. for diagnosis and therapy)

IT Anti-infective agents

Antimicrobial agents

Antitumor agents

Cardiovascular agents

Parasiticides

(radionuclide conjugates with DOTA-biotin derivs. for diagnosis and therapy)

IT Antitumor agents

(sarcoma; radionuclide conjugates with DOTA-biotin derivs. for diagnosis and therapy)

7440-54-2DP, Gadolinium, chelates with DOTA-biotin derivs., biological 10043-49-9DP, Gold 198, chelates with DOTA-biotin derivs., studies biological studies 10098-91-6DP, Yttrium 90, chelates with DOTA-biotin derivs., biological studies 13967-65-2DP, Holmium-166, chelates with DOTA-biotin derivs., biological studies 13968-53-1DP, Ruthenium 103, chelates with DOTA-biotin derivs., biological studies 13981-51-6DP, Mercury 197, chelates with DOTA-biotin derivs., biological studies 14119-09-6DP, Gallium 67, chelates with DOTA-biotin derivs., biological 14119-24-5DP, Osmium 191, chelates with DOTA-biotin derivs., biological studies 14133-76-7DP, Technetium 99, chelates with DOTA-biotin derivs., biological studies 14191-64-1DP, Praseodymium 142, chelates with DOTA-biotin derivs., biological studies 14265-75-9DP, Lutetium 177, chelates with DOTA-biotin derivs., biological studies 14265-85-1DP, Actinium 225, chelates with DOTA-biotin derivs., biological 14331-95-4DP, Ruthenium 105, chelates with DOTA-biotin derivs., biological studies 14378-26-8DP, Rhenium 188, chelates with DOTA-biotin derivs., biological studies 14391-11-8DP, Gold 199, chelates with DOTA-biotin derivs., biological studies 14391-19-6DP, Terbium 161, chelates with DOTA-biotin derivs., biological studies 14391-96-9DP, Scandium 47, chelates with DOTA-biotin derivs., biological studies 14687-25-3DP, Lead 203, chelates with DOTA-biotin derivs., biological 14885-78-0DP, Indium 113, chelates with DOTA-biotin derivs., biological studies 14913-49-6DP, Bismuth 212, chelates with DOTA-biotin derivs., biological studies 14913-89-4DP, chelates with DOTA-biotin derivs., biological studies 14914-68-2DP, Antimony 119, chelates with DOTA-biotin derivs., biological studies 14967-68-1DP, Palladium 103, chelates with DOTA-biotin derivs., biological studies 14981-64-7DP, Palladium 109, chelates with DOTA-biotin derivs., biological studies 14998-63-1DP, Rhenium 186, chelates with DOTA-biotin derivs., biological studies 15092-94-1DP, Lead 212, chelates with DOTA-biotin derivs., biological studies 15735-74-7DP, Platinum 197, chelates with DOTA-biotin derivs., biological studies 15750-15-9DP, Indium 111, chelates with DOTA-biotin derivs., biological studies 15756-62-4DP, Ruthenium 95, chelates with DOTA-biotin derivs., biological studies 15757-14-9DP, Gallium 68, chelates with DOTA-biotin derivs., biological studies 15757-86-5DP, Copper 67, chelates with DOTA-biotin derivs., biological studies 15758-35-7DP, Ruthenium 97, chelates with DOTA-biotin derivs., biological studies 15760-04-0DP, Silver 111, chelates with DOTA-biotin

derivs., biological studies 15765-78-3DP, Rhenium 189, chelates with DOTA-biotin derivs., biological studies 15766-00-4DP, Samarium 153, chelates with DOTA-biotin derivs., biological studies 294638-18-9P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(radionuclide conjugates containing DOTA-biotin derivs. for diagnosis and therapy)

IT 170908-81-3P 192221-17-3P 192221-18-4P 192221-19-5P 245758-39-8P 294637-28-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(radionuclide conjugates containing DOTA-biotin derivs. for diagnosis and therapy)

IT 294638-18-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(radionuclide conjugates containing DOTA-biotin derivs. for diagnosis and therapy)

RN 294638-18-9 ZCAPLUS

CN Yttrium-90Y, [10-[2-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]methylamino]ethyl]methylamino]-2-(oxo-κO)ethyl]1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)κN1,κN4,κN7,κN10,κΟ1,κΟ4,κΟ7](9CI) (CA INDEX NAME)

IT 245758-39-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(radionuclide conjugates containing DOTA-biotin derivs. for diagnosis and therapy)

RN 245758-39-8 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]methylamino]ethyl]methylamino]-2-oxoethyl]- (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

__СО2Н

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L79 ANSWER 17 OF 17 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2000:420994 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 133:59099

TITLE: Preparation of vitronectin receptor antagonist

pharmaceuticals

INVENTOR(S): Harris, Thomas David; Rajodadhye, Milind PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 300 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PAT	CENT	NO.			KIN)	DATE		•	APPL	ICAT	ION 1	NO.		D.	ATE	
	2000				A2		2000			WO 1	 999-	US30	315		1	9991	217
WO	2000	0354	92		А3		2001	0118									
	W:	AL,	ΑU,	BR,	CA,	CN,	CZ,	EE,	HU,	IL,	IN,	JP,	KR,	LT,	LV,	MK,	MX,
		NO,	NZ,	PL,	RO,	SG,	SI,	SK,	TR,	UA,	VN,	ZA,	AM,	AZ,	BY,	KG,	KΖ,
		MD,	RU,	ΤJ,	TM												
	RW:	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,
		PT,	SE														
US	6322	770			B1		2001	1127		US 1	999-	2812	0.7		1	9990.	330

```
US 2002015680
                       A1
                              20020207
                                         US 1999-281209
                                                                19990330
    US 6524553
                        В2
                              20030225
    US 6548663
                        В1
                              20030415
                                          US 1999-281050
                                                                19990330
    CA 2349501
                        Α1
                              20000622
                                          CA 1999-2349501
                                                                19991217
    EP 1140204
                        Α2
                              20011010
                                          EP 1999-967443
                                                                19991217
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    BR 9917079
                        Α
                              20011030
                                          BR 1999-17079
                                                                19991217
    JP 2002532440
                        Τ
                                          JP 2000-587811
                              20021002
                                                                19991217
    AU 766822
                              20031023
                                          AU 2000-23716
                        В2
                                                                19991217
    NZ 511677
                        Α
                              20031031
                                          NZ 1999-511677
                                                                19991217
    ZA 2001003675
                                          ZA 2001-3675
                        Α
                              20020607
                                                                20010507
    IN 2001MN00576
                        Α
                              20050304
                                          IN 2001-MN576
                                                                20010522
    MX 2001PA06151
                        Α
                              20020311
                                          MX 2001-PA6151
                                                                20010615
    US 2003124120
                        A1 20030703
                                          US 2002-269252
                                                                20021011
    US 2003149262
                       A1
                              20030807
                                          US 2002-306054
                                                                20021126
PRIORITY APPLN. INFO.:
                                          US 1998-112732P
                                                             P 19981218
                                                             P 19980331
                                          US 1998-80150P
                                                             P 19981218
                                          US 1998-112715P
                                          US 1998-112829P
                                                             P 19981218
                                          US 1998-112831P
                                                             P 19981218
                                          US 1999-281050
                                                             A3 19990330
                                          US 1999-281209
                                                             A3 19990330
                                          WO 1999-US30315
                                                             W 19991217
```

MARPAT 133:59099 OTHER SOURCE(S):

Compds. (Q)d-Ln-Ch (Q is a residue having a quinolone-type moiety, d = 1-10, AB Ln is a linking group, Ch is a metal-bonding unit) were prepared for use in the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compds. useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. Thus, [3-[1-[3-[N-1]]][3-[2-[N-(L-Asp-L-Asp)-3aminopropoxy]ethoxy]ethoxy]propyl]carbamoyl]propanoylamino]propyl]-7-[(imidazol-2-ylamino)methyl]-4-oxo(3-hydroquinolyl)carbonylamino]-2- [[(2,4,6trimethylphenyl)sulfonyl]amino]propanoic acid DOTA conjugate was prepared

(claimed compound). Syntheses of radiopharmaceuticals, e.g., 99mTc(VnA)(tricine)(phosphine), where VnA represents the vitronectin receptor antagonist, are also described.

- ICM A61K051-04 IC
- 34-3 (Amino Acids, Peptides, and Proteins) CC Section cross-reference(s): 8, 27, 28, 63, 78
- ΙT Angiogenesis

Antitumor agents

Atherosclerosis

Radiopharmaceuticals

(preparation of vitronectin receptor antagonist pharmaceuticals)

```
ΙT
    40324-66-1P 57932-18-0P 137076-54-1P 192635-89-5P 220156-99-0P
    250612-31-8P
                  277315-82-9P
                                 277315-83-0P
                                               277315-84-1P
                                                             277315-85-2P
                  277315-88-5P
    277315-86-3P
                                 277315-89-6P
                                               277315-90-9P
                                                             277315-91-0P
    277315-92-1P
                  277315-93-2P
                                 277315-94-3P
                                               277315-95-4P
                                                             277315-96-5P
    277315-97-6P
                  277315-98-7P
                                 277315-99-8P
                                               277316-00-4P
                                                             277316-01-5P
    277316-02-6P
                  277316-04-8P
                                 277316-06-0P
                                               277316-08-2P
                                                             277316-09-3P
    277316-10-6P
                  277316-12-8P
                                 277316-13-9P
                                               277316-15-1P
                                                             277316-16-2P
    277316-17-3P
                  277316-18-4P
                                 277316-19-5P
                                               277316-20-8P
                                                             277316-24-2P
    277316-27-5P
                  277316-28-6P
                                 277316-29-7P
                                               277316-30-0P
                                                             277316-31-1P
    277316-32-2P
                  277316-33-3P
                                 277316-34-4P
                                               277316-36-6P
                                                             277316-37-7P
    277316-39-9P 277316-40-2P
                                 277316-41-3P
                                               277316-42-4P
                                                             277316-43-5P
                  277316-45-7P 277316-47-9P 277316-48-0P
    277316-44-6P
    277316-50-4P
                  277316-52-6P 277316-53-7P 277316-54-8P 277316-56-0P
    277316-58-2P
```

```
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of vitronectin receptor antagonist pharmaceuticals)
ΙT
    5704-04-1DP, Tricine, technetium-99 complexes 10098-91-6DP, complexes
    with vitronectin receptor binding conjugates, preparation 14133-76-7DP,
    complexes with vitronectin receptor binding conjugates, preparation
    14265-75-9DP, complexes with vitronectin receptor binding conjugates,
    preparation 15750-15-9DP, complexes with vitronectin receptor binding
                            63995-70-0DP, TPPTS, technetium-99 complexes
    conjugates, preparation
                                 277315-53-4P
                                                277315-55-6P
    277315-51-2P
                   277315-52-3P
                                                              277315-56-7P
    277315-57-8P
                   277315-58-9P
                                  277315-59-0P
                                                 277315-60-3P 277315-61-4P
                                  277315-64-7P
    277315-62-5P
                   277315-63-6P
                                                 277315-65-8P
                                                               277315-67-0P
                  277315-69-2P
    277315-68-1P
                                  277315-70-5P
                                                 277315-72-7P
    277315-74-9P 277315-75-0P 277315-76-1P 277315-77-2P
    277315-78-3P
                   277315-79-4P
                                  277315-80-7P
                                                 277315-81-8DP, technetium-99
    complexes 277316-60-6P 277316-61-7P 277316-62-8P 277316-63-9P
    277316-64-0P
                   277316-65-1P 277316-66-2P 277316-67-3P
                                                              277316-68-4P
    277316-69-5P
                   277316-71-9DP, technetium-99 complexes 277316-72-0DP,
    technetium-99 complexes 277316-73-1DP, technetium-99 complexes
    277316-74-2DP, technetium-99 complexes 277316-75-3DP, technetium-99
    complexes 277316-76-4DP, technetium-99 complexes 278172-91-1P
    278172-92-2P 278172-93-3P 278172-94-4P
                                               278172-95-5P 278172-96-6P
    278172-97-7P 278172-98-8P 278172-99-9P
                                                 278173-00-5P
                                                               278173-01-6P
                   278173-03-8P 278173-04-9P 278173-05-0P
    278173-02-7P
                   278173-07-2P 278173-08-3P
    278173-06-1P
                                                 278173-09-4DP,
    gadolinium-labeled
    RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
    study); PREP (Preparation); USES (Uses)
        (preparation of vitronectin receptor antagonist pharmaceuticals)
ΙT
    277316-47-9P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of vitronectin receptor antagonist pharmaceuticals)
RN
    277316-47-9 ZCAPLUS
    1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[3-[[(2S)-
CN
    2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-
    7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-
    oxoethyl]-, \alpha, \alpha', \alpha''-tris(1,1-dimethylethyl) ester,
    tris(trifluoroacetate) (9CI) (CA INDEX NAME)
         1
    CM
    CRN 277316-46-8
    CMF C57 H85 N11 O13 S
```

t-BuO

N

OBu-t

OBu-t

OBu-t

OBu-t

OBu-t

CM 2

CRN 76-05-1

CMF C2 H F3 O2

F— C— CO₂H

oxoethyl] - (CA INDEX NAME)

Absolute stereochemistry.

HO2C N CO2H

(CH2) 3 NH

RN 277315-75-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[3-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-oxoethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 277315-74-9

CMF C45 H61 N11 O13 S

PAGE 1-A

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 278173-04-9 ZCAPLUS
CN Yttrate(1-)-90Y, [10-[2-[[3-[3-[[((2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-(oxo-κO)ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(4-)-κN1,κN4,κN7,κN10,κO1,κO4,κO7]-,hydrogen (9CI) (CA INDEX NAME)

PAGE 2-A

● H +

=> file registry
FILE 'REGISTRY' ENTERED AT 10:26:43 ON 21 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9 DICTIONARY FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9


New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html




ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12
ring/chain nodes:
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
ring/chain bonds:
9-25 10-21 11-17 12-13 13-14 14-16 14-15 17-18 18-20 18-19 21-22 22-24
22-23 25-26 26-28 26-27 28-29 29-30
ring bonds:
1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10
exact/norm bonds:
1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10 9-25 10-21 11-17
12-13 13-14 14-16 14-15 17-18 18-20 18-19 21-22 22-24 22-23 25-26 26-28 26-27 28-29
29-30

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS



chain nodes :
31 32
ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 ring/chain nodes : 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 chain bonds : 29-31 29-32 ring/chain bonds : $9-25 \quad 10-21 \quad 11-17 \quad 12-13 \quad 13-14 \quad 14-16 \quad 14-15 \quad 17-18 \quad 18-20 \quad 18-19 \quad 21-22 \quad 22-24$ 22-23 25-26 26-28 26-27 28-29 29-30 ring bonds : 1-2 1-9 2-12 3-4 3-10 4-11 5-6 5-12 6-11 7-8 7-9 8-10exact/norm bonds : $1-2 \quad 1-9 \quad 2-12 \quad 3-4 \quad 3-10 \quad 4-11 \quad 5-6 \quad 5-12 \quad 6-11 \quad 7-8 \quad 7-9 \quad 8-10 \quad 9-25 \quad 10-21 \quad 11-9 \quad 10-19 \quad$ 17 12-13 13-14 14-16 14-15 17-18 18-20 18-19 21-22 22-24 22-23 25-26 26-28 26-27 28-29 29-30 29-31 29-32

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 32:CLASS 32:CLASS 32:CLASS 32:CLASS

=> file zcaplus FILE 'ZCAPLUS' ENTERED AT 10:26:46 ON 21 FEB 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 21 Feb 2008 VOL 148 ISS 8 FILE LAST UPDATED: 20 Feb 2008 (20080220/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L64 L25 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

Structure attributes must be viewed using STN Express query preparation. 2020 SEA FILE=REGISTRY SSS FUL L25 L47 STR * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT * Structure attributes must be viewed using STN Express query preparation. L49 345 SEA FILE=REGISTRY SUB=L29 SSS FUL L47 L50 142 SEA FILE=REGISTRY ABB=ON PLU=ON L49 AND M/ELS L51 203 SEA FILE=REGISTRY ABB=ON PLU=ON L49 NOT L50 L56 112 SEA FILE=REGISTRY ABB=ON PLU=ON L50 AND LNTH/PG L62 25232 SEA FILE=ZCAPLUS ABB=ON PLU=ON ?SCAFFOLD?/BI 2 SEA FILE=ZCAPLUS ABB=ON PLU=ON (L51 OR L56) AND L62 L64 => d stat que L65 L25 * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT * Structure attributes must be viewed using STN Express query preparation. 2020 SEA FILE=REGISTRY SSS FUL L25 L29 L47 STR * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT * Structure attributes must be viewed using STN Express query preparation. 345 SEA FILE=REGISTRY SUB=L29 SSS FUL L47 L49 L50 142 SEA FILE=REGISTRY ABB=ON PLU=ON L49 AND M/ELS 203 SEA FILE=REGISTRY ABB=ON PLU=ON L49 NOT L50 L51 112 SEA FILE=REGISTRY ABB=ON PLU=ON L50 AND LNTH/PG L56 641196 SEA FILE=ZCAPLUS ABB=ON PLU=ON ?TUMOUR?/BI OR ?TUMOR?/BI L60 40 SEA FILE=ZCAPLUS ABB=ON PLU=ON (L51 OR L56) AND L60 L65 => s L64-L65 not L79,L73,L74 32 (L64 OR L65) NOT (L79 OR L73 OR L74) => d ibib abs hitind hitstr L80 1-32 L80 ANSWER 1 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2008:39770 ZCAPLUS Full-text DOCUMENT NUMBER: 148:145033 TITLE: Preparation of gastrin-releasing peptide compounds as diagnostic imaging agents or radiotherapeutic agents and methods of their use for treating prostate cancer INVENTOR(S): Cappelletti, Enrico; Lattuada, Luciano; Linder, Karen E.; Marinelli, Edmund; Nanjappan, Palaniappa; Nunn, Adrian D.; Raju, Natarajan; Ramalingam, Kondareddiar; Swenson, Rolf E.; Tweedle, Michael; Maddalena, Mary PATENT ASSIGNEE(S): Bracco Imaging S.p.A., Italy SOURCE: U.S. Pat. Appl. Publ., 218pp., Cont.-in-part of U.S. Ser. No. 352,156. CODEN: USXXCO DOCUMENT TYPE: Patent English LANGUAGE:

```
PATENT NO.
                        KIND DATE
                                            APPLICATION NO.
                                                                      DATE
     _____
                        ----
                                             _____
     US 2008008649
                         A1 20080110 US 2007-751337
                                                                      20070521
     US 2004136906
                          A1
                                20040715 US 2003-341577
                                                                      20030113
                          В2
     US 7226577
                                20070605
     20040805
                                             WO 2003-US41328
                                                                      20031224
                              20040923
            AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, HU, ID, IL, IN, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
             NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, UA,
             UG, US, UZ, VN, YU, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                       A1 20041216
                                            US 2004-828925
     US 2004253225
                                                                     20040420
                                             US 2005-165721 20050624
US 2006-352156 20060210
IN 2006-CN2330 20060626
US 2003-341577 A2 20030113
WO 2003-US41328 A2 20031224
US 2004-828925 A2 20040420
US 2005-165721 A2 20050624
US 2006-352156 A2 20060310
     US 2006018830
                          A1
                                20060126 US 2005-165721
                                                                     20050624
                         A1 20061026 US 2006-352156
A 20070706 IN 2006-CN2330
     US 2006239914
                                             IN 2006-CN2330
US 2003-341577
     IN 2006CN02330
PRIORITY APPLN. INFO.:
                                              US 2006-352156
                                                                  A2 20060210
                                              WO 2004-US22115 W 20040712
```

The invention is related to novel gastrin-releasing peptide (GRP) compds. of AB formula M-N-O-P-G (M is an optical label or a metal chelator complexed with a radionuclide; N, P are null, an amino acid or other linking group; O is an amino acid; at least one of N, O, or P is a non- α -amino acid; G is a GRP receptor targeting peptide) which are useful as diagnostic imaging agents or radiotherapeutic agents. The invention is also related to methods for treating prostate tumors or of delaying the progression of prostate tumors, including, methods of treating bone or soft tissue metastases of prostate cancer, methods for treating hormone sensitive and hormone refractory prostate cancer, methods for delaying the progression of hormone sensitive prostate cancer, for facilitating combination therapy in patients with hormone sensitive prostate cancer and for decreasing aberrant vascular permeability in patients with hormone sensitive prostate cancer. Thus, DOTA-Gly-4-NHC6H4CO-L-Gln-L-Trp-L-Ala-L- Val-Gly-L-His-L-Leu-L-Met-NH2 (DOTA = 1,4,7,10tetraazacyclododecane- 1,4,7,10-tetraacetic acid residue) was prepared by the solid-phase method and complexed with 177Lu for cell binding, biodistribution and aberrant vascular permeability in LNCaP tumors studies.

INCL 424001690

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 8, 78

IT Antitumor agents

Combination chemotherapy

Human

Radiography

Radiotherapy

(preparation of gastrin-releasing peptide compds. for use as diagnostic imaging agents or radio therapeutic agents)

```
721937-25-3P
               721937-27-5P
                              721937-29-7P
                                             721937-31-1P
                                                             721937-33-3P
721937-35-5P
              721937-37-7P
                              721937-40-2P
                                             721937-42-4P
                                                             721937-48-0P
721937-50-4P
              721937-52-6P
                              721937-54-8P
                                             721937-58-2P
                                                             721937-60-6P
721937-62-8P
               721937-64-0P
                              721937-66-2P
                                             721937-68-4P
                                                             721937-70-8P
               721937-74-2P
                                             721937-78-6P
721937-72-0P
                              721937-76-4P
                                                             721937-80-0P
721937-82-2P
               721937-84-4P
                              721937-86-6P
                                             721937-88-8P
721937-90-2P 721937-92-4P
                            721937-94-6P
                                           721937-96-8P
721937-98-0P
              721938-00-7P
                              721938-02-9P
                                             721938-04-1P
                                                             721938-06-3P
721938-08-5P
              721938-10-9P
                              721938-12-1P
                                             721938-14-3P
                                                             721938-16-5P
721938-18-7P
              721938-20-1P
                              721938-22-3P
                                             721938-24-5P
                                                             721938-26-7P
721938-28-9P
               721938-30-3P
                              721938-32-5P
                                             721938-34-7P
                                                             721938-36-9P
721938-38-1P
               721938-39-2P
                              721938-41-6P
                                             721938-43-8P
                                                             721938-45-0P
721938-47-2P
               721938-49-4P
                              721938-51-8P
                                             721938-54-1P
                                                             721938-56-3P
721938-58-5P
               721938-60-9P
                              721938-62-1P
                                             721938-64-3P
                                                             721938-66-5P
721938-68-7P
               721938-70-1P
                              721938-72-3P
                                             721938-74-5P
                                                             721938-76-7P
721938-78-9P
              721938-80-3P
                              721938-83-6P
                                             721938-85-8P
                                                             721938-87-0P
721938-89-2P
                              721938-99-4P
              721938-97-2P
                                             721939-01-1P
                                                             721939-03-3P
721939-05-5P
               721939-06-6P
                              721939-07-7P
                                             721939-08-8P
                                                             721939-10-2P
721939-11-3P
               721939-12-4P
                                             721939-16-8P
                                                             721939-17-9P
                              721939-14-6P
721939-18-0P
               721939-19-1P
                              721939-21-5P
                                             721939-23-7P
                                                             721939-25-9P
                                             721939-33-9P
721939-27-1P
               721939-29-3P
                              721939-31-7P
                                                             721939-35-1P
721939-37-3P
               722493-92-7P
                              722493-93-8P
                                             722493-94-9P
                                                             722493-95-0P
722493-96-1P
              722493-97-2P
                              722493-98-3P
                                             722493-99-4P
                                                             722494-00-0P
              722494-02-2P
                              808112-30-3P
                                             808112-31-4P
722494-01-1P
                                                             808112-32-5P
808112-33-6P
               808112-35-8P
                              808112-37-0P
                                             808112-39-2P
808112-41-6P
               808112-43-8P
                                             808112-45-0P
                              808112-44-9P
808112-46-1P
               808112-47-2P
                              808112-48-3P
                                             808112-49-4P
                                                             808112-50-7P
808112-51-8P
               808112-52-9P
                              808112-53-0P
                                             808112-54-1P
                                                             808112-55-2P
808112-56-3P
               808112-57-4P
                              808112-58-5P
                                             808112-59-6P
                                                             808112-60-9P
808112-61-0P
               808112-62-1P
                              808112-63-2P
                                             808112-64-3P
                                                             808112-65-4P
808112-67-6P
               808112-68-7P
                              808112-69-8P
                                             808112-70-1P
                                                             808112-71-2P
808112-72-3P
               808112-73-4P 808112-74-5P 808112-75-6P
               808113-15-7P
                                             808113-17-9P
808112-76-7P
                              808113-16-8P
                                                             808113-18-0P
808113-19-1P
               808113-20-4P
                              808113-21-5P
                                             808113-23-7P
                                                             808113-24-8P
808113-25-9P
               808113-26-0P
                              808113-27-1P
                                             808113-28-2P
                                                             808113-29-3P
809233-13-4P
               809233-16-7P
                                             874534-72-2P
                                                             874534-73-3P
                              874367-58-5P
874537-63-0P
               913581-98-3P
                              913582-14-6P
                                             913582-23-7P
                                                             913655-42-2P
913705-76-7P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic
use); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (preparation of gastrin-releasing peptide compds. for use as diagnostic
   imaging agents or radio therapeutic agents)
721937-82-2P 721937-90-2P 721937-92-4P
808112-41-6P 808112-74-5P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic
use); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (preparation of gastrin-releasing peptide compds. for use as diagnostic
   imaging agents or radio therapeutic agents)
721937-82-2 ZCAPLUS
L-Methioninamide, N2-[[4-oxo-6-[4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tris(carboxymethyl)]]
tetraazacyclododec-1-yl]acetyl]-1-piperazinyl]-3(4H)-quinazolinyl]acetyl]-
L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl-
(9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

ΙT

RN

CN

PAGE 1-A

PAGE 1-C

__SMe

RN 721937-90-2 ZCAPLUS

CN L-Methioninamide, N2-[[4-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-1-piperazinyl]acetyl]-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

PAGE 2-A

PAGE 2-B

RN 721937-92-4 ZCAPLUS

CN L-Methioninamide, N2-[[4-[2-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]-1-piperazinyl]acetyl]-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl- (9CI) (CA INDEX NAME)

RN 808112-41-6 ZCAPLUS

CN L-Methioninamide, N2-[4-[[[2-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]amino]carbonyl]benzoyl]-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-B

→SMe

PAGE 2-B

RN 808112-74-5 ZCAPLUS

CN L-Methioninamide, N2-[4-[bis[2-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]amino]-1,4-dioxobutyl]-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-B

$$\sim$$
SMe

PAGE 2-B

L80 ANSWER 2 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:1006173 ZCAPLUS Full-text

DOCUMENT NUMBER: 148:3337

TITLE: In vivo evaluation of a PAMAM-cystamine-(Gd-DO3A)

conjugate as a biodegradable macromolecular MRI

contrast agent

AUTHOR(S): Xu, Rongzuo; Wang, Yanli; Wang, Xuli; Jeong, Eun-Kee;

Parker, Dennis L.; Lu, Zheng-Rong

CORPORATE SOURCE: Dep. Parmaceutics and Pharmaceutical Chem., Univ.

Utah, Salt Lake City, UT, 84108, USA

SOURCE: Experimental Biology and Medicine (Maywood, NJ, United

States) (2007), 232(8), 1081-1089 CODEN: EBMMBE; ISSN: 1535-3702

PUBLISHER: Society for Experimental Biology and Medicine

DOCUMENT TYPE: Journal LANGUAGE: English

AB Macromol. Gd(III) chelates are superior magnetic resonance imaging (MRI) contrast agents for blood pool and tumor imaging. However, their clin. development is limited by the safety concerns related to the slow excretion and long-term gadolinium tissue accumulation. A generation 6 PAMAM Gd(III) chelate conjugate with a cleavable disulfide spacer, PAMAM-G6-cystamine-(Gd-D03A)1 was prepared as a biodegradable macromol. MRI contrast agent with rapid excretion from the body. T1 and T2 relaxivities of the contrast agent were 11.6 and 13.3 mM-1 sec-1 at 3T, resp. Blood pool and tumor contrast enhancement of the agent were evaluated in female nude mice bearing MDA-MB-231 human breast carcinoma xenograft swith a nondegradable conjugate PAMAM-G6-(Gd-D03A) as a control. PAMAM-G6-cystamine-(Gd-D03A) resulted in significant contrast enhancement in the blood for about 5 mins, and Gd-D03A was released

from the conjugate and rapidly excreted via renal filtration after the disulfide spacer was cleaved. The nondegradable control had much longer blood circulation and excreted more slowly from the body. PAMAM-G6-cystamine-(Gd-D03A) also resulted in more prominent tumor contrast enhancement than the control. However, PAMAM-G6-cystamine-(Gd-D03A) demonstrated high toxicity due to the intrinsic toxicity of PAMAM dendrimers. In conclusion, although PAMAM-G6-cystamine-(Gd-D03A) showed some advantages compared with the nondegradable control. PAMAM dendrimers are not suitable carriers for biodegradable macromol. MRI contrast agents, due to their high toxicity.

CC 8-9 (Radiation Biochemistry)
Section cross-reference(s): 9, 14

- ST MRI contrast PAMAM cystamine GdDO3A conjugate pharmacokinetics tumor imaging; mouse blood clearance MRI contrast agent disulfide spacer toxicity
- IT Imaging

(NMR, tumor imaging using; in vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromol. MRI contrast agent)

IT 958259-88-6P

RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(in vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromol. MRI contrast agent)

IT 99616-36-1P 150467-20-2P 958259-91-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(in vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromol. MRI contrast agent)

IT 585531-76-6DP, PAMAM dendrimeric gadolinium complexes 958259-88-6DP, PAMAM dendrimeric gadolinium complexes

RL: SPN (Synthetic preparation); PREP (Preparation)

(in vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromol. MRI contrast agent)

IT 958259-88-6P

RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(in vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromol. MRI contrast agent)

RN 958259-88-6 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-isothiocyanatoethyl)amino]-2-oxoethyl]- (CA INDEX NAME)

HO₂C-CH₂
$$\sim$$
 CH₂-

IT 150467-20-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(in vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromol. MRI contrast agent)

RN 150467-20-2 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]- (CA INDEX NAME)

IT 958259-88-6DP, PAMAM dendrimeric gadolinium complexes

RL: SPN (Synthetic preparation); PREP (Preparation)

(in vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromol. MRI contrast agent)

RN 958259-88-6 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-isothiocyanatoethyl)amino]-2-oxoethyl]- (CA INDEX NAME)

$$CH_2 - CH_2 -$$

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 3 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:969732 ZCAPLUS Full-text

DOCUMENT NUMBER: 147:294732

TITLE: Polyamine-substituted ligands for use as contrast

agents

INVENTOR(S): Wolf, Markus; Bauder-Wust, Ulrike; Haberkorn, Uwe;

Eisenhut, Michael; Mier, Walter

PATENT ASSIGNEE(S): Germany

SOURCE: U.S. Pat. Appl. Publ., 20pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
US 2007202047	A1	20070830	US 2007-649503	20070104		
PRIORITY APPLN. INFO.:			US 2006-756352P P	20060105		

10/573938 OTHER SOURCE(S): MARPAT 147:294732 The present invention relates to a polyamine-substituted ligand for the preparation of a contrast agent derived from a chelating mol. selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and diethylentriamine-pentaacetic acid (DTPA), wherein at least one of the carboxylic groups of the chelating mol. is reacted with an amine of formula HNR1R2 to form an amide bond, wherein R1, R2 are independently selected from the group consisting of H; (CH2)n-NR3R4; and R5; R3, R4 are independently selected from the group consisting of H; (CH2)m-NR6R7; and (CH2)m-1-CH3; R6, R7 are independently selected from the group consisting of H; and (CH2)o-1-CH3; n, m, o are independently 2, 3, or 4; R5 is of formula and optionally at least one of the carboxylic groups of the chelating mol. is further reacted with a monoalkylamine having 1 to 18 carbon atoms to form an amide bond; provided that at least one of R1, R2 is other than H. Furthermore, the invention relates to contrast agents for magnetic resonance imaging (MRI) comprising said ligands and in-vivo diagnostic methods based on MRI using said contrast agents. INCL 424009363; 534015000; 540474000 8-9 (Radiation Biochemistry) CC ST polyamine substituted ligand gadolinium MRI tumor imaging ΙT Imaging (tumor; polyamine-substituted ligands for use as MRI contrast ΙT 7440-54-2DP, Gadolinium, polyamine-substituted ligand conjugates 947391-67-5P 947391-68-6P 947391-69-7P 947391-70-0P 947391-71-1P 947391-72-2P 947391-73-3P RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (polyamine-substituted ligands for use as MRI contrast agents) ΙT 85503-20-4P 120131-72-8P 134935-60-7P 923952-46-9P 923952-47-0P 923952-49-2P 923952-50-5P 923952-48-1P 947337-79-3P 947337-80-6P 947337-81-7P 947337-82-8P 947337-83-9P 947337-85-1P 947337-86-2P 947337-87-3P 947337-84-0P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (polyamine-substituted ligands for use as MRI contrast agents)


To substituted ligands for use as MRI contrast agents)
1T 947391-70-0P 947391-71-1P 947391-72-2P
RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (polyamine-substituted ligands for use as MRI contrast agents)
RN 947391-70-0 ZCAPLUS
CN Gadolinium, [10-[2-[bis(2-aminoethyl)amino]-2-(oxo-κO)ethyl]1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(8-)-



 κ N7, κ N10, κ O1, κ O4] - (CA INDEX NAME)


RN 947391-71-1 ZCAPLUS

CN Gadolinium, $[10-[2-[(4-aminobuty1)(3-aminopropy1)amino]-2-(oxo-\kappa0)ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)- <math>\kappa$ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]- (CA INDEX NAME)



RN 947391-72-2 ZCAPLUS

CN Gadolinium, [10-[2-[(3-aminopropyl)] [4-[(3-aminopropyl)] amino]butyl]amino]-2-(οxο-κΟ)ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-κN1,κN4,κN7,κN10,κΟ1,κΟ4,κΟ7]-(CA INDEX NAME)



IT 947337-81-7P 947337-82-8P 947337-83-9P 947337-86-2P 947337-87-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(polyamine-substituted ligands for use as MRI contrast agents)

RN 947337-81-7 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[bis(2-aminoethyl)amino]-2-oxoethyl]- (CA INDEX NAME)

RN 947337-82-8 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(4-aminobutyl)(3-aminopropyl)amino]-2-oxoethyl]- (CA INDEX NAME)

RN 947337-83-9 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(3-aminopropyl)[4-[(3-aminopropyl)amino]butyl]amino]-2-oxoethyl]- (CA INDEX NAME)

RN 947337-86-2 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(4-aminobutyl)(3-aminopropyl)amino]-2-oxoethyl]-, 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)

947337-87-3 ZCAPLUS RN

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(3-1),4,7]aminopropyl)[4-[(3-aminopropyl)amino]butyl]amino]-2-oxoethyl]-, 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)

L80 ANSWER 4 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN 2007:960536 ZCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER: 147:464287

Polymer-based elemental tags for sensitive bioassays TITLE: AUTHOR(S): Lou, Xudong; Zhang, Guohua; Herrera, Isaac; Kinach, Robert; Olga, Ornatsky; Baranov, Vladimir; Nitz, Mark;

Winnik, Mitchell A.

CORPORATE SOURCE: Institute of Biomaterials and Biomedical Engineering,

University of Toronto, Toronto, ON, M5S 3G9, Can.

Angewandte Chemie, International Edition (2007), SOURCE:

> 46(32), 6111-6114, S6111/1-S6111/5 CODEN: ACIEF5; ISSN: 1433-7851

Wiley-VCH Verlag GmbH & Co. KGaA

PUBLISHER: DOCUMENT TYPE: Journal

LANGUAGE: English

A water-soluble polymer bearing multiple metal-chelating ligands has been used as a tag for bioassays with inductively coupled plasma mass spectrometry. tag was covalently conjugated to antibodies, and the polymer-antibody constructs were loaded with lanthanide ions (Ln3+) and used for the simultaneous assay of five orthogonally labeled antibodies against cell surface antigens that differ in abundance by more than two orders of magnitude.

9-5 (Biochemical Methods) CC

Section cross-reference(s): 14, 15, 35

Acute monocytic leukemia ΙT Acute myeloid leukemia

Chelating agents

Chelation

Diagnostic agents

Human

Immunoassay

Molecular recognition

Protein-protein interaction

Tumor markers

(water-soluble polymer bearing multiple metal-chelating ligands tag for bioassays with inductively coupled plasma mass spectrometry applied to leukemia)

IT 115597-84-7 150463-52-8D, t-Bu, dithiobenzoate terminated 173308-19-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(water-soluble polymer bearing multiple metal-chelating ligands tag for bioassays with inductively coupled plasma mass spectrometry applied to leukemia)

IT 100-46-9DP, Benzenemethanamine, reaction with acrylamide/acrylic acid polymer, preparation 150467-20-2DP, reaction with

acrylamide/acrylic acid polymer 173308-19-5DP, reaction with acrylamide/acrylic acid polymer

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(water-soluble polymer bearing multiple metal-chelating ligands tag for bioassays with inductively coupled plasma mass spectrometry applied to leukemia)

IT 173308-19-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(water-soluble polymer bearing multiple metal-chelating ligands tag for bioassays with inductively coupled plasma mass spectrometry applied to leukemia)

RN 173308-19-5 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]-, 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)

t-Buo_C CH₂
$$CH_2$$
 CH_2 CH_2

IT 150467-20-2DP, reaction with acrylamide/acrylic acid polymer 173308-19-5DP, reaction with acrylamide/acrylic acid polymer

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(water-soluble polymer bearing multiple metal-chelating ligands tag for bioassays with inductively coupled plasma mass spectrometry applied to leukemia)

RN 150467-20-2 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]- (CA INDEX NAME)

RN 173308-19-5 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]-, 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)

$$\begin{array}{c} \text{t-Buo-C-CH}_2 \\ \text{ } \\ \text{ }$$

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 5 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:545418 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 147:206685

TITLE: Noninvasive Visualization of Pharmacokinetics,

Biodistribution and Tumor Targeting of

 ${\tt Poly[N-(2-hydroxypropyl)methacrylamide]} \ \, {\tt in Mice Using} \\$

Contrast Enhanced MRI

AUTHOR(S): Wang, Yanli; Ye, Furong; Jeong, Eun-Kee; Sun, Yongen;

Parker, Dennis L.; Lu, Zheng-Rong

CORPORATE SOURCE: Department of Pharmaceutics and Pharmaceutical

Chemistry, University of Utah, Salt Lake City, UT,

84108, USA

SOURCE: Pharmaceutical Research (2007), 24(6), 1208-1216

CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

Purpose: To study a non-invasive method of using contrast enhanced magnetic resonance imaging (MRI) to visualize the real-time pharmacokinetics, biodistribution and tumor accumulation of paramagnetically labeled poly[N-(2-hydroxypropyl)methacrylamide] (PHPMA) copolymer conjugates with different mol. wts. and spacers in tumor-bearing mice. Materials and Methods:

Paramagnetically labeled HPMA copolymer conjugates were synthesized by free radical copolymn. of HPMA with monomers containing a chelating ligand, followed by complexation with Gd(OAc)3. A stable paramagnetic chelate, Gd-DO3A, was conjugated to the copolymers via a degradable spacer GlyPheLeuGly

and a non-degradable spacer GlyGly, resp. The conjugates with mol. wts. of 28, 60 and 121 kDa and narrow mol. weight distributions were prepared by fractionation with size exclusion chromatog. The conjugates were injected into athymic nude mice bearing MDA-MB-231 human breast carcinoma xenografts via a tail vein. MR images were acquired before and at various time points after the injection with a 3D FLASH sequence and a 2D spin-echo sequence at 3T. Pharmacokinetics, biodistribution and tumor accumulation of the conjugates were visualized based on the contrast enhancement in the blood, major organs and tumor tissue at various time points. The size effect of the conjugates was analyzed among the conjugates. Results: Contrast enhanced MRI resulted in a real-time, three-dimensional visualization of blood circulation, pharmacokinetics, biodistribution and tumor accumulation of the conjugates, and the size effect on these pharmaceutical properties. HPMA copolymer conjugates with high mol. weight had a prolonged blood circulation time and high passive tumor targeting efficiency. Non-biodegradable HPMA copolymers with mol. wts. higher than the threshold of renal filtration demonstrated higher efficiency for temor drug delivery than biodegradable poly(L-glutamic acid). Conclusions: Contrast enhanced MRI is an effective method for noninvasive visualization of in vivo properties of the paramagnetically labeled polymer conjugates in preclin. studies.

- CC 8-9 (Radiation Biochemistry)
- ST contrast MRI gadolinium hydroxypropyl methacrylamide copolymer pharmacokinetics tumor imaging
- IT Human

Pharmacokinetics

(MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics and tumor targeting)

IT Imaging agents

(NMR contrast; MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics and tumor targeting)

IT Imaging

(NMR; MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics and tumor targeting)

IT Mammary gland, neoplasm

(carcinoma; MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics and tumor targeting)

IT Carcinoma

(mammary; MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics and tumor targeting)

IT Imaging

(tumor; MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics and tumor targeting)

IT 944834-63-3P 944834-65-5P

RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics and tumor targeting)

IT 21442-01-3, N-(2-Hydroxypropyl)methacrylamide 57950-79-5 100424-71-3 912576-20-6 944731-76-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics and tumor targeting)

IT 944731-74-2P 944731-75-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics and tumor targeting)


IT 944834-63-3P 944834-65-5P

RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics
and tumor targeting)
RN 944834-63-3 ZCAPLUS
CN Gadolinium, [N-(2-methyl-1-oxo-2-propen-1-yl)glycyl-N-[6-[[2-[4,7,10-tris[(carboxy-κ0)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]acetyl-κO]amino]hexyl]glycinamidato(3-)]-, polymer with
N-(2-hydroxypropyl)-2-methyl-2-propenamide (CA INDEX NAME)
CM 1

CRN 944834-62-2 CMF C30 H49 Gd N8 O10 CCI CCS

PAGE 1-A



PAGE 1-B

$$\stackrel{\circ}{\text{II}}$$
 $\stackrel{\text{CH}_2}{\text{II}}$ $\stackrel{\text{Me}}{\text{Me}}$

CM 2

CRN 21442-01-3 CMF C7 H13 N O2


RN 944834-65-5 ZCAPLUS

CN Gadolinium, [N-(2-methyl-1-oxo-2-propen-1-yl)glycyl-L-phenylalanyl-L-leucyl-N-[2-[[2-[4,7,10-tris[(carboxy- κ 0)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl- κ 0]amino]ethyl]glycinamidato(3-)]-, polymer with N-(2-hydroxypropyl)-2-methyl-2-propenamide (CA INDEX NAME)

CM 1

CRN 944834-64-4 CMF C41 H61 Gd N10 O12 CCI CCS

PAGE 1-A



PAGE 1-B

CM 2

CRN 21442-01-3 CMF C7 H13 N O2

RL: RCT (Reactant); RACT (Reactant or reagent)
(MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics and tumor targeting)

RN 912576-20-6 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(6-aminohexyl)amino]-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 889140-15-2 CMF C22 H42 N6 O7

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 944731-76-4 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 150467-20-2 CMF C18 H34 N6 O7

CM 2

CRN 76-05-1 CMF C2 H F3 O2

IT 944731-74-2P 944731-75-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(MRI visualization of polyhydroxypropyl methacrylamide pharmacokinetics and tumor targeting)

RN 944731-74-2 ZCAPLUS

CN Glycinamide, N-(2-methyl-1-oxo-2-propen-1-yl)glycyl-N-[6-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]hexyl]-(CA INDEX NAME)

$$\begin{array}{c} \text{PAGE 1-A} \\ \text{HO2C-CH2} \\ \text{N} \\ \text{CH}_{2}\text{-CO}_{2}\text{H} \\ \end{array}$$

RN 944731-75-3 ZCAPLUS

CN Glycinamide, N-(2-methyl-1-oxo-2-propen-1-yl)glycyl-L-phenylalanyl-L-leucyl-N-[2-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 6 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:402215 ZCAPLUS $\underline{\text{Full-text}}$

DOCUMENT NUMBER: 146:421772

TITLE: Biotin diamino derivatives and their conjugates with

macrocyclic chelating agents

INVENTOR(S): Carminati, Paolo; Ginanneschi, Mauro; Paganelli,

Giovanni; Chinol, Marco

PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,

Italy

SOURCE: PCT Int. Appl., 25pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT	KIN	D	DATE			APPL	ICAT	DATE								
WO 200	 A1	_	2007	0412	•	WO 2	 006-:		20060918							
W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
	GE,	GH,	GM,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KN,	KP,
	KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,
	MW,	MX,	MY,	MZ,	NA,	NG,	NΙ,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RS,

RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO:

CASREACT 146:421772; MARPAT 146:421772

GI

$$L = -CO-M P Y X$$

Biotin diamino derivs. I [A = CH2, C:O; B = H, CHO, CO2H; C = (CH2)c; D = AΒ (CH2)d; W = C1-12-alkylene, C2-12-alkenylene, functionalized polyethylene glycol, C6-10-aromatic residue, glucofuranosyl residue; R = linear or branched C1-4-alkyl, cycloalkyl, heterocycle, (CH2)qT; T = SMe, OH, CO2H; Q = 0, 1, 2; R', R'' = L; M = (CH2)m; P = (CH2)p; X = H, CH2U, (CHJ)oZ; Y = H, (un)branchedC1-44-alkyl, (CH2) mCO2H; U = Me, Et, C6H4NH2-4; Z = NH2, NHC(:NH)NH2, SR2, 5or 6-membered heterocycle containing one or more O, S, NR1; R1 = H, linear or branched C1-4-alkyl; R2 = linear or branched C1-4-alkyl; J = H, Me, Et; n = 4-12; a, b = 0 - n-1; c, d = 3 - 10; m = 1 - 3; o = 1 - 5; p = 2, 3] are described. Processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathol. conditions such as tumors. Thus, I [A = W = CH2, B = R = H, Q = (CH2)6, c = d]= 3, R' = R'' = 4,7,10-tri(carboxymethyl) - 1,4,7,10-tetrazacyclododecane-1acetyl] was prepared from reduced biotin N-hexylamide via acylation with N,Nbis[3-[(9-fluorenylmethoxycarbonyl)amino]propyl]qlycine potassium sulfate, deprotection with piperidine in DMF and acylation with DOTA.

CC 26-8 (Biomolecules and Their Synthetic Analogs)

Section cross-reference(s): 8, 63, 78

IT Radiopharmaceuticals

(antitumor; preparation of biotin conjugates with macrocyclic amines for therapeutic use as chelating agents)

IT Antitumor agents

Neoplasm

(radiopharmaceuticals; preparation of biotin conjugates with macrocyclic amines for therapeutic use as chelating agents)

IT 934166-99-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); USES (Uses)

(preparation of biotin conjugates with macrocyclic amines for therapeutic use as chelating agents)

IT 934166-99-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biotin conjugates with macrocyclic amines for therapeutic use as chelating agents)

RN 934166-99-1 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[[[2-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]pentyl]amino]hexyl]amino]-2-oxoethyl]imino]bis[3,1-propanediylimino(2-oxo-2,1-ethanediyl)]]bis- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

PAGE 2-A

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 7 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:377649 ZCAPLUS Full-text

DOCUMENT NUMBER: 147:66371

TITLE: Physicochemical and MRI characterization of

Gd3+-loaded polyamidoamine and hyperbranched

dendrimers

Jaszberenyi, Zoltan; Moriggi, Loieck; Schmidt, AUTHOR(S):

Philipp; Weidensteiner, Claudia; Kneuer, Rainer;

Merbach, Andre E.; Helm, Lothar; Toth, Eva

CORPORATE SOURCE: Institut des Sciences et Ingenierie Chimiques, Ecole

Polytechnique Federale de Lausanne, ISIC, BCH,

Lausanne, 1015, Switz.

JBIC, Journal of Biological Inorganic Chemistry SOURCE:

(2007), 12(3), 406-420

CODEN: JJBCFA; ISSN: 0949-8257

PUBLISHER: Springer GmbH

Journal DOCUMENT TYPE: English LANGUAGE:

Generation 4 polyamidoamine (PAMAM) and, for the first time, hyperbranched AΒ poly(ethylene imine) or polyglycerol dendrimers have been loaded with Gd3+ chelates, and the macromol. adducts have been studied in vitro and in vivo with regard to MRI contrast agent applications. The Gd3+ chelator was either a tetraazatetracarboxylate DOTA-pBn4- or a tetraazatricarboxylate monoamide DO3A-MA3- unit. The water exchange rate was determined from a 170 NMR and 1H Nuclear Magnetic Relaxation Dispersion study for the corresponding monomer analogs [Gd(DO3A-AEM)(H2O)] and [Gd(DOTA-pBn-NH2)(H2O)]- (k = 3.4 and 6.6×10^{-2} 106 s-1, resp.), where ${\tt H3DO3A-AEM}$ is ${\tt \{4-[(2-acetylaminoethylcarbamoyl)methyl]-}$ 7,10-bis(carboxymethyl-1,4,7,10- tetraazacyclododec-1-yl)}-acetic acid and H4DOTA-pBn-NH2 is 2-(4-aminobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetic acid. For the macromol. complexes, variable-field proton relaxivities have been measured and analyzed in terms of local and global motional dynamics by using the Lipari-Szabo approach. At frequencies below 100 MHz, the proton relaxivities are twice as high for the dendrimers loaded with the neg. charged Gd(DOTA-pBn)- in comparison with the analogous mol. bearing the neutral Gd(DO3A-MA). We explained this difference by the different rotational dynamics: the much slower motion of Gd(DOTA-pBn)--loaded dendrimers is likely related to the neq. charge of the chelate which creates more rigidity and increases the overall size of the macromol. compared with dendrimers loaded with the neutral Gd(DO3A-MA). Attachment of poly(ethylene glycol) chains to the dendrimers does not influence relaxivity. Both hyperbranched structures were found to be as good scaffolds as regular PAMAM dendrimers in terms of the proton relaxivity of the Gd3+ complexes. vivo MRI studies on tumor-bearing mice at 4.7 T proved that all dendrimeric


complexes are suitable for angiog. and for the study of vasculature parameters like blood volume and permeability of tumor vessels. CC 6-7 (General Biochemistry) Section cross-reference(s): 1, 63 ΙT 941280-58-6P RL: DGN (Diagnostic use); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (nod c,att o d,mov,joi; physicochem. and MRI characterization of Gd3+-loaded polyamidoamine and hyperbranched dendrimers) 9002-98-6DP, reaction products with PAMAM, gadolinium complexes ΙT 9004-74-4DP, PAMAM-PEI derivs. 25618-55-7DP, Polyglycerol, 26937-01-9DP, reaction products with amine-functionalized polyethylenimine, gadolinium complexes 120041-09-0DP, PAMAM-PEI 123317-52-2DP, PAMAM-PEI gadolinium gadolinium dendritic derivs. ethoxylated/polyglycerol dendritic derivs. 940961-69-3P 941280-59-7P RL: DGN (Diagnostic use); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (physicochem. and MRI characterization of Gd3+-loaded polyamidoamine and hyperbranched dendrimers) 941280-58-6P ΙT RL: DGN (Diagnostic use); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (nod c, att o d, mov, joi; physicochem. and MRI characterization of Gd3+-loaded polyamidoamine and hyperbranched dendrimers) 941280-58-6 ZCAPLUS RN CN Gadolinium, $[10-[2-[[2-(acetylamino)ethyl]amino]-2-(oxo-\kappa0)ethyl]-$ 1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)κΝ1, κΝ4, κΝ7, κΝ10, κΟ1, κΟ4, κΝ7] aqu a- (CA INDEX NAME) *** STRUCTURE DIAGRAM IS NOT AVAILABLE *** 940961-69-3P TΤ RL: DGN (Diagnostic use); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(physicochem. and MRI characterization of Gd3+-loaded polyamidoamine

and hyperbranched dendrimers)

940961-69-3 ZCAPLUS RN

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-(acetylamino)ethyl]amino]-2-oxoethyl]- (CA INDEX NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 8 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN 2007:249358 ZCAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: 146:501325

SOURCE:

TITLE: Synthesis of DOTA-conjugated multivalent cyclic-RGD

peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor

targeting and tumor imaging purposes

AUTHOR(S): Dijkgraaf, Ingrid; Rijnders, Anneloes Y.; Soede,

Annemieke; Dechesne, Annemarie C.; Van Esse, G. Wilma; Brouwer, Arwin J.; Corstens, Frans H. M.; Boerman, Otto C.; Rijkers, Dirk T. S.; Liskamp, Rob M. J.

CORPORATE SOURCE: Department of Medicinal Chemistry and Chemical

Biology, Utrecht Institute for Pharmaceutical

Sciences, Utrecht University, Utrecht, 3508 TB, Neth. Organic & Biomolecular Chemistry (2007), 5(6), 935-944

CODEN: OBCRAK; ISSN: 1477-0520

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:501325

The design and synthesis of a series of $\alpha V\beta 3$ integrin-directed monomeric, AΒ dimeric and tetrameric cyclo[Arg-Gly-Asp-d-Phe-Lys] dendrimers using "click chemical" is described. It was found that the unprotected N-.vepsiln.-azido derivative of cyclo[Arg-Gly-Asp-d-Phe-Lys] underwent a highly chemoselective conjugation to amino acid-based dendrimers bearing terminal alkynes using a microwave-assisted Cu(i)-catalyzed 1,3-dipolar cycloaddn. The $\alpha V\beta 3$ binding characteristics of the dendrimers were determined in vitro and their in vivo $\alpha V \beta 3$ targeting properties were assessed in nude mice with s.c. growing human SK-RC-52 tumors. The multivalent RGD-dendrimers were found to have enhanced affinity toward the $\alpha V\beta 3$ integrin receptor as compared to the monomeric derivative as determined in an in vitro binding assay. In case of the DOTAconjugated 111In-labeled RGD-dendrimers, it was found that the radiolabeled multimeric dendrimers showed specifically enhanced uptake in $\alpha V \beta 3$ integrin expressing tumors in vivo. These studies showed that the tetrameric RGDdendrimer had better tumor targeting properties than its dimeric and monomeric congeners.

CC 34-3 (Amino Acids, Peptides, and Proteins) Section cross-reference(s): 1, 28

ST DOTA cyclic RGD peptide conjugated dendrimer prepn tumor imaging; cyclic RGD peptide solid phase prepn DOTA dipolar cycloaddn

IT Cycloaddition reaction

 $(1,3-{
m dipolar};$ preparation and tumor targeting and imaging use of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using microwave-assisted dipolar cycloaddn. as the key step for the conjugation)

IT Microwave

(irradiation; preparation and tumor targeting and imaging use of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using microwave-assisted dipolar cycloaddn. as the key step for the conjugation)

IT Antitumor agents

Human

Pharmacokinetics

(preparation and tumor targeting and imaging use of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using microwave-assisted dipolar cycloaddn. as the key step for the conjugation)

IT RGD peptides

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and tumor targeting and imaging use of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using

```
microwave-assisted dipolar cycloaddn. as the key step for the
       conjugation)
ΙT
     Imaging
     Imaging agents
        (tumor; preparation and tumor targeting and imaging use
        of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using
       microwave-assisted dipolar cycloaddn. as the key step for the
        conjugation)
     Integrins
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\alpha v \beta 3; preparation and tumor targeting and imaging use
        of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using
       microwave-assisted dipolar cycloaddn. as the key step for the
        conjugation)
     936125-37-0P 936125-39-2P 936235-89-1P
ΙT
     RL: DGN (Diagnostic use); PAC (Pharmacological activity); PKT
     (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study);
     PREP (Preparation); USES (Uses)
        (preparation and tumor targeting and imaging use of
       DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using
       microwave-assisted dipolar cycloaddn. as the key step for the
       conjugation)
     99-06-9, 3-Hydroxybenzoic acid, reactions 99-10-5, 3,5-Dihydroxybenzoic
ΤT
           106-96-7, Propargyl bromide 107-15-3, 1,2-Ethanediamine,
     reactions
                29022-11-5, Fmoc-Gly-OH
                                          39684-80-5, tert-Butyl
     (2-bromoethyl)carbamate
                              71989-14-5 71989-26-9
                                                       86123-10-6
     137076-54-1 154445-77-9
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation and tumor targeting and imaging use of
        DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using
       microwave-assisted dipolar cycloaddn. as the key step for the
        conjugation)
ΙT
     2150-44-9P, 3,5-Dihydroxybenzoic acid, methyl ester 19438-10-9P,
     3-Hydroxybenzoic acid, methyl ester 57260-73-8P 85607-73-4P
     160893-68-5P 184916-28-7P 250612-44-3P 664334-21-8P 680572-35-4P
     768387-51-5P 866088-22-4P 936125-14-3P 936125-18-7P 936125-20-1P
     936125-22-3P 936125-24-5P 936125-26-7P
                                 942131-93-3P 942131-95-5P
     936125-28-9P 936125-31-4P
     942131-99-9P 942132-29-8P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation and tumor targeting and imaging use of
        DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using
        microwave-assisted dipolar cycloaddn. as the key step for the
        conjugation)
     868845-24-3P
                   868845-25-4P 936125-33-6P
ΤТ
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (preparation and tumor targeting and imaging use of
        DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using
       microwave-assisted dipolar cycloaddn. as the key step for the
        conjugation)
     936125-37-0P 936125-39-2P
ΙT
     RL: DGN (Diagnostic use); PAC (Pharmacological activity); PKT
     (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study);
     PREP (Preparation); USES (Uses)
        (preparation and tumor targeting and imaging use of
        DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using
       microwave-assisted dipolar cycloaddn. as the key step for the
        conjugation)
     936125-37-0 ZCAPLUS
RN
```

CN Cyclo[L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-6-[4-[[3-[[2-[[2[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1yl]acetyl]amino]ethyl]amino]carbonyl]phenoxy]methyl]-1H-1,2,3-triazol-1yl]-L-norleucyl] (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

RN 936125-39-2 ZCAPLUS

CN Cyclo(L-arginylglycyl-L- α -aspartyl-D-phenylalanyl-L-norleucyl), 56,5'6-[[5-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]amino]carbonyl]-1,3-phenylene]bis(oxymethylene-1H-1,2,3-triazole-4,1-diyl)]bis- (CA INDEX NAME)

PAGE 1-A

PAGE 2-B

PAGE 3-A

R---

PAGE 3-B

IT 936125-22-3P 936125-24-5P 936125-28-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and temor targeting and imaging use of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers using microwave-assisted dipolar cycloaddn. as the key step for the conjugation)

RN 936125-22-3 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-oxo-2-[[2-[[3-(2-propyn-1-yloxy)benzoyl]amino]ethyl]amino]ethyl]-, 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)

PAGE 1-A

CH2 N CH2 C OBu-t CH2 C OBu-t

RN 936125-24-5 ZCAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[[3,5-bis(2-propyn-1-yloxy)benzoyl]amino]ethyl]amino]-2-oxoethyl]-,
 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)

RN 936125-28-9 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[[3,5-bis[2-[[3,5-bis(2-propyn-1-yloxy)benzoyl]amino]ethoxy]benzoyl]amino]ethyl]amino]-2-oxoethyl]-, 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

PAGE 2-A

$$CH2$$
 N
 $CH2$
 $CH2$
 $CH2$
 $CH2$
 $CH2$
 $CH2$
 $CH2$
 $CH2$
 C
 $CH2$
 C
 $CH2$
 $CH2$

REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 9 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:230231 ZCAPLUS Full-text

DOCUMENT NUMBER: 146:288424

TITLE: Non-invasive diagnostic agents of cancer and methods

of diagnosing cancer, especially leukemia and lymphoma

INVENTOR(S): Norenberg, Jeffrey P.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 19pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

US 2007048216 A1 20070301 US 2006-507846 20060822

PRIORITY APPLN. INFO: US 2005-710665P P 20050823

The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively mol. imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compds. according to the present invention may be used as diagnostic tools for a number of conditions and disease states as well as therapeutic agents for treating such conditions and disease states.

INCL 424001110; 534011000; 534014000

CC 1-6 (Pharmacology)

Section cross-reference(s): 4, 8, 63

IT Acute lymphocytic leukemia

Acute myeloid leukemia

Acute promyelocytic leukemia

Adult T-cell leukemia

Anti-inflammatory agents

Anti-ischemic agents

Antidiabetic agents

Antirheumatic agents

Antitumor agents

Arthritis

Autoimmune disease

Blood analysis

Burn

Cardiopulmonary bypass

Diabetes mellitus

Diagnostic agents

Drug toxicity

Hairy cell leukemia

Hematopoiesis

Human

Imaging

Immunity

Inflammation

Inflammatory bowel diseases

Ischemia

Monocytic leukemia

Multiple sclerosis

Myeloid leukemia

Myocardial infarction

Neoplasm

Osteoarthritis

Polymorphonuclear leukocyte

Psoriasis

Respiratory distress syndrome

Rheumatoid arthritis

Skin, disease

Stem cell

Transplant rejection

Uveitis

Wart

(non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma)

IT 927833-57-6 927833-59-8

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); DGN (Diagnostic use); PKT (Pharmacokinetics); BIOL (Biological study); USES (Uses)

(non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma)


IT 927833-57-6

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); DGN (Diagnostic use); PKT (Pharmacokinetics); BIOL (Biological study); USES (Uses)

(non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma)

RN 927833-57-6 ZCAPLUS

CN Lutetium-177Lu, [10-[2-[[4-[5-[(4-bromophenyl)methyl]-3-(3,5-dichlorophenyl)-5-methyl-2,4-dioxo-1-imidazolidinyl]butyl]amino]-2-(oxoκ0)ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)κN1,κN4,κN7,κN10]- (CA INDEX NAME)



L80 ANSWER 10 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:78033 ZCAPLUS Full-text

DOCUMENT NUMBER: 147:517229

TITLE: PET imaging of apoptosis with 64Cu-labeled

streptavidin following pretargeting of

phosphatidylserine with biotinylated annexin-V

AUTHOR(S): Cauchon, Nicole; Langlois, Rejean; Rousseau, Jacques

A.; Tessier, Guillaume; Cadorette, Jules; Lecomte, Roger; Hunting, Darel J.; Pavan, Roberto A.; Zeisler,

Stefan K.; Lier, Johan E.

CORPORATE SOURCE: Sherbrooke Molecular Imaging Centre and Department of

Nuclear Medicine and Radiobiology, Faculty of Medicine

and Health Sciences, Universite de Sherbrooke,

Sherbrooke, QC, Can.

SOURCE: European Journal of Nuclear Medicine and Molecular

Imaging (2007), 34(2), 247-258 CODEN: EJNMA6; ISSN: 1619-7070

PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

AΒ In vivo detection of apoptosis is a diagnostic tool with potential clin. applications in cardiol. and oncol. Radiolabeled annexin-V (anxV) is an ideal probe for in vivo apoptosis detection owing to its strong affinity for phosphatidylserine (PS), the mol. flag on the surface of apoptotic cells. Most clin. studies performed to visualize apoptosis have used 99mTc-anxV; however, its poor distribution profile often compromises image quality. In this study, tumor apoptosis after therapy was visualized by positron emission tomog. (PET) using 64Cu-labeled streptavidin (SAv), following pre-targeting of apoptotic cells with biotinylated anxV. Apoptosis was induced in tumor-bearing mice by photodynamic therapy (PDT) using phthalocyanine dyes as photosensitizers, and red light. After PDT, mice were injected i.v. with biotinylated anxV, followed 2 h later by an avidin chase, and after another 2 h with 64Cu-DOTA-biotin-SAv. PET images were subsequently recorded up to 13 h after PDT. PET images delineated apoptosis in treated tumors as early as 30 min after 64Cu-DOTA-biotin-SAv administration, with tumor-to-background ratios reaching a maximum at 3 h post-injection, i.e., 7 h post-PDT. Omitting the administration of biotinylated anxV or the avidin chase failed to provide a clear PET image, confirming that all three steps are essential for adequate visualization of apoptosis. Furthermore, differences in action mechanisms between photosensitizers that target tumor cells directly or via initial vascular stasis were clearly recognized through differences in tracer uptake patterns detecting early or delayed apoptosis. This study demonstrates the efficacy of a three-step 64Cu pretargeting procedure for PET imaging of apoptosis. These data also confirm the usefulness of small animal PET to evaluate cancer treatment protocols.

CC 8-9 (Radiation Biochemistry)

ST copper 64 DOTA biotin streptavidin PET PDT apoptosis; PET imaging annexin V targeted tumor apoptosis photosensitizer

IT Imaging

(tumor; use of pretargeting procedure of phosphatidylserine with biotinylated annexin-V for PET imaging of apoptosis with 64Cu-SAv complex)

IT 956262-96-7P 956428-39-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(use of pretargeting procedure of phosphatidylserine with biotinylated annexin-V for PET imaging of apoptosis with 64Cu-SAv complex)

IT 956262-96-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(use of pretargeting procedure of phosphatidylserine with biotinylated annexin-V for PET imaging of apoptosis with 64 Cu-SAv complex)

RN 956262-96-7 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[4-[[5-[(3aS,4R,6aR)-octahydro-2,5-dioxo-4-cyclopentimidazolyl]-1-oxopentyl]amino]butyl]amino]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

─_co2H

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 11 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:872573 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 145:425460

TITLE: Noninvasive Visualization of in Vivo Drug Delivery of

Poly(L-glutamic acid) Using Contrast-Enhanced MRI

AUTHOR(S): Ye, Furong; Ke, Tianyi; Jeong, Eun-Kee; Wang, Xuli;

Sun, Yongen; Johnson, Melody; Lu, Zheng-Rong

CORPORATE SOURCE: Departments of Pharmaceutics and Pharmaceutical

Chemistry and Radiology, University of Utah, Salt Lake

City, UT, 84108, USA

SOURCE: Molecular Pharmaceutics (2006), 3(5), 507-515

CODEN: MPOHBP; ISSN: 1543-8384

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:425460

Biomedical imaging is valuable for noninvasive investigation of in vivo drug AB delivery with polymer conjugates. It can provide real-time information on pharmacokinetics, biodistribution, and drug delivery efficiency of the conjugates. Noninvasive visualization of in vivo drug delivery of polymer conjugates with contrast-enhanced magnetic resonance imaging (MRI) was studied with paramagnetically labeled poly(L-glutamic acid) in an animal tumor model. Poly(L-glutamic acid) is a biocompatible and biodegradable drug carrier for diagnostics and therapeutics. Poly(L-glutamic acid)-1,6-hexanediamine-(Gd-DO3A) conjugates with mol. wts. of 87, 50, and 28 kDa and narrow mol. weight distributions were prepared and studied in mice bearing MDA-MB-231 human breast cancer xenografts. Contrast-enhanced MRI resulted in real-time and three-dimensional visualization of blood circulation, pharmacokinetics, biodistribution, and tumor accumulation of the conjugates, and the size effect on these pharmaceutics properties. The conjugate of 28 kDa rapidly cleared from the circulation and had a relatively lower tumor accumulation. The conjugates with higher mol. wts. exhibited a more prolonged blood circulation and higher tumor accumulation. The difference between the conjugates of 87

and 50 kDa was not significant. Contrast-enhanced MRI is effective for noninvasive real-time visualization of in vivo drug delivery of paramagnetically labeled polymer conjugates.

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 8

IT 912576-20-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(noninvasive visualization of in vivo drug delivery of poly(L-glutamic acid) using contrast-enhanced MRI)

IT 22541-19-1, Gd3+, biological studies 912576-20-6D, reaction

products with polyglutamic acid, gadolinium complexes

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(noninvasive visualization of in vivo drug delivery of poly(L-glutamic acid) using contrast-enhanced MRI)

IT 912576-20-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(noninvasive visualization of in vivo drug delivery of poly(L-glutamic acid) using contrast-enhanced MRI)

RN 912576-20-6 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(6-aminohexyl)amino]-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 889140-15-2 CMF C22 H42 N6 O7

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (noninvasive visualization of in vivo drug delivery of poly(L-glutamic

AUTHOR(S):

acid) using contrast-enhanced MRI

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 12 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:836023 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 147:26007

TITLE: Biodegradable cystamine spacer facilitates the

clearance of Gd(III) chelates in poly(glutamic acid) Gd-DO3A conjugates for contrast-enhanced MR imaging Ke, Tianyi; Feng, Yi; Guo, Junyu; Parker, Dennis L.;

Lu, Zhena-Rona

CORPORATE SOURCE: Department of Pharmaceutics and Pharmaceutical

Chemistry, University of Utah, Salt Lake City, UT,

84108, USA

SOURCE: Magnetic Resonance Imaging (2006), 24(7), 931-940

CODEN: MRIMDQ; ISSN: 0730-725X

PUBLISHER: Elsevier Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

Poly(-glutamic acid) (PGA)-cystamine-[gadolinium (Gd)-DO3A] was prepared in high yield with a high Gd-DO3A conjugation efficiency. Approx. 55% of the carboxylic groups in PGA were loaded with Gd-DO3A via cystamine as the spacer. Cystamine can be readily cleaved by endogenous thiols to release the Gd(III) chelates from the conjugate facilitating Gd(III) excretion after the magnetic resonance imaging (MRI). The contrast-enhanced MRI with PGA-cystamine-(Gd-DO3A) was investigated in mice bearing MDA-MB-231 breast carcinoma xenografts. PGA-1,6-hexanediamine-(Gd-DO3A), a paramagnetic polymer conjugate of a nondegradable spacer, was used as a control. Both conjugates resulted in similar contrast enhancement in the heart, vasculature, liver and kidneys in the first hour post injection. More substantial signal intensity reduction was observed for PGA-cystamine-(Gd- DO3A) in these organs than PGA-1,6hexanediamine-(Gd-DO3A) due to release of the Gd chelates from PGA-cystamine-(Gd-DO3A) after the cleavage of the disulfide spacer by the endogenous thiols. Both conjugates resulted in similar tumor enhancement with approx. 70% increased signal intensity in the tumor periphery and 10-40% increased signal intensity in tumor interstitium. No cross-reaction was observed between PGAcystamine-(Gd-DO3A) and human serum albumin, a plasma protein containing a cysteine residue. PGA-cystamine-(Gd-DO3A) resulted in significantly lower Gd(III) tissue retention than PGA-1,6-hexanediamine-(Gd-DO3A) 10 days after the injection in the mice (P<.05). The conjugation of Gd(III) chelates to biomedical copolymers via the degradable disulfide spacer resulted in significant contrast enhancement in the blood pool and tumor tissue but minimal long-term Gd(III) tissue retention.

CC 8-9 (Radiation Biochemistry)

IT Imaging

(tumor; role of biodegradable cystamine spacer in clearance of Gd(III)chelates in poly(glutamic acid)Gd-DO3A conjugates for contrast enhanced magnetic resonance imaging of breast carcinomas)

IT 25513-46-6DP, reaction products with acetic acid tetraazacyclododecane cystamine derivs. 585531-76-6DP, polyglutamic acid derivs., gadolinium complexes 889140-15-2DP, polyglutamic acid derivs., gadolinium complexes

RL: PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(role of biodegradable cystamine spacer in clearance of Gd(III)chelates in poly(glutamic acid)Gd-DO3A conjugates for contrast enhanced magnetic resonance imaging of breast carcinomas)

IT 114873-37-9P 122555-91-3P 485800-28-0P 585531-76-6P 889140-15-2P 938041-81-7P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(role of biodegradable cystamine spacer in clearance of Gd(III) chelates in poly(glutamic acid)Gd-DO3A conjugates for contrast enhanced magnetic resonance imaging of breast carcinomas)

IT 889140-15-2DP, polyglutamic acid derivs., gadolinium complexes

RL: PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(role of biodegradable cystamine spacer in clearance of Gd(III)chelates in poly(glutamic acid)Gd-DO3A conjugates for contrast enhanced magnetic resonance imaging of breast carcinomas)

RN 889140-15-2 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(6-aminohexyl)amino]-2-oxoethyl]- (CA INDEX NAME)

IT 889140-15-2P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(role of biodegradable cystamine spacer in clearance of Gd(III)chelates in poly(glutamic acid)Gd-DO3A conjugates for contrast enhanced magnetic resonance imaging of breast carcinomas)

RN 889140-15-2 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(6-aminohexyl)amino]-2-oxoethyl]- (CA INDEX NAME)

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 13 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:779890 ZCAPLUS Full-text

DOCUMENT NUMBER: 145:391420

TITLE: Structure-Activity Relationships of 111In- and

99mTc-Labeled Quinolin-4-one Peptidomimetics as Ligands for the Vitronectin Receptor: Potential

Tumor Imaging Agents

AUTHOR(S): Harris, Thomas D.; Kalogeropoulos, Shirley; Nguyen,

Tiffany; Dwyer, Gregory; Edwards, D. Scott; Liu,

Shuang; Bartis, Judit; Ellars, Charles; Onthank, Dave; Yalamanchili, Padmaja; Heminway, Stuart; Robinson,

Simon; Lazewatsky, Joel; Barrett, John

CORPORATE SOURCE: Discovery Research, Bristol-Myers Squibb Medical

Imaging, N. Billerica, MA, 01862, USA

SOURCE: Bioconjugate Chemistry (2006), 17(5), 1294-1313

CODEN: BCCHES; ISSN: 1043-1802

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

- The integrin receptor $\alpha v \beta 3$ is overexpressed on the endothelial cells of AB growing tumous and on some tumor cells themselves. Radiolabeled $\alpha v \beta 3$ antagonists have demonstrated potential application as tumor imaging agents and as radiotherapeutic agents. This report describes the total synthesis of eight new HYNIC and DOTA conjugates of receptor $\alpha v \beta 3$ antagonists belonging to the quinolin-4-one class of peptidomimetics, and their radiolabeling with 99mTc (for HYNIC) and 111In (for DOTA). Tethering of the radionuclidechelator complexes was achieved at two different sites on the quinolin-4-one mol. All such derivs. maintained high affinity for receptor $\alpha v \beta 3$ and high selectivity vs. receptors $\alpha IIb\beta 3$, $\alpha v\beta 5$, $\alpha 5\beta 1$. Biodistribution of the radiolabeled compds. was evaluated in the c-neu Oncomouse mammary adenocarcinoma model. DOTA conjugate 111In-TA138 presented the best biodistribution profile. Tumor uptake at 2 h postinjection was 9.39% of injected dose/g of tissue (%ID/g). Activity levels in selected organs was as follows: blood, 0.54% ID/g; liver, 1.94% ID/g; kidney, 2.33% ID/g; lung, 2.74% ID/g; bone, 1.56% ID/g. A complete biodistribution anal. of 111In-TA138 and the other radiolabeled compds. of this study are presented and discussed. A scintigraphic imaging study with 111In-TA138 showed a clear delineation of the tumors and rapid clearance of activity from nontarget tissues.
- CC 8-9 (Radiation Biochemistry)
- ST prepn radiolabeled quinolinone peptidomimetic vitronectin receptor tumor imaging
- IT Scintigraphic agents

Scintigraphy

Structure-activity relationship

(SAR and preparation of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for vitronectin receptor and potential tumor imaging agents)

IT Vitronectin receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SAR and preparation of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for vitronectin receptor and potential tumor imaging agents)

IT Mammary gland, neoplasm

(adenocarcinoma; SAR and preparation of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for vitronectin receptor and potential tumor imaging agents)

IT Carcinoma

(mammary adenocarcinoma; SAR and preparation of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for vitronectin receptor and potential tumor imaging agents)

IT Pharmacokinetics

(organ uptake; SAR and preparation of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for vitronectin receptor and potential tumor imaging agents)

IT Imaging

(tumor; SAR and preparation of 111In- and 99mTc-labeled

```
10/573938
       quinolin-4-one peptidomimetics as ligands for vitronectin receptor and
       potential tumor imaging agents)
ΙT
     Integrins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\alpha IIb\beta 3; SAR and preparation of 111In- and 99mTc-labeled
        quinolin-4-one peptidomimetics as ligands for vitronectin receptor and
       potential tumor imaging agents)
ΙT
     Integrins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\alpha v \beta 3; SAR and preparation of 111In- and 99mTc-labeled
        quinolin-4-one peptidomimetics as ligands for vitronectin receptor and
       potential tumor imaging agents)
ΙT
     Integrins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\alpha v \beta 5; SAR \text{ and preparation of } 111In-\text{ and } 99mTc-labeled
        quinolin-4-one peptidomimetics as ligands for vitronectin receptor and
       potential tumor imaging agents)
ΙT
     Integrins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\alpha 5\beta 1; SAR and preparation of 111In- and 99mTc-labeled
        quinolin-4-one peptidomimetics as ligands for vitronectin receptor and
       potential tumor imaging agents)
     15750-15-9DP, Indium 111, conjugates, biological studies 278172-91-1P
ΤT
     278172-95-5P
                  278172-98-8P 278172-99-9P 378784-45-3DP, Technetium
     99m, conjugates, biological studies 498575-44-3DP, technetium-99 complex
     498575-49-8DP, technetium-99 complex 498575-53-4DP, technetium-99
              911209-04-6P
     complex
     RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic
     preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
        (SAR and preparation of 111In- and 99mTc-labeled quinolin-4-one
        peptidomimetics as ligands for vitronectin receptor and potential
       tumor imaging agents)
               3406-84-6, Biphenyl-4, 4'-disulfonyl chloride 4246-51-9
ΙT
     501-53-1
     7790-94-5, Chlorosulfonic acid 66414-73-1 72080-83-2, Benzyl
     N-(2-aminoethyl)carbamate 77087-60-6 83948-53-2
                                                          98541-64-1
     114559-25-0
                 137076-54-1, DOTA tri(tert-butyl) ester 185563-93-3
                                             277315-96-5
     206055-18-7
                  208580-23-8 208580-27-2
                                                             277316-23-1
     277316-26-4 277316-29-7 848083-49-8
                                             911141-44-1
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (SAR and preparation of 111In- and 99mTc-labeled quinolin-4-one
       peptidomimetics as ligands for vitronectin receptor and potential
       tumor imaging agents)
     40324-66-1P
                  57932-18-0P
                                220156-99-0P
                                               250612-31-8P
                                                              277315-53-4P
ΙT
     277315-71-6P
                   277315-77-2P 277315-83-0P
                                                 277315-84-1P 277315-85-2P
     277315-86-3P
                   277315-87-4P
                                  277315-89-6P
                                                 277315-90-9P
                                                                 277315-97-6P
     277315-98-7P
                   277315-99-8P
                                  277316-00-4P
                                                 277316-01-5P
                                                                277316-02-6P
     277316-03-7P 277316-09-3P 277316-10-6P 277316-11-7P
                                                                277316-24-2P
     277316-28-6P 277316-40-2P
                                  277316-41-3P 277316-42-4P
                                                                277316-43-5P
     277316-46-8P 277316-50-4P 277316-51-5P 277316-58-2P
     498575-82-9P 498575-84-1P 498575-86-3P 569328-06-9P
                                                                911141-43-0P
     911141-45-2P
                  911141-46-3P
                                  911141-47-4P
                                                911141-48-5P
                                                                911141-49-6P
     911141-50-9P 911141-52-1P
                                  911141-53-2P 911141-54-3P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (SAR and preparation of 111In- and 99mTc-labeled quinolin-4-one
```

peptidomimetics as ligands for vitronectin receptor and potential tumor imaging agents)

IT 911141-45-2DP, technetium-99 complex 911141-55-4P 911141-56-5P RL: SPN (Synthetic preparation); PREP (Preparation)

(SAR and preparation of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for vitronectin receptor and potential tumor imaging agents)

IT 277316-46-8P 911141-54-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(SAR and preparation of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for vitronectin receptor and potential tumor imaging agents)

RN 277316-46-8 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[3-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-oxoethyl]-, α,α',α'' -tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 911141-54-3 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[3-[[(2S)-2-carboxy-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-oxoethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 277315-74-9

CMF C45 H61 N11 O13 S

Absolute stereochemistry.

CM 2

CRN 76-05-1 CMF C2 H F3 O2

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 14 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:681369 ZCAPLUS Full-text

DOCUMENT NUMBER: 145:146029

TITLE: Preparation of peptide-containing compounds for

targeting cells expressing NP-1 receptor

INVENTOR(S): Von Wronski, Mathew A.; Marinelli, Edmund R.; Nunn,

Adrian D.; Pillai, Radhakrishna; Ramalingam,

Kondareddiar; Tweedle, Michael F.; Linder, Karen E.;

Nanjappan, Palaniappa; Raju, Natarajan

PATENT ASSIGNEE(S): Bracco International B.V., Neth.

SOURCE: U.S. Pat. Appl. Publ., 98 pp., Cont.-in-part of Ser.

No. US 2001-871974,

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PAT	PATENT NO.						DATE		-	APPLICATION NO.						DATE			
US	US 2006153775					_	2006	0713		 US 2	006-		20060127						
US	US 2002147136					A1 20021010				US 2	001-		20010604						
US	US 7109167					B2 200			0060919										
WO	WO 2007090022				A2 20070809			0809	,	WO 2	007-		20070125						
WO	2007090022			A3 20071122															
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,		
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,		
		GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KN,		
		KP,	KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,		
		MN,	MW,	MX,	MY,	MΖ,	NA,	NG,	NΙ,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,		
		RS,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,	SY,	ΤJ,	TM,	TN,	TR,	TT,		
		TZ,	UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	ZW								
	RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,		
		IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,		
		CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,	GH,		
		GM,	ΚE,	LS,	MW,	MΖ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,		
		KG,	KΖ,	MD,	RU,	ΤJ,	TM,	AP,	EA,	EP,	OA								
PRIORITY	RIORITY APPLN. INFO.:								US 2000-585364							B2 20000602			
									US 2001-871974						A2 20010604				
	US 2006-342050										A 20060127								

OTHER SOURCE(S): MARPAT 145:146029

The invention provides compds. for targeting endothelial cells, tumor cells or other cells that express the neuropilin-1 (NP-1) receptor, compns. containing the same and methods for their use. The compds. are of the formula A-L-B (A = a monomer, multimer or polymer of TKPPR or analog which specifically binds to NP-1 or cells expressing NP-1 with avidity equal or greater than TKPPR; L = a lipid or a non-lipid (e.g., polymer) linker; B = a substrate). Addnl., the present invention includes diagnostic, therapeutic and radio-therapeutic compns. useful for visualization, therapy or radiotherapy. For example, DPPE-glutaroyl-Gly-Thr-Lys-Pro-Pro- Arg-OH (DPPE-Glu-GTKPPR) was prepared and formulated into gas-filled microbubble compns. for ultrasonic echog. The bubbles bind to human aortic endothelial cells (HAEC) under flow. The number of bubbles bound may increase with time for several minutes at a given flow rate, up to a flow rate producing 1.53 dynes/cm2, while bubbles without the targeting moiety (DPPE-Glu-GTKPPR) may not bind. However, once bound under a lesser flow rate (e.g., 1.53 dynes/cm2), the shear stress on bubbles

containing DPPE-Glu-GTKPPR may be increased to 6.1 dynes/cm2 without dislodging many of the bound bubbles.

INCL 424009340; 530326000

CC 34-3 (Amino Acids, Peptides, and Proteins) Section cross-reference(s): 1, 8, 63

ST peptide neuropilin receptor endothelium tumor targeting; antitumor angiogenesis inhibitor peptide deriv prepn; gene therapy radiotherapy peptide deriv; ultrasound imaging endothelium neuropilin peptide

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (human aortic endothelial cells activated by; preparation of peptidecontaining

compds. and compns. for targeting cells expressing neuropilin-1 receptor for diagnosis, imaging, and therapy)

IT 100-46-9, Benzenemethanamine, reactions 1155-64-2 1663-39-4 4530-20-5 5681-36-7 7672-27-7 15401-08-8 29022-11-5 33662-26-9 71989-26-9 71989-35-0 76931-93-6 82911-69-1 106392-12-5 120791-76-6 129223-22-9 166108-71-0 167393-62-6 169543-81-1 198139-51-4 251450-64-3 283176-26-1 377087-81-5D, resin bound 377087-83-7D, resin-bound 470444-40-7 897930-81-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of peptide-containing compds. and compns. for targeting cells expressing neuropilin-1 receptor for diagnosis, imaging, and therapy)

IT 897930-81-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of peptide-containing compds. and compns. for targeting cells expressing neuropilin-1 receptor for diagnosis, imaging, and therapy)

RN 897930-81-3 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-[[5-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopentyl]amino]propyl]amino]-2-oxoethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L80 ANSWER 15 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:542454 ZCAPLUS Full-text

DOCUMENT NUMBER: 145:34213

TITLE: MRI-guided photodynamic therapy for cancer INVENTOR(S): Lu, Zheng-Rong; Viadya, Anagha; Ke, Tianyi PATENT ASSIGNEE(S): University of Utah Research Foundation, USA

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PA:	FENT 1	NO.			KIND DATE					APPL:	ICAT		DATE				
					A2 20060608 A3 20060824			WO 2005-US44012						20051202				
	WO	W: AE, AG, AL,							DΛ	DD	BC	ВD	TD TAT	ΒV	B 7	C_{Δ}	СП	
		VV •						DE,										
			•	•	•			ID,		•		•	,			•		•
								LT,									•	•
								NZ,									•	•
								ТJ,	ΙМ,	T 1/1 ,	IK,	ΙΙ,	14,	UA,	UG,	05,	UΔ,	vc,
		DII	,	,	,	ZM,		0.5	DII	DI		ПО		пр	O.D.	O.D.		T.D.
		KW:						CZ,			•						•	•
						•		MC,						•	•			
								GN,										
								NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
			,	,	,	RU,	,											
														20051202				
	CA 2589881					A1		2006	0608		CA 2	005-	2589	20051202				
	EΡ	1830	879			A2		2007	0912		EP 2	005-	8530	48		2	0051	202
		R:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	IE,
			IS,	ΙΤ,	LI,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR	
	KR 2007086803							2007	0827		KR 2	007-	7149	20070629				
PRIOF	RIT	Y APP	LN.	INFO	.:						US 2004-633255P						0041	203
											WO 2	005-1	Ţ	W 2	0051	202		

AB Disclosed is a method of therapy used in combination with a diagnostic tool for enhanced photodynamic therapy using MRI, called (magnetic resonance imaging)-guided photodynamic therapy. The methods of the present invention include administration of MRI contrast agent-labeled polymer photosensitizer conjugates, detection and localization of tumor or cancer tissues with contrast-enhanced MRI and specific illumination and treatment of localized target tissues, such as tumors or cancer cells, using laser energy. The delivered laser energy activates the photosensitizer accumulated in the target tissue, resulting in treatment. Also disclosed are novel conjugate compds., such as PLGA-Mce6-DOTA-Gd complexes, having multi-functionality in that the

complex may include an MRI contrasting agent linked to a photosensitizing agent.

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 8

ST polyglutamate photosensitizer MRI contrast agent delivery tumor; photodynamic therapy MRI imaging breast cancer

IT Antitumor agents

Human

Neoplasm

Photodynamic therapy

Photosensitizers, pharmaceutical

(delivery systems for MRI-guided photodynamic therapy of cancer)

11 668-74-6DP, reaction products with polyglutamic acids and DOTA, gadolinium complexes 7440-54-2DP, Gadolinium, reaction products with polyglutamic acids, DOTA, and Mce6 25014-27-1DP, deprotected, pyrrolidone esters, DOTA/porphine gadolinium complexes 25038-53-3DP, deprotected, pyrrolidone esters, DOTA/porphine derivs., gadolinium complexes 889140-15-2DP, reaction products with polyglutamic acids, gadolinium complexes

RL: DGN (Diagnostic use); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(delivery systems for MRI-guided photodynamic therapy of cancer)

889140-15-2DP, reaction products with polyglutamic acids, gadolinium complexes

RL: DGN (Diagnostic use); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(delivery systems for MRI-guided photodynamic therapy of cancer)

RN 889140-15-2 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(6-aminohexyl)amino]-2-oxoethyl]- (CA INDEX NAME)

L80 ANSWER 16 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:343390 ZCAPLUS Full-text

DOCUMENT NUMBER: 144:398254

TITLE: Targeted imaging and/or therapy using the Staudinger

ligation

INVENTOR(S): Robillard, Marc S.; Gruell, Holger

PATENT ASSIGNEE(S): Koninklijke Philips Electronics N.V., Neth.

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

```
KIND DATE
                                         APPLICATION NO. DATE
                       ____
                              _____
                                          _____
    WO 2006038185
                        A2
                               20060413
                                         WO 2005-IB53258
                                                                 20051004
    WO 2006038185
                        A3
                              20060713
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
            NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
            SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
            YU, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
    EP 1799273
                        A2 20070627 EP 2005-788346
        R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
    CN 101068577
                       A 20071107 CN 2005-80034471
                                                                 20051004
    IN 2007CN01400
                               20070831
                                          IN 2007-CN1400
                        Α
                                                                 20070405
PRIORITY APPLN. INFO.:
                                          EP 2004-104913
                                                              A 20041007
                                          WO 2005-IB53258
                                                            W 20051004
                       MARPAT 144:398254
OTHER SOURCE(S):
     The use of a selective chemical and bioorthogonal reaction providing a
AΒ
     covalent ligation such as the Staudinger ligation (reaction between an azide
     and a phosphine), in targeted mol. imaging and therapy is presented, more
     specifically with interesting applications for pre-targeted imaging or
     therapy. Current pre-targeted imaging is hampered by the fact that it relies
     solely on natural/biol. targeting constructs (i.e. biotin/streptavidin). Size
     considerations and limitations associated with their endogenous nature
     severely limit the number of applications. The present invention describes
     how the use of an abiotic, bio-orthogonal reaction which forms a stable adduct
     under physiol. conditions, by way of a small or undetectable bond, can
     overcome these limitations. As an example of pre-targeted imaging, injection
     of a targeting probe comprising a somatostatin receptor-binding peptide linked
     to an azide is followed by a secondary radiolabeled probe linked to a
     Staudinger phosphine group. Following in vivo Staudinger ligation, the
     radiolabel enables detection of the presence of somatostatin receptor-pos.
     tissue such as neuroendocrine tumor.
CC
    63-5 (Pharmaceuticals)
    Section cross-reference(s): 1, 8, 21
ΙT
    57260-73-8P 137076-54-1P 149299-82-1P 153086-78-3P
                                                              175854-39-4P
    192635-89-5P 251564-45-1P 299173-24-3P 361154-31-6P
                                                              726698-17-5P
    868394-26-7P 882518-79-8P 882518-80-1P
                                               882518-81-2P
                                                              882518-82-3P
    882518-83-4P 882518-85-6P 882518-86-7P 882518-88-9P
    882518-89-0P
                 882518-90-3P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (targeted imaging and/or therapy using Staudinger ligation)
ΙT
    882518-83-4P 882518-85-6P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (targeted imaging and/or therapy using Staudinger ligation)
    882518-83-4 ZCAPLUS
RN
CN
    1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[[3-
    (diphenylphosphino)-4-(methoxycarbonyl)benzoyl]amino]ethyl]amino]-2-
```

oxoethyl]-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A

RN 882518-85-6 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[[3-(diphenylphosphino)-4-(methoxycarbonyl)benzoyl]amino]ethyl]amino]-2-oxoethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 882518-84-5 CMF C39 H49 N6 O10 P

PAGE 1-A

PAGE 2-A

CM 2

CRN 76-05-1 CMF C2 H F3 O2

L80 ANSWER 17 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER.

ACCESSION NUMBER: 2006:79358 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 144:156642

TITLE: Compositions and methods for treating cancer INVENTOR(S): Mayers, George, L.; Lee, David; Chin, Hsiao Ling

PATENT ASSIGNEE(S): Oncologic, Inc., USA SOURCE: PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
PATENT NO.
                   KIND DATE APPLICATION NO. DATE
                      ----
                                         ______
                              _____
                       A2 20060126
                                         WO 2005-US26248
    WO 2006010165
                                                              20050725
    WO 2006010165
                       A3 20070208
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
            NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
            SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
            ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
                             20060126 US 2004-897530
    US 2006018908
                     A1
                                                                20040723
                              20060126 AU 2005-265425
    AU 2005265425
                       A1
                                                                20050725
                             20060126 CA 2005-2572825
20070725 EP 2005-802465
    CA 2572825
EP 1809332
                       A1
                                                               20050725
                       A2
                                                                20050725
        R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
            BA, HR, MK, YU
                                          US 2004-897530 A 20040723
WO 2005-US26248 W 20050725
PRIORITY APPLN. INFO.:
```

The invention features compns. and methods for treating or alleviating a AΒ symptom of cancer. The compns. and methods of the invention direct supra-LDs of radiation, called Hot-Spots, to virtually all cancer cell types. Cancer is treated by administering a step 1 reagent containing a cell-targeting agent linked to a platform building material; a step 3 reagent containing a targeting moiety and an isotope trapping moiety; and a radiolabeled aqueous soluble set 4 reagent. The cell targeting agent augments cellular uptake of the step 1 reagent. The platform building material detaches from the cell targeting agent upon uptake of the step 1 reagent into the cell and forms an aqueous insol. nano-platform to which the targeting moiety of the step 3 reagent binds. Optionally, a step 2 cell-killing reagent is administered to the subject prior to, after or concurrently with the step 3 reagent to relocate the nano-platform into the tumor extracellular matrix. An example of an agent is an anti-EGF-antibody- dextran-3-indoxyl phosphate-phosphoenol pyruvate conjugate.

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 8, 15

IT Drug delivery systems

(carriers; radiolabeled tumor-targeted antibody carrier
conjugates)

IT Antibodies and Immunoglobulins

Galactosides

Glycosides

Porphyrins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (conjugates; radiolabeled tumor-targeted antibody carrier conjugates)

IT Glycosides

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

```
(glucuronides, conjugates; radiolabeled tumor-targeted
        antibody carrier conjugates)
ΙT
    Drug delivery systems
        (immunoconjugates; radiolabeled tumor-targeted antibody
       carrier conjugates)
ΙT
    Drug delivery systems
        (immunotoxins; radiolabeled tumox-targeted antibody carrier
        conjugates)
    Antitumor agents
ΙT
    Human
    Radiopharmaceuticals
        (radiolabeled tumor-targeted antibody carrier conjugates)
    Albumins, biological studies
ΙT
    Antibodies and Immunoglobulins
    Lactams
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (radiolabeled tumor-targeted antibody carrier conjugates)
    62229-50-9, Eqf
ΤТ
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (antibodies to, conjugates; radiolabeled tumor-targeted
        antibody carrier conjugates)
    9024-60-6, Ornithine decarboxylase 9024-77-5, Arginine decarboxylase
ΙT
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (inhibitors; radiolabeled tumor-targeted antibody carrier
       conjugates)
    9073-60-3
ΙT
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (radiolabeled tumor-targeted antibody carrier conjugates)
    104-87-0 109-97-7, Pyrrol 119-24-4 122-85-0
                                                       616-34-2
                                                                   619 - 44 - 3
ΙT
    619-66-9
              874-60-2 2646-51-7 3068-32-4 4203-49-0
                                                            16522-41-1
                30924-93-7 37293-51-9, Aminodextran
    21442-01-3
                                                       38862-25-8
    58626-38-3 60239-18-1, Dota 63379-64-6 76470-66-1, Loracarbef
    76931 - 93 - 6 \qquad 88738 - 51 - 6 \qquad 89992 - 70 - 1 \qquad 102262 - 50 - 0 \qquad 109448 - 27 - 3
    115416 - 38 - 1 \qquad 125878 - 06 - 0 \qquad 220935 - 13 - 7 \qquad 236404 - 46 - 9 \qquad 874201 - 16 - 8
    874201-25-9 874201-26-0 874201-36-2
                                              874201-81-7 874201-87-3
    RL: RCT (Reactant); RACT (Reactant or reagent)
        (radiolabeled tumor-targeted antibody carrier conjugates)
ΙT
    61449-63-6P 64244-53-7P 66646-88-6P 78658-49-8P 147804-55-5P
    214554-43-5P 214554-44-6P 266341-16-6P 266341-19-9P 623907-52-8P
    762241-39-4P 847944-61-0P 847944-62-1P 847944-63-2P 874201-13-5P
    874201-14-6P 874201-15-7P 874201-17-9P 874201-18-0P 874201-19-1P
    874201-20-4P 874201-21-5P 874201-22-6P 874201-23-7P 874201-24-8P
    874201-27-1P 874201-28-2P 874201-29-3P 874201-30-6P 874201-31-7P
    874201-32-8P 874201-33-9P 874201-34-0P 874201-35-1P 874201-37-3P
    874201-39-5P 874201-40-8P 874201-41-9P 874201-42-0P 874201-43-1P
    874201-44-2P 874201-45-3P 874201-46-4P 874201-47-5P 874201-48-6P
    874201-49-7P 874201-51-1P 874201-53-3P 874201-55-5P 874201-59-9P
    874201-61-3P 874201-64-6P 874201-65-7P 874201-66-8P 874201-67-9P
    874201-68-0P 874201-69-1P 874201-71-5P 874201-73-7P 874201-75-9P
    874201-77-1P 874201-81-7DP, conjugates with polymer 874201-83-9P
    874201-84-0P 874201-85-1P 874201-86-2P
                                               874201-88-4P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (radiolabeled tumor-targeted antibody carrier conjugates)
ΙT
    59-30-3DP, Folic acid, conjugates 9013-20-1DP, Streptavidin, conjugates
    9023-27-2DP, UDP-N-acetylglucosamine enolpyruvyltransferase, conjugates
    10098-91-6DP, Yttrium 90, conjugated complexes, biological studies
    21442-01-3DP, polymer conjugated derivs. 847944-66-5DP, yttrium
    90 complexes 847944-67-6P 847944-68-7P 847944-69-8P 847944-70-1P
    RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
```

study); PREP (Preparation); USES (Uses)

(radiolabeled tumor-targeted antibody carrier conjugates)

IT 138-08-9D, Phosphoenol pyruvic acid, conjugated derivs. 619-66-9D, 4-Carboxybenzaldehyde, conjugates 9001-78-9D, conjugates 9004-54-0D, Dextran, conjugated derivs. 9031-11-2D, conjugates 13822-19-0D,

3-Indoxyl phosphate, conjugated derivs. 70052-12-9D,

 α -Difluoromethylornithine, conjugated derivs. 724705-43-5D,

Carbacephem, conjugated derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (radiolabeled tumor-targeted antibody carrier conjugates)

IT 847944-66-5DP, yttrium 90 complexes

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); USES (Uses)

(radiolabeled tumor-targeted antibody carrier conjugates)

RN 847944-66-5 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[5-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

— CO2H

L80 ANSWER 18 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:79312 ZCAPLUS Full-text

DOCUMENT NUMBER: 144:171259

TITLE: Preparation of gastrin-releasing peptide compounds for

use in diagnostic imaging or therapy

INVENTOR(S): Cappelletti, Enrico; Lattuada, Luciano; Linder, Karen

E.; Marinelli, Edmund; Nanjappan, Palaniappa; Raju, Natarajan; Ramalingam, Kondareddiar; Swenson, Rolf E.;

Tweedle, Michael

PATENT ASSIGNEE(S): Bracco Imaging S.p.A., Italy

SOURCE: U.S. Pat. Appl. Publ., 194 pp., Cont.-in-part of U.S.

Ser. No. 828,925.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

	PATENT NO.					KIND DATE				APPL		ION	D.					
	2006				A1 20060126				US 2005-165721							0050		
US	2004	1369	06		A1 20040715				US 2003-341577						20030113			
US	7226	577			B2 20070605													
WO	2004	0654	07		A2 20040805				WO 2003-US41328						20031224			
WO	2004	0654	07		A3 20040923													
	W:	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	ВG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,	
										HU,								
										LU,								
										SG,								
					VN,			ĺ	·	·	·	·	·	·	·	·	·	
	RW:	BW,	GH,	GM,	KE,	LS,	MW.	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	
										BE,								
										LU,								
										GN,			•		•			ΤG
US	2004			,	A1	•	2004			US 2				,		0040		
	2006239914				A1		2006			US 2								
	2007002500				A1			0104		WO 2006-US24641						0060 0060		
	W:			AL,	AM.					BB,				BY.	BZ.	CA,	CH.	
										DZ,								
										IN,								
										LU,								
										OM,								
										TJ,								
							ZM,		/	,	,	,	,	,	,	,	,	
	RW:								DK.	EE,	ES.	FI.	FR.	GB.	GR.	HU.	IE.	
										PT,								
									•	ML,			•		•			
										SZ,								
					RU,			,		,	,	,	,	,	,	,	,	
IN	2006			,	Α		2007	0706		IN 2	006-	CN23	30		2	0060	626	
	2008				A1		2008			US 2						0070		
PRIORITY				. :						US 2					A2 2			
										WO 2					A2 2			
										US 2					A2 2			
										WO 2						0040		
										US 2					A2 2			
										US 2					A2 2			
OTHER SO	DURCE	(S):			MAR:	PAT	144:	1712		- -		-			- -			

^{*} STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. M-N-O-P-G (M is a metal chelator, preferably an Aazta metal chelator or a derivative; N-O-P is a linker containing at least one non- α -amino acid and at least one substituted bile acid; G is the GRP receptor targeting peptide) for use in diagnostic imaging, radiotherapy or phototherapy. Thus, peptide I was prepared and its complex with 177Lu was evaluated for tumor targeting capacity, biodistribution and kinetics in the human PC-3 nude mouse model.

INCL 424001690; 514183000; 534011000

CC 34-3 (Amino Acids, Peptides, and Proteins)

```
Section cross-reference(s): 8, 78
ΙT
     55749-98-9P
                   55749-99-0P
                                 87096-84-2P, Neuromedin B (swine spinal cord)
     422512-72-9P
                    422512-75-2P
                                   422512-81-0P
                                                   721936-47-6P
                                                                  721936-49-8P
     721936-51-2P
                    721936-53-4P
                                   721936-55-6P
                                                   721936-57-8P
                                                                  721936-59-0P
     721936-61-4P
                    721936-63-6P
                                   721936-67-0P
                                                   721936-69-2P
                                                                  721936-71-6P
     721936-73-8P
                    721936-75-0P
                                   721936-76-1P
                                                   721936-78-3P
                                                                  721936-80-7P
     721936-82-9P
                    721936-92-1P
                                   721936-94-3P
                                                   721936-96-5P
                                                                  721936-98-7P
     721936-99-8P
                   721937-01-5P
                                   721937-03-7P
                                                   721937-05-9P
                                                                  721937-07-1P
     721937-09-3P
                   721937-11-7P
                                   721937-13-9P
                                                  721937-15-1P
                                                                  721937-17-3P
     721937-19-5P
                   721937-21-9P
                                                  721937-25-3P
                                                                  721937-27-5P
                                   721937-23-1P
     721937-29-7P
                   721937-31-1P
                                   721937-33-3P
                                                  721937-35-5P
                                                                  721937-37-7P
     721937-40-2P
                    721937-42-4P
                                   721937-44-6P
                                                   721937-46-8P
                                                                  721937-48-0P
     721937-50-4P
                    721937-52-6P
                                   721937-54-8P
                                                   721937-56-0P
                                                                  721937-58-2P
     721937-60-6P
                    721937-62-8P
                                   721937-64-0P
                                                   721937-66-2P
                                                                  721937-68-4P
                                   721937-74-2P
                                                   721937-76-4P
     721937-70-8P
                    721937-72-0P
                                                                  721937-78-6P
     721937-80-0P 721937-82-2P
                                 721937-84-4P
                                                721937-86-6P
     721937-88-8P 721937-90-2P 721937-92-4P
                                              721937-94-6P
     721937-96-8P
                    721937-98-0P
                                   721938-00-7P
                                                   721938-02-9P
                                                                  721938-04-1P
                                                                  721938-14-3P
     721938-06-3P
                    721938-08-5P
                                   721938-10-9P
                                                   721938-12-1P
     721938-16-5P
                    721938-18-7P
                                   721938-20-1P
                                                   721938-22-3P
                                                                  721938-24-5P
     721938-26-7P
                    721938-28-9P
                                   721938-30-3P
                                                   721938-32-5P
                                                                  721938-34-7P
     721938-36-9P
                    721938-38-1P
                                   721938-39-2P
                                                   721938-41-6P
                                                                  721938-43-8P
     721938-45-0P
                    721938-47-2P
                                   721938-49-4P
                                                  721938-51-8P
                                                                  721938-54-1P
     721938-56-3P
                   721938-58-5P
                                   721938-60-9P
                                                  721938-62-1P
                                                                  721938-64-3P
                                                  721938-72-3P
                                                                  721938-74-5P
     721938-66-5P
                    721938-68-7P
                                   721938-70-1P
     721938-76-7P
                    721938-78-9P
                                   721938-80-3P
                                                   721938-83-6P
                                                                  721938-85-8P
     721938-87-0P
                    721938-89-2P
                                                   721938-99-4P
                                                                  721939-01-1P
                                   721938-97-2P
     721939-03-3P
                                   721939-06-6P
                                                   721939-07-7P
                                                                  721939-08-8P
                    721939-05-5P
     721939-10-2P
                    721939-11-3P
                                   721939-12-4P
                                                   721939-14-6P
                                                                  721939-16-8P
     721939-17-9P
                   721939-18-0P
                                   721939-19-1P
                                                   721939-21-5P
                                                                  721939-23-7P
     721939-25-9P
                    721939-27-1P
                                   721939-29-3P
                                                   721939-31-7P
                                                                  721939-33-9P
     721939-35-1P
                    721939-37-3P
                                   722493-92-7P
                                                   722493-93-8P
                                                                  722493-94-9P
     722493-95-0P
                    722493-96-1P
                                   722493-97-2P
                                                   722493-98-3P
                                                                  722493-99-4P
                    722494-01-1P
     722494-00-0P
                                   722494-02-2P
                                                   808112-30-3P
                                                                  808112-31-4P
     808112-32-5P
                    808112-33-6P
                                   808112-35-8P
                                                   808112-37-0P
                                                                  808112-39-2P
     808112-41-6P
                    808112-43-8P
                                   808112-44-9P
                                                  808112-45-0P
     808112-46-1P
                    808112-47-2P
                                   808112-48-3P
                                                   808112-49-4P
                                                                  808112-50-7P
     808112-51-8P
                    808112-52-9P
                                   808112-53-0P
                                                   808112-54-1P
                                                                  808112-55-2P
     808112-56-3P
                    808112-57-4P
                                   808112-58-5P
                                                                  808112-60-9P
                                                   808112-59-6P
     808112-61-0P
                    808112-62-1P
                                   808112-63-2P
                                                   808112-64-3P
                                                                  808112-65-4P
     808112-67-6P
                    808112-68-7P
                                   808112-69-8P
                                                   808112-70-1P
                                                                  808112-71-2P
                    808112-73-4P 808112-74-5P 808112-75-6P
     808112-72-3P
     808112-76-7P
                    808113-00-0P
                                   808113-01-1P
                                                  808113-02-2P
                                                                  808113-03-3P
     808113-04-4P
                    808113-05-5P
                                   808113-06-6P
                                                   808113-07-7P
                                                                  808113-08-8P
     808113-09-9P
                    808113-10-2P
                                   808113-11-3P
                                                   808113-12-4P
                                                                  808113-14-6P
     809233-13-4P
                    874367-58-5P
                                   874534-72-2P
                                                   874534-73-3P
                                                                  874537-63-0P
     RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic
     use); BIOL (Biological study); PREP (Preparation); USES (Uses)
        (preparation of gastrin-releasing peptide compds. for use in diagnostic
        imaging or therapy)
ΙT
     721937-82-2P 721937-90-2P 721937-92-4P
     808112-41-6P 808112-74-5P
     RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic
     use); BIOL (Biological study); PREP (Preparation); USES (Uses)
        (preparation of gastrin-releasing peptide compds. for use in diagnostic
        imaging or therapy)
RN
     721937-82-2 ZCAPLUS
     L-Methioninamide, N2-[[4-oxo-6-[4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tris(carboxymethyl)]]
CN
     tetraazacyclododec-1-yl]acetyl]-1-piperazinyl]-3(4H)-quinazolinyl]acetyl]-
     L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl-
```

(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

$$_{\rm HO_{2C}}$$

PAGE 1-C

__SMe

RN 721937-90-2 ZCAPLUS

CN L-Methioninamide, N2-[[4-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-1-piperazinyl]acetyl]-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

PAGE 2-A

PAGE 2-B

RN 721937-92-4 ZCAPLUS

CN L-Methioninamide, N2-[[4-[2-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]-1-piperazinyl]acetyl]-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl- (9CI) (CA INDEX NAME)

RN 808112-41-6 ZCAPLUS

CN L-Methioninamide, N2-[4-[[[2-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]amino]carbonyl]benzoyl]-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-B

→SMe

PAGE 2-B

RN 808112-74-5 ZCAPLUS

CN L-Methioninamide, N2-[4-[bis[2-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]amino]-1,4-dioxobutyl]-L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-B

 ${\color{red} \frown}_{\text{SMe}}$

HO₂C

PAGE 2-B

L80 ANSWER 19 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2005:1355513 ZCAPLUS Full-text

DOCUMENT NUMBER: 144:99915

TITLE: Preparation of lipophilic derivatives of chelate

monoamides for use in magnetic resonance imaging

INVENTOR(S): Riley, Dennis Patrick; McGhee, William D.

PATENT ASSIGNEE(S): Kereos, Inc., USA SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT NO.					KIND		DATE		APPLICATION NO.						DATE			
WO	WO 2005122891				A1	_	20051229		•	WO 2005-US19966					20050607			
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KP,	KR,	KΖ,	
		LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	
		NG,	NΙ,	NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	
		SL,	SM,	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	
		ZA,	ZM,	ZW														
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MΖ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	
		ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IS,	ΙΤ,	LT,	LU,	MC,	NL,	PL,	PT,	
		RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	

```
MR, NE, SN, TD, TG
    AU 2005253962
                    A1
                               20051229
                                        AU 2005-253962
                                                                 20050607
    CA 2569461
                         Α1
                               20051229
                                         CA 2005-2569461
                                                                 20050607
    US 2006008417
                         Α1
                               20060112
                                          US 2005-146651
                                                                 20050607
    EP 1768558
                               20070404
                                          EP 2005-757440
                                                                 20050607
                         Α1
        R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
    JP 2008502726
                        Τ
                               20080131
                                          JP 2007-527646
                                                                 20050607
PRIORITY APPLN. INFO.:
                                           US 2004-578474P
                                                              P 20040609
                                           US 2004-605180P
                                                              P 20040827
                                          WO 2005-US19966
                                                              W 20050607
                       CASREACT 144:99915; MARPAT 144:99915
OTHER SOURCE(S):
GΙ
```

AB Compds. useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components. The compds. are conveniently prepared from achiral derivs. of chelating moieties. Thus, the gadolinium complex of the lipophilic DOTA derivative (I) was prepared in a multistep procedure. This complex was then associated with a nanoparticle/microparticle emulsion and a targeting mol. and used in the magnetic resonance imaging of carcinoma tumors implanted in rabbits.

IC ICM A61B005-055 ICS C07D225-00

for

CC 78-7 (Inorganic Chemicals and Reactions)

Section cross-reference(s): 8

IT 7440-54-2DP, Gadolinium, DOTA monoamide derivative complexes 871560-93-9P 871560-95-1P

RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of lipophilic derivs. of gadolinium-DOTA chelate monoamides

use in magnetic resonance imaging)


IT 115265-97-9P 115288-21-6P 201867-18-7P 871560-74-6P 871560-77-9P 871560-80-4P 871560-85-9P 871560-89-3P 871560-91-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of lipophilic derivs. of gadolinium-DOTA chelate monoamides for use in magnetic resonance imaging) 871560-93-9P 871560-95-1P ΙT RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of lipophilic derivs. of gadolinium-DOTA chelate monoamides for use in magnetic resonance imaging) RN 871560-93-9 ZCAPLUS CN Gadolinate(1-), $[10-[23-hydroxy-23-oxido-2-(oxo-\kappa0)-11,18,29-trioxo-$ 26-[(1-oxohexadecyl)oxy]-22,24,28-trioxa-3,10,12,19-tetraaza-23phosphatetratetracont-1-yl]-1,4,7,10-tetraazacyclododecane-1,4,7triacetato (4-) - κ N1, κ N4, κ N7, κ N10, κ O1, κ O $4,\kappa$ 07]-, hydrogen (9CI) (CA INDEX NAME)



PAGE 1-A




● H+


PAGE 2-B

871560-95-1 ZCAPLUS RN

Gadolinate(1-), $[10-[23-hydroxy-23-oxido-2-(oxo-\kappa0)-11,18,29-trioxo-ko]$ CN 26-[(1-oxohexadecyl)oxy]-22,24,28-trioxa-3,10,12,19-tetraaza-23phosphatetratetracont-1-yl]-1,4,7,10-tetraazacyclododecane-1,4,7triacetato (4-) - κ N1, κ N4, κ N7, κ N10, κ O1, κ O $4, \kappa 07$] - (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-B

871560-77-9P 871560-80-4P 871560-85-9P 871560-89-3P 871560-91-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of lipophilic derivs. of gadolinium-DOTA chelate monoamides

use in magnetic resonance imaging)

871560-77-9 ZCAPLUS RN

for

1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[[(1,1-CN dimethylethoxy)carbonyl]amino]hexyl]amino]-2-oxoethyl]-, tris(phenylmethyl) ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{Ph-CH}_2-\text{O-CH}_2 \\ \text{Ph-CH}_2-\text{O-CH}_2 \\ \text{N} \\ \text{N} \\ \text{CH}_2-\text{C-O-CH}_2-\text{Ph} \\ \text{CH}_2-\text{C-O-CH}_2-\text{Ph} \\ \end{array}$$

RN 871560-80-4 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(6-aminohexyl)amino]-2-oxoethyl]-, tris(phenylmethyl) ester (9CI) (CA INDEX NAME)

$$CH_{2}-O-CH_{2}-O-CH_{2}-Ph$$
 $CH_{2}-C-O-CH_{2}-Ph$
 $CH_{2}-C-O-CH_{2}-Ph$
 $CH_{2}-C-O-CH_{2}-Ph$

RN 871560-85-9 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[[(4-nitrophenoxy)carbonyl]amino]hexyl]amino]-2-oxoethyl]-, tris(phenylmethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

RN 871560-89-3 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(26R)-23-hydroxy-23-oxido-2,11,18,29-tetraoxo-26-[(1-oxohexadecyl)oxy]-22,24,28-trioxa-3,10,12,19-tetraaza-23-phosphatetratetracont-1-yl]-, tris(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

RN 871560-91-7 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(26R)-23-hydroxy-23-oxido-2,11,18,29-tetraoxo-26-[(1-oxohexadecyl)oxy]-22,24,28-trioxa-3,10,12,19-tetraaza-23-phosphatetratetracont-1-yl]- (CA INDEX NAME)

PAGE 1-B

H020

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 20 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2005:1133071 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 144:57302

TITLE: Preparation and Characterization of a

DOTA-Lysine-Biotin Conjugate as an Effector Molecule

for Pretargeted Radionuclide Therapy

AUTHOR(S): Hainsworth, James; Harrison, Peter; Mather, Stephen J.

CORPORATE SOURCE: Nuclear Medicine Group, Cancer Research UK, St.

Bartholomew's Hospital, London, UK

SOURCE: Bioconjugate Chemistry (2005), 16(6), 1468-1474

CODEN: BCCHES; ISSN: 1043-1802

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

AB Pretargeted radionuclide therapy depends on the establishment of a high concentration of secondary binding sites at a tumor to which low-mol. weight radiolabeled effector mols. can be directed. This study describes the simple synthesis of an effector mol. and its subsequent characterization to determine the extent to which it complied with the ideal requirements of such a compound (ϵ) -DOTA- (α) -biotinamidolysine (DLB) was synthesized in high yield and purity using conventional SPPS methodol. High radiochem, purities were obtained when labeled with several potentially useful radionuclides. The radiolabeled analog bound to streptavidin efficiently with a stoichiometry similar to that of native biotin and showed high stability in serum and upon challenge with acid conditions. Biodistribution studies in normal animals showed a rapid rate of clearance from the blood and low retention of radioactivity by normal

tissues. This design of effector mol. therefore shows promise for further pretargeted radionuclide therapy studies.

CC 63-8 (Pharmaceuticals)

IT Antitumor agents

Radiotherapy

Stability

(preparation and characterization of a DOTA-lysine-biotin conjugate as an effector mol. for pretargeted radionuclide therapy)

IT 188428-79-7P 871576-45-3P 871576-46-4P 871576-47-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and characterization of a DOTA-lysine-biotin conjugate as an effector mol. for pretargeted radionuclide therapy)

IT 871576-46-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and characterization of a DOTA-lysine-biotin conjugate as an effector mol. for pretargeted radionuclide therapy)

RN 871576-46-4 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]hexyl]amino]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

CO2H

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 21 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2005:673150 ZCAPLUS Full-text

DOCUMENT NUMBER: 143:168816

TITLE: Methods for imaging the lymphatic system using

dendrimer-based contrast agents

INVENTOR(S): Brechbiel, Martin W.; Kobayashi, Hisataka; Choyke,

Peter L.; Morris, John C.; Waldmann, Thomas A.

PATENT ASSIGNEE(S): The Government of the United States of America as

Represented by the Secretary of the Department of

Health and Human Services, USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

112			
CH,			
GD,			
LC,			
NI,			
SY,			
ZW			
AM,			
DK,			
PT,			
ML,			
20040113			
112			
IE,			
·			
SK, TR A 20040113			
112			
1			

- AB Methods are disclosed for lymphatic-system imaging using dendrimer conjugates as contrast agents. The disclosed methods are applicable to the imaging of all lymphatic structures, but in particular embodiments are particularly suited for imaging specific parts of the lymphatic system such as lymph nodes or lymphatic vessels. The methods permit the assessment of abnormal conditions within the lymphatic system, such as lymphoma/lymphoproliferative disease, inflammation, and cancer metastasis. The methods also may be used to identify and locate lymph nodes into which lymph fluid flows from a tumor.
- IC ICM A61K049-00
- CC 8-9 (Radiation Biochemistry)
- 5109-69-3D, Doxa, ΙT 67-43-6D, Dtpa, dendrimer-conjugated complexes dendrimer-conjugated complexes 14701-22-5D, Nickel ion (2+), dendrimer-conjugated complexes, biological studies 14913-52-1D, Neodymium ion (3+), dendrimer-conjugated complexes, biological studies 15158-11-9D, Copper ion (2+), dendrimer-conjugated complexes, biological studies 15438-31-0D, Ferrous ion, dendrimer-conjugated complexes, biological studies 16065-83-1D, Chromium ion (3+), dendrimer-conjugated complexes, biological studies 16397-91-4D, Manganese ion (2+), 18472-30-5D, Erbium dendrimer-conjugated complexes, biological studies ion (3+), dendrimer-conjugated complexes, biological studies 18923-27-8D, Ytterbium ion (3+), dendrimer-conjugated complexes, biological studies 20074-52-6D, Ferric ion, dendrimer-conjugated 22541-14-6D, Praseodymium ion (3+), complexes, biological studies dendrimer-conjugated complexes, biological studies 22541-17-9D, Samarium ion (3+), dendrimer-conjugated complexes, biological studies 22541-19-1D, Gadolinium ion (3+), dendrimer-conjugated complexes, biological studies 22541-20-4D, dendrimer-conjugated complexes, biological studies 22541-21-5D, Dysprosium ion (3+), dendrimer-conjugated complexes, biological studies 22541-22-6D, Holmium ion (3+), dendrimer-conjugated complexes, biological studies

22541-53-3D, Cobalt ion (2+), dendrimer-conjugated complexes, biological studies 56491-86-2D, Nota, dendrimer-conjugated complexes 60239-18-1D, Dota, dendrimer-conjugated complexes 60239-22-7D, Teta, dendrimer-conjugated complexes 108414-96-6D, 1b4m, dendrimer-conjugated complexes 113786-33-7D, Bopta, dendrimer-conjugated complexes 114873-3 7-9D, DO 3A, dendrimer-conjugated complexes 120041-08-9D, Hp-do3a, dendrimer-conjugated complexes 149979-17-9D, DO 3MA, dendrimer-conjugated complexes 150467-20-20, dendrimer-conjugated complexes 160363-61-1D, dendrimer-conjugated complexes RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses) (imaging the lymphatic system using dendrimer-based contrast agents) 149979-17-9D, DO 3MA, dendrimer-conjugated complexes ΙT 150467-20-2D, dendrimer-conjugated complexes RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses) (imaging the lymphatic system using dendrimer-based contrast agents) RN 149979-17-9 ZCAPLUS CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid, $10-[2-[(2-aminoethyl)amino]-2-oxoethyl]-\alpha,\alpha',\alpha''$ trimethyl- (9CI) (CA INDEX NAME)

RN 150467-20-2 ZCAPLUS 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-CN aminoethyl)amino]-2-oxoethyl]- (CA INDEX NAME)

NH-CH2-CH2-NH2 Сн2—со2н

L80 ANSWER 22 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2005:238416 ZCAPLUS Full-text

DOCUMENT NUMBER: 142:303552

TITLE: Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic

precipitates in the cancer

INVENTOR(S): Mayers, George L.; Rose, Samuel; Rose, Lottie

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 78 pp., Cont.-in-part of U.S.

Ser. No. 226,288. CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005058652	A1	20050317	US 2004-898585	20040723
US 2003068382	A1	20030410	US 2002-226288	20020822
PRIORITY APPLN. INFO.:			US 2002-226288 A	2 20020822
			US 1999-314422 A	3 19990518

AB The invention features compns. and methods for treating or alleviating a symptom of cancer. The compns. and methods of the invention direct supra-LDs of radiation, called Hot-Spots, to virtually all cancer cell types. The compns. comprise a cell-targeting agent (such as an antibody) which augments cellular uptake of the reagent linked to a platform building material by a carrier. The platform building material detaches from the targeting agent upon uptake of the reagent into the cell. Examples of such compns. are: anti-EGFR antibody-dextran-indoxylphosphate- phosphoenolpyruvate conjugate, transferrin-albumin-bis-3-indoxyl glycoside-Loracarbef conjugate, folate-Ig-porphyrin- difluoromethylornithine conjugate. Above compns. are administered with enzyme conjugates such as β -lactamase-anti-nitroiodophenol antibody, and with radiopharmaceuticals such as 131I-5-iodo-3-indoxyl galactoside.

IC ICM G01N033-53

ICS G01N033-567; A61K049-00; A61K039-395

INCL 424178100; 530391100; 435007200

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 8, 15

ST antitumor immunoconjugate immunotoxin radiopharmaceutical enzyme

IT Antitumor agents

Neoplasm

Nicotinic agonists Peptidomimetics Radiopharmaceuticals Radiotherapy

(targeted immunoconjugate radiopharmaceutical compns.)

59-30-3DP, Folic acid, porphyrin-Iq-difluoromethylornithine conjugate 619-66-9DP, 4-Carboxybenzaldehyde, reaction product with ornithine decarboxylase 9001-78-9DP, lactamase conjugate 9013-20-1DP, Streptavidin, UDP-N-Acetylqlucosamine enolpyruvyltransferase conjugate 9023-27-2DP, UDP-N-Acetylglucosamine enolpyruvyltransferase, streptavidin 9024-60-6DP, Ornithine decarboxylase, reaction product with carboxybenzaldehyde 9031-11-2DP, lactamase conjugate 9073-60-3DP, galactosidase conjugate 10043-66-0DP, Iodine 131, compds., biological 10098-91-6DP, Yttrium 90, conjugated complexes, biological studies 37293-51-9DP, Aminodextran, antibody conjugate 40704-75-4DP, N-(2-Hydroxypropyl) methacrylamide polymer, crosslinked conjugates 62229-50-9DP, 61449-63-6DP, folate-Ig-difluoromethylornithine conjugate Egf, Loracarbef-polymer conjugates 70052-12-9DP, porphyrin-Ig-folate 76470-66-1DP, Loracarbef, conjugates 847944-58-5DP, antibody-dextran conjugate 847944-59-6DP, antibody-dextran conjugate 847944-60-9DP, antibody-dextran conjugate 847944-61-0DP, albumin-transferrin conjugate 847944-62-1P 847944-64-3DP, EGF-Loracarbef conjugates 847944-66-5DP, yttrium 90 complexes 847944-67-6P 847944-68-7P 847944-69-8P 847944-70-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(targeted immunoconjugate radiopharmaceutical compns.)

IT 847944-66-5DP, yttrium 90 complexes


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(targeted immunoconjugate radiopharmaceutical compns.)

RN 847944-66-5 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B

$$\sim_{\text{CO}_2\text{H}}$$

L80 ANSWER 23 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2005:14435 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 142:107822

TITLE: Pharmaceutical composition comprising somatostatin

analog

INVENTOR(S): Lambert, Oliver; Moser, Katrin

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT NO.					KIN	D	DATE			APPL	ICAT	D.	DATE						
						_													
	WO 2005000893					A2 20050106				WO 2004-EP6794						20040623			
	WO	WO 2005000893				АЗ		20050407											
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,	

```
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
                                20050106
                                            AU 2004-251866
     AU 2004251866
                          Α1
                                                                   20040623
    CA 2529449
                                20050106
                                            CA 2004-2529449
                          Α1
                                                                   20040623
     EP 1648934
                          Α2
                                20060426
                                            EP 2004-740213
                                                                   20040623
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
     CN 1812997
                                20060802
                                            CN 2004-80017884
                                                                    20040623
                          Α
     BR 2004011820
                                20060808
                                            BR 2004-11820
                                                                   20040623
                          Α
     JP 2007536195
                         Τ
                                20071213
                                            JP 2006-516037
                                                                   20040623
     US 2007093412
                         A1
                                20070426
                                            US 2005-560751
                                                                   20051214
                                            MX 2005-PA13821
     MX 2005PA13821
                                20060228
                                                                   20051216
                         Α
                                            NO 2006-375
     NO 2006000375
                          Α
                                20060124
                                                                   20060124
PRIORITY APPLN. INFO.:
                                            GB 2003-14695
                                                                A 20030624
                                            GB 2003-25388
                                                                A 20031030
                                            WO 2004-EP6794
                                                                W 20040623
OTHER SOURCE(S):
                         MARPAT 142:107822
AΒ
     The present invention describes parenteral pharmaceutical compns. comprising a
     somatostatin analog and novel somatostatin analogs.
IC
     ICM C07K014-655
     ICS A61K038-31; C07K007-06
     2-5 (Mammalian Hormones)
CC
     Section cross-reference(s): 34, 63
ΙT
    Antitumor agents
     Cushing's syndrome
     Drug delivery systems
     Neoplasm
        (pharmaceutical composition comprising somatostatin analog)
     820232-46-0P 820232-47-1P 820232-48-2P
ΤТ
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (pharmaceutical composition comprising somatostatin analog)
ΙT
     820232-48-2P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (pharmaceutical composition comprising somatostatin analog)
RN
     820232-48-2 ZCAPLUS
CN
     Cyclo[(2R)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-
     L-phenylalanyl-(4R)-4-[[[2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tris(carboxymethyl)]]]
     tetraazacyclododec-1-yl]acetyl]amino]ethyl]amino]carbonyl]oxy]-L-prolyl]
     (9CI) (CA INDEX NAME)
```

PAGE 1-A

$$H2N-(CH2)$$
 $H2N-(CH2)$
 $H2N$

PAGE 1-B

L80 ANSWER 24 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2002:657986 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 137:190759

TITLE: Amino derivatives of biotin and their conjugates with

macrocyclic chelating agents

INVENTOR(S): Paganelli, Giovanni; Chinol, Marco; Ginanneschi, Mauro

PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,

Italy

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT NO.	KIND DATE	E APPL	ICATION NO.	DATE			
WO 2002066075	A2 2002	20829 WO 2	002-IT91	20020215			
WO 2002066075	A3 2003	30130					
W: AE, AG, AL,	AM, AT, AU,	, AZ, BA, BB,	BG, BR, BY, BZ,	CA, CH, CN,			
CO, CR, CU,	CZ, DE, DK,	, DM, DZ, EC,	EE, ES, FI, GB,	GD, GE, GH,			

```
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                         A1 20020829 CA 2002-2436242
                                                                  20020215
     CA 2436242
     AU 2002237517
                                20020904
                                           AU 2002-237517
                                                                   20020215
                         Α1
     EP 1359943
                         Α2
                                20031112
                                          EP 2002-703851
                                                                   20020215
     EP 1359943
                                20051012
                         В1
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     HU 2003003151
                         A2
                                20031229
                                           HU 2003-3151
                                                                   20020215
     BR 2002007327
                         Α
                                20040210
                                           BR 2002-7327
                                                                   20020215
     JP 2004524305
                         Τ
                                20040812
                                           JP 2002-565633
                                                                   20020215
     CN 1531445
                         Α
                               20040922
                                           CN 2002-805086
                                                                   20020215
     AT 306283
                         Т
                               20051015
                                           AT 2002-703851
                                                                   20020215
     ES 2248522
                         Т3
                                           ES 2002-703851
                                                                   20020215
                               20060316
     MX 2003PA07317
                                20040630
                                           MX 2003-PA7317
                                                                   20030815
                         Α
     US 2004067199
                         A1
                                20040408
                                           US 2003-468075
                                                                   20030930
PRIORITY APPLN. INFO.:
                                            IT 2001-RM79
                                                               A 20010216
                                            WO 2002-IT91
                                                               W 20020215
OTHER SOURCE(S):
                        MARPAT 137:190759
     Amino biotin derivs. are prepared and used for the preparation of conjugates
AΒ
     with radionuclides for use in human and animal therapy and diagnostics,
     particularly for the diagnosis and therapy of pathol. conditions such as
     tumors. A reduced biotinylhexamethylenediamine conjugate with DOTA was
     prepared
     ICM A61K051-04
IC
     63-6 (Pharmaceuticals)
CC
     Section cross-reference(s): 8, 26
IT
     Antitumor agents
     Chelating agents
     Diagnostic agents
     Radiopharmaceuticals
     Radiotherapy
        (amino derivs. of biotin and their conjugates with macrocyclic
        chelating agents)
ΙT
     451478-45-8P
     RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
        (amino derivs. of biotin and their conjugates with macrocyclic
        chelating agents)
     451478-45-8P
ΙT
     RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
        (amino derivs. of biotin and their conjugates with macrocyclic
        chelating agents)
RN
     451478-45-8 ZCAPLUS
CN
     1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[[5-
     [(3aS, 4S, 6aR)-hexahydro-2-oxo-1H-thieno[3, 4-d]imidazol-4-
     yl]pentyl]amino]hexyl]amino]-2-oxoethyl]- (CA INDEX NAME)
```

PAGE 1-A

PAGE 1-B

__СО2Н

L80 ANSWER 25 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2002:107368 ZCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 136:167700

TITLE: Preparation of somatostatin analogues for

pharmaceutical use

INVENTOR(S): Albert, Rainer; Bauer, Wilfried; Bodmer, David; Bruns,

Christian; Felner, Ivo; Hellstern, Heribert; Lewis, Ian; Meisenbach, Mark; Weckbecker, Gisbert; Wietfeld,

Bernhard

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen

Verwaltungsgesellschaft m.b.H.; et al.

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT NO.	KIND DAT	E APPL	JICATION NO.	DATE			
WO 2002010192	A2 200)20207 WO 2	:001-EP8824	20010730			
WO 2002010192	A3 200	20919					
WO 2002010192	A9 200	21017					
W: AE, AG, AL,	AM, AT, AU	J, AZ, BA, BB,	BG, BR, BY, BZ,	CA, CH, CN,			
CO, CR, CU,	CZ, DE, DK	K, DM, DZ, EC,	EE, ES, FI, GB,	GD, GE, GH,			
GM, HR, HU,	ID, IL, IN	I, IS, JP, KE,	KG, KP, KR, KZ,	LC, LK, LR,			

(9CI) (CA INDEX NAME)

```
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
             UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     TW 282341
                          В
                                20070611 TW 2001-90118314
                                                                   20010726
     CA 2416293
                         Α1
                                20020207
                                           CA 2001-2416293
                                                                   20010730
     EP 1307486
                                20030507
                                            EP 2001-969555
                         Α2
                                                                   20010730
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                20030701
                                           BR 2001-12859
     BR 2001012859
                         Α
                                                                   20010730
     HU 2003000684
                         Α2
                                20030929
                                           HU 2003-684
                                                                   20010730
     HU 2003000684
                         А3
                                20040830
     JP 2004505095
                               20040219 JP 2002-515921
                                                                   20010730
                         Τ
     JP 3829118
                        В2
                               20061004
    NZ 523836
                        Α
                               20040827
                                          NZ 2001-523836
                                                                   20010730
     RU 2287533
                        C2
                              20061120 RU 2003-105817
                                                                   20010730
     ZA 2003000406
                              20040402
                                           ZA 2003-406
                                                                   20030115
                         Α
     IN 2003CN00143
                         Α
                               20050408
                                            IN 2003-CN143
                                                                   20030123
                        A 20030408
A 20030319
A 20030609
     NO 2003000484
                                          NO 2003-484
                                                                   20030130
                                           MX 2003-PA991
    MX 2003PA00991
                                                                   20030131
                        A1 20050120
     US 2005014686
                                            US 2003-343288
                                                                   20030826
PRIORITY APPLN. INFO.:
                                            GB 2000-18891
                                                                A 20000801
                                            WO 2001-EP8824
                                                               W 20010730
     The invention provides cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phq-DTrp-Lys-Tyr(4-
AΒ
     Benzyl)-Phe] (I) , optionally in protected form, or a pharmaceutically
     acceptable salt or complex thereof, which has interesting pharmaceutical
     properties. The ability of I to bind to human somatostatin receptors, inhibit
     GH release, and decrease IGF-1 plasma levels is exemplified. Pharmaceutical
     compns. containing the analogs are also claimed.
IC
     ICM C07K007-00
CC
     34-3 (Amino Acids, Peptides, and Proteins)
     Section cross-reference(s): 2
ΙT
     Antitumor agents
        (pancreas; preparation of somatostatin analogs for pharmaceutical use)
     Angiogenesis inhibitors
ΙT
     Antidiarrheals
      Antitumor agents
     Diagnosis
     Drug delivery systems
     Human
        (preparation of somatostatin analogs for pharmaceutical use)
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (preparation of somatostatin analogs for pharmaceutical use in combination
        with other drugs)
ΤТ
     396091-82-0P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (preparation of somatostatin analogs for pharmaceutical use in combination
        with other drugs)
     396091-82-0 ZCAPLUS
RN
     Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-
     L-phenylalanyl-(4R)-4-[[[2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tris(carboxymethyl)]]
     tetraazacyclododec-1-yl]acetyl]amino]ethyl]amino]carbonyl]oxy]-L-prolyl]
```

PAGE 1-A

PAGE 1-B

L80 ANSWER 26 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2001:935597 ZCAPLUS $\underline{Full-text}$

DOCUMENT NUMBER: 136:54028

TITLE: Preparation of vitronectin receptor antagonist

pharmaceuticals

INVENTOR(S): Rajopadhye, Milind; Barrett, John A.; Carpenter, Alan

P., Jr.; Cheesman, Edward H.; Harris, Thomas D.

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 449 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
WO 2001098294	A2	20011227	WO 2001-US19794	20010621		
WO 2001098294	A3	20030109				

```
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
            ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                               20011227
                                         CA 2001-2413957
    CA 2413957
                         Α1
                                                                  20010621
    AU 2001070025
                               20020102
                                           AU 2001-70025
                         Α5
                                                                  20010621
                               20030402
                                           EP 2001-948554
    EP 1296678
                         Α2
                                                                  20010621
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                           US 2000-213212P
                                                                  20000621
PRIORITY APPLN. INFO.:
                                                               P
                                           WO 2001-US19794
                                                               W
                                                                 20010621
OTHER SOURCE(S):
                        MARPAT 136:54028
AΒ
     Compds. (Q)d-Ln-(Ch)d' (Q is a residue having an indazole-type moiety , d=1-
     10, d' = 1-100, Ln is a linking group, Ch is a metal-bonding unit) were
     prepared for use in the diagnosis and treatment of cancer. The present
     invention provides novel compds. useful for the treatment of rheumatoid
     sulfophenyl)vinyl]amino](3-pyridyl)]carbonylamino]propoxy]ethoxy]ethoxy]pr
     opyl]amino]sulfonyl]phenyl]phenyl]sulfonyl]amino]-3-[[1-[3-(indazole-2-
     ylamino)propyl](1H-indazol-5-yl)]carbonylamino]propanoic acid was prepared
     (claimed compound). Syntheses of radiopharmaceticals, e.g.,
     99mTc(VnA)(tricine)(phosphine), where VnA represents the vitronectin receptor
     antagonist, are also described.
    ICM C07D403-00
IC
CC
    34-3 (Amino Acids, Peptides, and Proteins)
    Section cross-reference(s): 8, 28, 63, 78
ΙT
    Angiogenesis
      Antitumor agents
    Atherosclerosis
    Radiopharmaceuticals
    Rheumatoid arthritis
        (preparation of vitronectin receptor antagonist pharmaceuticals)
ΙT
    5704-04-1DP, Tricine, amino acid derivative, TPPTS technetium-99m complexes
                   277328-74-2P
                                  277328-75-3P
                                                 277328-76-4P
                                                                277328-78-6P
    277328-73-1P
                                                                277328-83-3P
    277328-79-7P
                   277328-80-0P
                                  277328-81-1P
                                                 277328-82-2P
    277328-84-4P
                   277328-85-5P
                                  277328-86-6P
                                                 277328-87-7P
                                                                277328-88-8P
    277328-89-9P
                   277328-90-2P
                                  277328-91-3P
                                                 277328-92-4P
                                                                277328-93-5P
    277328-94-6P
                   277328-95-7P
                                  277328-96-8P
                                                 277328-97-9P
                                                                277328-98-0P
    277328-99-1P
                   277329-00-7P
                                  277329-01-8P
                                                 277329-02-9P
    277329-03-0P
                   277329-04-1P
                                  277329-05-2P 277329-06-3P
    277329-07-4P
                   277329-08-5P
                                  277329-09-6DP, technetium-99m, tricine
    tris(m-sulfophenyl)-phosphine complexes 277329-10-9DP, technetium-99m,
    tricine tris(m-sulfophenyl)-phosphine complexes
                                                     277329-11-0DP,
    technetium-99m, tricine tris(m-sulfophenyl)-phosphine complexes
    277329-12-1DP, technetium-99m, tricine tris(m-sulfophenyl)-phosphine
                277329-13-2DP, technetium-99m, tricine tris(m-sulfophenyl)-
    phosphine complexes 277329-14-3DP, technetium-99m, tricine
    tris(m-sulfophenyl)-phosphine complexes
                                            277332-11-3DP, technetium-99m,
    tricine tris(m-sulfophenyl)-phosphine complexes
                                                      278174-58-6P
    278174-59-7P
                   278174-60-0P
                                 278174-61-1P
                                                 278174-62-2P
                                                                278174-63-3P
    278174-64-4P
                   278174-65-5P
                                  278174-66-6P
                                                 278174-67-7P
                                                                278174-68-8P
    278174-69-9P
                   278174-70-2P
                                  278174-71-3P
                                                 278177-22-3DP,
                        278177-32-5DP, yttrium-90-labeled
    indium-111-labeled
    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
```

RN

(Uses)

(preparation of vitronectin receptor antagonist pharmaceuticals) 277329-03-0P 277329-06-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of vitronectin receptor antagonist pharmaceuticals) 277329-03-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[[4-[4-[(1S)-1-carboxy-2-[[[1-[2-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]ethyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxyl-1-oxobutyl]amino]ethyl]amino]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

RN 277329-06-3 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[[[4'-[[(1S)-1-carboxy-2-[[[3-[(1H-imidazol-2-ylamino)methyl]-1-methyl-1H-indazol-6-yl]carbonyl]amino]ethyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]sulfonyl]amino]ethyl]amino]-2-oxoethyl]- (CA INDEX NAME)

HO2C NO THE CO2H CO2H CO2H

PAGE 1-B

L80 ANSWER 27 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2000:420991 ZCAPLUS Full-text

DOCUMENT NUMBER: 133:59098

TITLE: Preparation of vitronectin receptor antagonist

pharmaceuticals

INVENTOR(S): Rajopadhye, Milind; Harris, Thomas David; Cheesman,

Edward H.

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 362 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PA:	TENT 1	NO.			KINI)	DATE			APPL	ICAT	ION I	NO.		D.	ATE	
						_									_		
WO 2000035488					A2	A2 20000622			,	WO 1	999-		19991217				
WO	WO 2000035488				A3		20001109										
	W:	AL,	ΑU,	BR,	CA,	CN,	CZ,	EE,	HU,	IL,	IN,	JP,	KR,	LT,	LV,	MK,	MX,
		NO,	NZ,	PL,	RO,	SG,	SI,	SK,	TR,	UA,	VN,	ZA,	AM,	AZ,	BY,	KG,	KΖ,
		MD,	RU,	ΤJ,	TM												
	RW:	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FΙ,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,
		PT,	SE														
US	6322	770			В1		2001	1127		US 1	999-	2812	07		1	9990.	330
US	2002	0156	80		A1		2002	0207		US 1	999-	2812	09		1	9990.	330

```
US 6524553
                         В2
                               20030225
    US 6548663
                         В1
                               20030415
                                           US 1999-281050
                                                                  19990330
    CA 2346935
                         Α1
                               20000622
                                           CA 1999-2346935
                                                                  19991217
    AU 2000023715
                         Α
                               20000703
                                           AU 2000-23715
                                                                  19991217
                                           EP 1999-967442
    EP 1140203
                         A2
                               20011010
                                                                  19991217
    EP 1140203
                         В1
                               20070523
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, CY
    TR 200101775
                         Τ2
                               20020722
                                           TR 2001-1775
                                                                  19991217
    AT 362772
                               20070615
                                           AT 1999-967442
                                                                  19991217
    ES 2288040
                         Т3
                               20071216
                                           ES 1999-967442
                                                                  19991217
    US 2003124120
                                           US 2002-269252
                         Α1
                               20030703
                                                                  20021011
    US 2003149262
                         Α1
                               20030807
                                           US 2002-306054
                                                                  20021126
PRIORITY APPLN. INFO.:
                                           US 1998-112829P
                                                               P 19981218
                                           US 1998-80150P
                                                               P 19980331
                                           US 1998-112715P
                                                              P 19981218
                                           US 1998-112732P
                                                               P 19981218
                                           US 1998-112831P
                                                               P 19981218
                                           US 1999-281050
                                                               A3 19990330
                                           US 1999-281209
                                                               A3 19990330
                                           WO 1999-US30312
                                                               W 19991217
                        MARPAT 133:59098
OTHER SOURCE(S):
     Compds. (Q) d-Ln-Ch (Q is a residue having an indazole-type moiety, d = 1-10,
     Ln is a linking group, Ch is a metal-bonding unit) were prepared for use in
     the diagnosis and treatment of cancer, methods of imaging tumons in a patient,
     and methods of treating cancer in a patient. The present invention also
     provides novel compds. useful for monitoring therapeutic angiogenesis
     treatment and destruction of new angiogenic vasculature. Thus, 2-[[[4-[4-[[[3-
     [2-[2-[3-[6-[1-aza-2-(2-sulfophenyl)vinyl]amino](3-
     pyridyl)|carbonylamino|propoxy|ethoxy|propyl|amino|sulfonyl|phenyl|
     phenyl]sulfonyl]amino]-3-[[1-[3-(indazole-2-ylamino)propyl](1H-indazol-5-
     v1)]carbonylamino]propanoic acid was prepared (claimed compound). Syntheses
     of radiopharmaceticals, e.g., 99mTc(VnA)(tricine)(phosphine), where VnA
     represents the vitronectin receptor antagonist, are also described.
TC
    ICM A61K047-48
    ICS A61K049-00; A61K051-04
CC
    34-3 (Amino Acids, Peptides, and Proteins)
    Section cross-reference(s): 8, 28, 63, 78
    Angiogenesis
IT
      Antitumor agents
    Atherosclerosis
    Radiopharmaceuticals
    Rheumatoid arthritis
        (preparation of vitronectin receptor antagonist pharmaceuticals)
    5704-04-1DP, Tricine, amino acid derivative, TPPTS technetium-99m complexes
ΙT
    14133-76-7DP, Technetium-99, amino acid derivative, tricine and TPPTS
    complexes, preparation 63995-70-0DP, TPPTS, amino acid derivative, tricine
                                                             277328-75-3P
    technetium-99m complexes
                              277328-73-1P 277328-74-2P
    277328-76-4P 277328-78-6P
                                 277328-79-7P
                                                 277328-80-0P
                                                                277328-81-1P
```

277328-82-2P 277328-83-3P 277328-84-4P 277328-85-5P 277328-86-6P 277328-87-7P 277328-88-8P 277328-89-9P 277328-90-2P 277328-91-3P 277328-92-4P 277328-93-5P 277328-94-6P 277328-95-7P 277328-96-8P 277328-97-9P 277328-98-0P 277328-99-1P 277329-00-7P 277329-01-8P 277329-02-9P 277329-03-0P 277329-04-1P 277329-05-2P 277329-06-3P 277329-07-4P 277329-08-5P 277329-09-6DP, technetium-99m, tricine tris(m-sulfophenyl)-phosphine complexes 277329-10-9DP, technetium-99m, tricine tris(m-sulfophenyl)-phosphine complexes 277329-11-0DP, technetium-99m, tricine tris(m-sulfophenyl)phosphine complexes 277329-12-1DP, technetium-99m, tricine tris(m-sulfophenyl)-phosphine complexes 277329-13-2DP, technetium-99m,

ΙT

RN

tricine tris(m-sulfophenyl)-phosphine complexes 277329-14-3DP, technetium-99m, tricine tris(m-sulfophenyl)-phosphine complexes 277332-11-3DP, technetium-99m, tricine tris(m-sulfophenyl)-phosphine complexes 278174-58-6P 278174-59-7P 278174-60-0P 278174-61-1P 278174-62-2P 278174-63-3P 278174-64-4P 278174-65-5P 278174-66-6P 278174-67-7P 278174-68-8P 278174-69-9P 278174-70-2P 278174-71-3P 278177-22-3DP, indium-111-labeled 278177-32-5DP, yttrium-90-labeled RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of vitronectin receptor antagonist pharmaceuticals) 277329-03-0P 277329-06-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of vitronectin receptor antagonist pharmaceuticals) 277329-03-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[[4-[4-[(1S)-1-carboxy-2-[[[1-[2-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]ethyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]amino]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

RN 277329-06-3 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[[4'-[[(1S)-1-carboxy-2-[[[3-[(1H-imidazol-2-ylamino)methyl]-1-methyl-1H-indazol-6-yl]carbonyl]amino]ethyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]sulfonyl]amino]ethyl]amino]-2-oxoethyl]- (CA INDEX NAME)

PAGE 1-B

L80 ANSWER 28 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN 2000:64531 ZCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER: 133:39944

TITLE: Synthesis, characterization, and imaging performance

of a new class of macrocyclic hepatobiliary MR

contrast agents

Marinelli, Edmund R.; Neubeck, Richard; Song, Bo; AUTHOR(S):

Wagler, Thomas; Ranganathan, Ramachandran S.;

Sukumaran, Kozikhott; Wedeking, Paul W.; Nunn, Adrian;

Runge, Val M.; Tweedle, Michael F.

CORPORATE SOURCE: Bracco Research USA, Princeton, NJ, 08540, USA SOURCE:

Investigative Radiology (2000), 35(1), 8-24

CODEN: INVRAV; ISSN: 0020-9996

Lippincott Williams & Wilkins PUBLISHER:

DOCUMENT TYPE: Journal LANGUAGE: English

RATIONALE AND OBJECTIVES. To investigate the effect of substituent AB lipophilicity, substituent position, and overall charge on the hepatobiliary clearance and tolerance of a series of aromatic ring-containing macrocyclic Gd chelates to select a candidate compound for evaluation as a hepatobiliary imaging agent. METHODS. Hepatobiliary clearance was studied in rats. Tissue distribution and tolerance were studied in mice. Imaging was performed in cats, rabbits, and Rhesus monkeys using T1-weighted pulse sequences or T1weighted breath-hold pulse sequences. RESULTS. All the compds. were excreted bimodally. Gd-2,5-BPA-DO3A was found to have the optimal combination of hepatobiliary clearance (47% in rats, 29% in mice) and tolerance (min. LD 5.0

CC

ΙT

ΙT

ΙT

ΙT

RN

CN

```
mmol/kg). Initial imaging studies in cats demonstrated the feasibility of Gd-
2,5-BPA-DO3A for hepatic imaging. In rabbits with implanted VX-2
adenocarcinoma as a model for metastatic liver disease, Gd-2,5-BPA-DO3A
provided sustained hepatic signal intensity (SI) enhancement and lesion
conspicuity over a 120-min imaging time course. In Rhesus monkeys with normal
liver function, Gd-2,5-BPA-DO3A afforded sustained hepatic SI enhancement and
a time-dependent increase in gallbladder SI over the entire 90-min imaging
time course. CONCLUSIONS. Gd-2,5-BPA-DO3A provides dramatic and sustained SI
enhancement of hepatic tissue in cats, rabbits, and Rhesus monkeys that was
superior in all respects to the extracellular space MRI agent, Gd-HP-DO3A,
that was employed as a control.
8-9 (Radiation Biochemistry)
Section cross-reference(s): 78
Imaging
   (tumor; synthesis, characterization, and imaging performance
   of macrocyclic Gd chelates as hepatobiliary MR contrast agents)
7440-54-2DP, Gadolinium, complexes, biological studies 173526-55-1P
173526-57-3P
              173526-61-9P
                             173526-65-3P 173526-70-0P
                                                           173526-77-7P
173526-81-3P
              275801-54-2P
                             275801-55-3P
                                            275801-56-4P
275801-57-5P
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
(Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); PROC (Process); USES (Uses)
   (synthesis, characterization, and imaging performance of macrocyclic Gd
   chelates as hepatobiliary MR contrast agents)
                                           173526-80-2P
84827-47-4P
            167867-06-3P
                                                          173526-83-5P
                            173526-69-7P
173526-84-6P
              173526-85-7P
                             173526-86-8P
                                            173526-88-0P
                                                           173526-89-1P
173526-90-4P
              173526-91-5P
                             173526-93-7P
                                            173526-94-8P
                                                           173527-03-2P
173527-04-3P 173527-05-4P 173527-12-3P 173527-13-4P
173527-14-5P 173527-20-3P 173527-21-4P 173527-22-5P
                                                           275371-48-7P
275371-49-8P 275371-50-1P
                             275371-51-2P 275371-52-3P
                                                           275371-53-4P
                                                           275371-60-3P
275371-54-5P 275371-55-6P
                             275371-56-7P
                                            275371-59-0P
275371-61-4P
              275371-62-5P
                             275371-63-6P
                                            275371-64-7P
                                                           275371-65-8P
275371-67-0P
              275371-68-1P
                             275371-70-5P
                                            275371-72-7P
275371-73-8P 275371-74-9P
                             275371-75-0P
                                            275371-77-2P
                                                           275371-78-3P
                             275371-85-2P 275371-87-4P
275371-80-7P 275371-81-8P
                                                           275371-90-9P
275371-91-0P 275371-92-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
   (synthesis, characterization, and imaging performance of macrocyclic Gd
   chelates as hepatobiliary MR contrast agents)
275801-57-5P
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
(Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); PROC (Process); USES (Uses)
   (synthesis, characterization, and imaging performance of macrocyclic Gd
   chelates as hepatobiliary MR contrast agents)
275801-57-5 ZCAPLUS
Gadolinate(1-), [10-[2-[(2-[(carboxymethyl)(phenylmethyl)amino]ethyl](4-
cyclohexylphenyl) amino] -2-(\infty -\kappa 0) ethyl] -1, 4, 7, 10-
```

tetraazacyclododecane-1,4,7-triacetato(4-)- κ N1, κ N4, κ N7,. kappa.N10, κ O1, κ O4, κ O7]-, sodium (9CI) (CA INDEX NAME)

Na+

IT 173527-05-4P 275371-67-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis, characterization, and imaging performance of macrocyclic Gd chelates as hepatobiliary MR contrast agents)

RN 173527-05-4 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(4-cyclohexylphenyl)[2-[[2-(1,1-dimethylethoxy)-2-oxoethyl](phenylmethyl)amino]ethyl]amino]-2-oxoethyl]-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A

RN 275371-67-0 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(4-cyclohexylphenyl)[2-[[2-(1,1-dimethylethoxy)-2-oxoethyl] (phenylmethyl)amino]ethyl]amino]-2-oxoethyl]- (CA INDEX NAME)

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L80 ANSWER 29 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 1999:401701 ZCAPLUS Full-text

DOCUMENT NUMBER: 131:55892

TITLE: DOTA-biotin derivative metal complexes for therapeutic

and diagnostic use using a pre-targeting protocol

INVENTOR(S): Griffiths, Gary L.; Hansen, Hans; Govindan, Serengulam

V.

PATENT ASSIGNEE(S): Immunomedics, Inc., USA SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 19

PATENT INFORMATION:

PATENT	NO.			KIN	D	DATE			APPL	ICAT	ION I	NO.		D.	ATE	
WO 9930 WO 9930				A2 A3		 1999 2000		,	WO 1	998-	US26	579		1	9981	215
W:	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	ВG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,
	DK,	EE,	ES,	FI,	GB,	GE,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,
	KΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,	MX,	NO,	NΖ,
	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	TM,	TR,	TT,	UA,	UG,
	US,	UZ,	VN,	YU,	ZW											
RW:	GH,	GM,	ΚE,	LS,	MW,	SD,	SZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,	ES,
	FI,	FR,	GB,	GR,	IE,	ΙΤ,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,
	CM,	GΑ,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	ΤG						
US 6120	768			A		2000	0919		US 1	997-	9908	43		1	9971	215

```
AU 1999-18258
                                                              19981215
    AU 9918258
                      A
                             19990705
                                                          A1 19971215
PRIORITY APPLN. INFO.:
                                        US 1997-990843
                                        US 1993-62662
                                                          B1 19930517
                                         US 1995-409960
                                                          A2 19950323
                                        US 1995-486166
                                                           B2 19950607
                                        US 1996-688781
                                                           A2 19960731
                                        WO 1998-US26579
                                                           W 19981215
```

OTHER SOURCE(S): MARPAT 131:55892

- AB A radionuclide-chelator conjugate composition for detecting and/or treating lesions in a patient in a pre-targeting protocol comprises pre-targeting the target cell, tissue, or pathogen with a substrate, using a targeting protein that specifically binds a marker substance on the target cell, tissue, or pathogen and to which the substrate is directly or indirectly bound; parenterally injecting the detection or therapeutic composition of the invention which comprises a chelate conjugate of biotin, a chelator, and a chelatable detection or therapeutic agent, and allowing the composition to accrete at the targeted cell, tissue, or pathogen; wherein the chelate conjugate is purified by chromatog. after chelate formation, or further comprises a blood transit-modifying linker or addend that is covalently bound within the chelate conjugate, or both; and using the detection or therapeutic agent to detect or treat the targeted cell, tissue, or pathogen.
- IC ICM A61K051-00
- CC 8-9 (Radiation Biochemistry)

Section cross-reference(s): 28, 63, 78

IT Anti-infective agents

Antimicrobial agents

Antitumor agents

Cardiovascular agents

Diagnosis

Drug targeting

Infection

Neoplasm

Paramagnetic materials

Parasiticides

(DOTA-biotin derivative metal complexes for the rapeutic and diagnostic use using a pre-targeting protocol) $\,$

IT Antitumor agents

(carcinoma; DOTA-biotin derivative metal complexes for therapeutic and diagnostic use using a pre-targeting protocol)

IT Antitumor agents

(glioma; DOTA-biotin derivative metal complexes for therapeutic and diagnostic use using a pre-targeting protocol)

IT Antitumor agents

(leukemia; DOTA-biotin derivative metal complexes for therapeutic and diagnostic use using a pre-targeting protocol)

IT Antitumor agents

(lymphoma; DOTA-biotin derivative metal complexes for therapeutic and diagnostic use using a pre-targeting protocol)

IT Antitumor agents

(melanoma; DOTA-biotin derivative metal complexes for therapeutic and diagnostic use using a pre-targeting protocol)

IT Antitumor agents

(myeloma; DOTA-biotin derivative metal complexes for therapeutic and diagnostic use using a pre-targeting protocol)

IT Antitumor agents

(neuroblastoma; ${\tt DOTA-biotin}$ derivative metal complexes for therapeutic and diagnostic use using a pre-targeting protocol)

IT Antitumor agents

(sarcoma; DOTA-biotin derivative metal complexes for therapeutic and diagnostic use using a pre-targeting protocol)

153-94-6D, D-Tryptophan, linker between biotin and DOTA 319-78-8D, D-Isoleucine, linker between biotin and DOTA 328-38-1D, D-Leucine, linker between biotin and DOTA 556-02-5D, D-Tyrosine, linker between biotin and DOTA 640-68-6D, D-Valine, linker between biotin and DOTA 673-06-3D, D-Phenylalanine, linker between biotin and DOTA D-Lysine, linker between biotin and DOTA 10043-49-9D, Gold-198, complexes with biotin-linked-DOTA conjugates, biological studies 10098-91-6D, Yttrium-90, complexes with biotin-linked-DOTA conjugates, biological studies 13967-65-2D, Holmium-166, complexes with biotin-linked-DOTA conjugates, biological studies 13968-53-1D, Ruthenium-103, complexes with biotin-linked-DOTA conjugates, biological studies 13981-51-6D, Mercury-197, complexes with biotin-linked-DOTA conjugates, biological studies 14119-09-6D, Gallium-67, complexes with biotin-linked-DOTA conjugates, biological studies 14119-24-5D, Osmium-191, complexes with biotin-linked-DOTA conjugates, biological 14133-76-7D, Technetium-99, complexes with biotin-linked-DOTA conjugates, biological studies 14191-64-1D, Praseodymium-142, complexes with biotin-linked-DOTA conjugates, biological studies 14265-75-9D, Lutetium-177, complexes with biotin-linked-DOTA conjugates, biological studies 14265-85-1D, Actinium-225, complexes with biotin-linked-DOTA conjugates, biological studies 14331-95-4D, Ruthenium-105, complexes with biotin-linked-DOTA conjugates, biological studies 14378-26-8D, Rhenium-188, complexes with biotin-linked-DOTA conjugates, biological 14391-11-8D, Gold-199, complexes with biotin-linked-DOTA studies conjugates, biological studies 14391-19-6D, Terbium-161, complexes with biotin-linked-DOTA conjugates, biological studies 14391-96-9D, Scandium-47, complexes with biotin-linked-DOTA conjugates, biological studies 14687-25-3D, Lead-203, complexes with biotin-linked-DOTA conjugates, biological studies 14885-78-0D, Indium-113, complexes with biotin-linked-DOTA conjugates, biological studies 14913-49-6D, Bismuth-212, complexes with biotin-linked-DOTA conjugates, biological studies 14913-89-4D, complexes with biotin-linked-DOTA conjugates, biological studies 14914-68-2D, Antimony-119, complexes with biotin-linked-DOTA conjugates, biological studies 14967-68-1D, Palladium-103, complexes with biotin-linked-DOTA conjugates, biological 14981-64-7D, Palladium-109, complexes with biotin-linked-DOTA studies conjugates, biological studies 14981-79-4D, Praseodymium-143, complexes with biotin-linked-DOTA conjugates, biological studies 14998-63-1D, Rhenium-186, complexes with biotin-linked-DOTA conjugates, biological 15092-94-1D, Lead-212, complexes with biotin-linked-DOTA conjugates, biological studies 15735-74-7D, Platinum-197, complexes with biotin-linked-DOTA conjugates, biological studies 15750-15-9D, Indium-111, complexes with biotin-linked-DOTA conjugates, biological studies 15756-62-4D, Ruthenium-95, complexes with biotin-linked-DOTA conjugates, biological studies 15757-14-9D, Gallium-68, complexes with biotin-linked-DOTA conjugates, biological studies 15757-86-5D, Copper-67, complexes with biotin-linked-DOTA conjugates, biological studies 15758-35-7D, Ruthenium-97, complexes with biotin-linked-DOTA conjugates, biological studies 15760-04-0D, Silver-111, complexes with biotin-linked-DOTA conjugates, biological studies 15765-78-3D, Rhenium-189, complexes with biotin-linked-DOTA conjugates, biological studies 15766-00-4D, Samarium-153, complexes with biotin-linked-DOTA conjugates, biological studies 60239-18-1D, DOTA, biotin-linker conjugates, metal complexes 60239-18-1D, DOTA, biotin-D-amino acid linked 177959-15-8D, linker between biotin and DOTA 227948-63-2D, linker between biotin and DOTA 227948-64-3D, linker between biotin and DOTA 227948-65-4 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

IT 227948-65-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(DOTA-biotin derivative metal complexes for therapeutic and diagnostic use using a pre-targeting protocol)

RN 227948-65-4 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]methylamino]methyl]methylamino]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

-CO2H

L80 ANSWER 30 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 1997:579696 ZCAPLUS Full-text

DOCUMENT NUMBER: 127:228839

TITLE: Pharmaceutical agents containing perfluoroalkyl-

containing metal complexes and the use thereof in

tumor therapy and intervention al radiology

INVENTOR(S): Platzek, Johannes; Niedballa, Ulrich; Raduchel, Bernd;

Schlecker, Wolfgang; Weinmann, Hanns-Joachim; Frenzel,

Thomas

PATENT ASSIGNEE(S): Schering A.-G., Germany SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
10/573938
     WO 9730969
                         Α1
                               19970828
                                          WO 1997-EP684
                                                                  19970214
         W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS,
            JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW,
            MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG,
            UZ, VN
         RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     DE 19608278
                         A1
                               19970828 DE 1996-19608278
                                                                  19960223
                         A1
     CA 2247253
                               19970828
                                           CA 1997-2247253
                                                                  19970214
     AU 9717692
                               19970910
                                           AU 1997-17692
                                                                  19970214
                         Α
     EP 882010
                               19981209
                                          EP 1997-903278
                         Α1
                                                                  19970214
     EP 882010
                               20010502
                        В1
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
                               20000418
                                           JP 1997-529766
     JP 2000504736
                         Τ
                                                                  19970214
                               20010515
                                           AT 1997-903278
    AT 200894
                         Τ
                                                                  19970214
    ES 2158493
                         Т3
                               20010901 ES 1997-903278
                                                                  19970214
     PT 882010
                        Т
                               20011030
                                          PT 1997-903278
                                                                  19970214
     US 6180113
                        В1
                               20010130
                                          US 1997-801983
                                                                  19970219
                       A 19971030
B 20020301
A 19981022
B1 20070611
     ZA 9701537
                               19971030
                                          ZA 1997-1537
                                                                  19970221
     TW 477699
                                           TW 1997-86102174
                                                                  19970222
     NO 9803875
                               19981022
                                          NO 1998-3875
                                                                  19980821
     NO 323547
     GR 3036306
                        Т3
                               20011031
                                           GR 2001-401156
                                                                  20010731
PRIORITY APPLN. INFO.:
                                           DE 1996-19608278
                                                             A 19960223
                                           US 1996-12506P
                                                             P 19960229
                                                             W 19970214
                                           WO 1997-EP684
OTHER SOURCE(S):
                        MARPAT 127:228839
     The invention relates to pharmaceutical agents containing perfluoro alkylated
     metal complexes RF-L-A and the use thereof in tumor therapy and interventional
     radiol., in which formula RF is a perfluorinated, straight-chain or branched C
     chain with the formula -CnF2nX (X = terminal F, Cl, Br, I or H atom and n = 4-
     30), L is a binding group, and A is a metal complex or the salts thereof of
     organic and/or inorg. bases or amino acids or amino acid amides. Thus
     Gd/Dy/Y/Mn complexes of tetraazacyclododecane having amide pendants with
     perfluoroalkyl groups or polyaminopolycarboxylic acids with pendants
     containing perfluoroalkyl groups were prepared
IC
     ICM C07C229-06
     ICS C07C229-76; C07C237-12; C07C311-00; C07D257-02; A61K033-00;
         C07F001-00; C07F003-00; C07F005-00; C07F007-00
CC
     78-7 (Inorganic Chemicals and Reactions)
     Section cross-reference(s): 8, 23, 28, 63
     lanthanide polyaminopolycarboxylate tetraazacyclododecane perfluoroalkyl
ST
     pendant prepn; tetraazacyclododecane perfluoroalkyl pendant lanthanide
```

- pendant prepn; tetraazacyclododecane perfluoroalkyl pendant lanthanide manganese prepn; gadolinium polyaminopolycarboxylate tetraazacyclododecane perfluoroalkyl pendant prepn; dysprosium polyaminopolycarboxylate tetraazacyclododecane perfluoroalkyl pendant prepn; yttrium polyaminopolycarboxylate tetraazacyclododecane perfluoroalkyl pendant prepn; polyaminopolycarboxylate tetraazacyclododecane perfluoroalkyl pendant prepn; polyaminopolycarboxylate perfluoroalkyl pendant lanthanide prepn; tumor therapy perfluoroalkyl pendant aza complex; interventional radiol perfluoroalkyl pendant aza complex
- IT Antitumor agents

(rare earth and manganese perfluoroalkyl-containing tetraazacyclododecane and polyaminopolycarboxylate complexes)

IT 195047-10-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(for preparation of rare earth/manganese complexes for use as ${\tt pharmaceutical}$

agents in tumor therapy and interventional radiol.)

IT 98-59-9, p-Toluenesulfonyl chloride 100-46-9, Benzylamine, reactions

```
106-89-8, reactions 107-15-3, 1,2-Ethanediamine, reactions 108-30-5,
    Succinic acid anhydride, reactions 108-55-4, Glutaric acid anhydride
    110-85-0, Piperazine, reactions 111-26-2, Hexylamine 111-40-0
    112-29-8, n-Decyl bromide 112-60-7, Tetraethylene glycol
                                                              123-31-9,
    1,4-Benzenediol, reactions 143-33-9, Sodium cyanide 294-90-6,
    1,4,7,10-Tetraazacyclododecane 307-35-7, Perfluorooctylsulfonyl fluoride
    598-21-0, Bromoacetyl bromide 603-35-0, Triphenylphosphine, reactions
    647-42-7, 3,3,4,4,5,5,6,6,7,7,8,8,8-Tridecafluoro-1-octanol
                                                               678-39-7,
    3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-Heptadecafluoro-1-decanol
    1138-80-3, Benzyloxycarbonylglycine 1738-76-7, Glycine benzyl ester
    p-toluenesulfonate 2016-57-1, Decylamine
                                               2043-47-2,
    3,3,4,4,5,5,6,6,6-Nonafluoro-1-hexanol 2043-53-0 2043-57-4
    2566-20-3, N-Benzyloxycarbonyltriglycine 2834-05-1, 11-Bromoundecanoic
                      4799-67-1, Glycerin-1-monobenzyl ether
           4151-50-2
                                                            5292-43-3,
                             6117-80-2 7148-74-5, 2-Bromopropionyl chloride
    tert-Butyl bromoacetate
    23911-26-4, Diethylenetriaminepentaacetic acid dianhydride 25711-25-5,
    N-Benzyloxycarbonylaziridine 30670-30-5, 1H,1H,2H,2H-Perfluorodecylamine
    34143-74-3, 1H, 1H, 2H, 2H-Perfluorodecanethiol 38436-14-5,
    1-Bromo-3,3,4,4,5,5,6,6,6-nonafluorohexane 38565-52-5
                                                           59524-02-6
    78277-26-6, Benzyl 6-bromohexanoate 78277-30-2, Benzyl
    11-bromoundecanoate 114873-37-9 121326-92-9 130147-42-1,
    Pentaerythrite monobenzylether 135984-68-8, 2H,2H-Perfluorodecanal
    137679-68-6
                146432-43-1 168078-14-6 193530-47-1
    RL: RCT (Reactant); RACT (Reactant or reagent)
       (for preparation of rare earth/manganese fluoroalkyl-containing
       polyaminopolycarboxylate/tetraazacyclododecane complexes for use as
       pharmaceutical agents in tomor therapy and interventional
       radiol.)
    473-25-6P 2991-50-6P 13406-91-2P
                                         50598-29-3P
                                                       51740-38-6P
ΙT
    55427-54-8P 89932-70-7P 94190-73-5P 94190-74-6P 113584-32-0P
    113823-56-6P 114482-33-6P
                               122193-68-4P
                                              124628-09-7P
                                                            137091-62-4P
    147011-35-6P 186095-24-9P
                                               186095-26-1P 193528-82-4P
                                 186095-25-0P
    193528-87-9P 193528-89-1P 193528-92-6P 193528-94-8P
    193528-98-2P 193529-00-9P 193529-02-1P 193529-04-3P
                                                            193529-08-7P
    193529-11-2P 193529-13-4P 193529-15-6P 193529-23-6P 193529-25-8P
    193529-29-2P 193529-33-8P 193529-35-0P 193529-44-1P 193529-58-7P
    193529-60-1P 193529-61-2P 193529-62-3P 193529-63-4P 193529-64-5P
    193529-65-6P 193529-66-7P 193529-67-8P 193529-68-9P 193529-73-6P
    193529-74-7P 193529-75-8P 193529-76-9P 193529-77-0P 193529-78-1P
    193529-79-2P 193529-80-5P 193529-81-6P 193529-82-7P 193529-84-9P
                                193529-91-8P 193529-93-0P
    193529-88-3P 193529-89-4P
                                                             193529-95-2P
    193529-96-3P 193529-98-5P 193530-00-6P 193530-01-7P 193530-02-8P
    193530-04-0P 193530-05-1P 193530-06-2P 193530-07-3P 193530-08-4P
    193530-09-5P 193530-10-8P 193530-11-9P 193530-12-0P 193530-13-1P
    193530-14-2P 193530-24-4P 193530-26-6P 193530-29-9P 193530-31-3P
    193530-44-8P 195046-89-0P 195046-92-5P 195046-94-7P 195047-00-8P
    195047-01-9P 195047-03-1P 195047-05-3P 195047-12-2P
    195047-13-3P 195047-14-4P 195047-15-5P 195047-16-6P
                                                            195047-17-7P
    195047-18-8P 195047-19-9P 195047-22-4P 195047-23-5P
                                                            195047-24-6P
    195047-25-7P 195047-37-1P 195047-39-3P 195047-44-0P
                                                             195047-45-1P
    195047-46-2P
                 195047-47-3P 195047-48-4P 195047-49-5P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
    (Reactant or reagent)
       (for preparation of rare earth/manganese fluoroalkyl-containing
       polyaminopolycarboxylate/tetraazacyclododecane complexes for use as
       pharmaceutical agents in tumor therapy and interventional
       radiol.)
    193528-81-3P
                 195047-04-2P
ΙT
    RL: BUU (Biological use, unclassified); RCT (Reactant); SPN (Synthetic
    preparation); THU (Therapeutic use); BIOL (Biological study); PREP
```

(Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and demetalation and use as pharmaceutical agent in tumor therapy and interventional radiol.)

ΤТ 193528-86-8P 193528-88-0P 193528-90-4P 193528-91-5P 193528-93-7P 193529-09-8P 193529-12-3P 193529-16-7P 193529-24-7P 193529-26-9P 193529-28-1P 193529-30-5P 193529-34-9P 193529-36-1P 193529-41-8P 193529-46-3P 193529-49-6P 193529-52-1P 193529-55-4P 193529-57-6P 193530-48-2P 195046-83-4P 195046-84-5P 195046-86-7P 195046-88-9P 195046-95-8P 195046-98-1P 195046-99-2P 195047-02-0P 195047-06-4P 195047-07-5P 195047-08-6P 195047-09-7P 195047-50-8P

RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and use as pharmaceutical agent in tumor therapy and interventional radiol.)

IT 193528-99-3P 193529-01-0P 193529-03-2P 193529-05-4P 195046-90-3P 195046-93-6P

RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and use as pharmaceutical agent in tumor therapy and interventional radiol..)

IT 193528-92-6P 195047-03-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(for preparation of rare earth/manganese fluoroalkyl-containing polyaminopolycarboxylate/tetraazacyclododecane complexes for use as pharmaceutical agents in tumor therapy and interventional radiol.)

RN 193528-92-6 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-(9-ethyl-11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,18-heptadecafluoro-10,10-dioxido-2,7-dioxo-10-thia-3,6,9-triazaoctadec-1-yl)- (CA INDEX NAME)

RN 195047-03-1 ZCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[4-[(heptadecafluorooctyl)sulfonyl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


IT 193528-93-7P 195047-02-0P

RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and use as pharmaceutical agent in tumox therapy and interventional radiol.)


RN 193528-93-7 ZCAPLUS

CN Gadolinium, [10-[9-ethyl-11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,1 8-heptadecafluoro-10,10-dioxido-2-(oxo-κ0)-7-oxo-10-thia-3,6,9-triazaoctadec-1-yl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-κN1,κN4,κN7,κN10,κΟ1,κΟ4,κΟ7]-(9CI) (CA INDEX NAME)



RN 195047-02-0 ZCAPLUS

CN Gadolinium, $[10-[2-[4-[(heptadecafluorooctyl)sulfonyl]-1-piperazinyl]-2-(oxo-<math>\kappa$ O)ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]- (9CI) (CA INDEX NAME)



L80 ANSWER 31 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:184679 ZCAPLUS Full-text

DOCUMENT NUMBER: 126:171905

TITLE: Somatostatin peptides

INVENTOR(S): Albert, Rainer; Bauer, Wilfried; Bruns, Christian;

Chandramouli, Nagarajan; Lewis, Ian; Weckbecker,

Gisbert

PATENT ASSIGNEE(S): Sandoz Ltd., Switz.; Sandoz-Patent-Gmbh;

Sandoz-Erfindungen Verwaltungsgesellschaft M.B.H.; Albert, Rainer; Bauer, Wilfried; Bruns, Christian; Chandramouli, Nagarajan; Lewis, Ian; Weckbecker,

Gisbert

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PAT	CENT 1	NO.			KIN	D	DATE			APPI	ICAT	ION	NO.		D.	ATE	
	9701 9701									 WO 1	 -996-	 EP28	40		1	9960	628
	₩:	ES,	FI, LU,	GB,	GE,	HU,	IL,	IS,	JP,	KE,	CA, KG, NO,	KP,	KR,	KΖ,	LK,	LR,	LS,
	RW:	•									DE,					GB,	GR,
CA AU AU ZA EP	19961 2222 9665 7144 9605 8352 8352	MA01 524 150 47 538 63	094	,	A A1 A B2 A A2 B1	ŕ	2005 1997 1997 2000 1997 1998 2001	0304 0116 0130 0106 1229 0415 1205	,	IN 1 CA 1 AU 1 ZA 1 EP 1	CF, -996- -996- -996- -996-	MA10 2222 6515 5538 9248	94 524 0	,	1 1 1 1	9960 9960 9960 9960	628 628 628 628
	R:	AT, SI,		CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	PT,	IE,
BR JP	1189 9609 1150 3445	166 335 6108			A A T B2		1999 1999	0729 0525 0602 0908		BR 1	.996- .996- .996-	9335			1	9960 9960 9960	628

НU 9901455	A2	19990928	HU	1999-1455		19960628
HU 9901455	A3	20001128				
RU 2160741	C2	20001220	RU	1998-101506		19960628
AT 210152	T	20011215	ΑT	1996-924811		19960628
PT 835263	T	20020429	PΤ	1996-924811		19960628
ES 2169251	Т3	20020701	ES	1996-924811		19960628
PL 184947	B1	20030131	PL	1996-323943		19960628
JP 2003104998	A	20030409	JP	2002-208012		19960628
SK 284087	В6	20040908	SK	1997-1770		19960628
IL 122243	A	20050925	IL	1996-122243		19960628
CZ 297381	В6	20061115	CZ	1997-4196		19960628
TW 491854	В	20020621	TW	1996-85109489		19960806
NO 9706064	A	19980216	ИО	1997-6064		19971223
NO 317867	B1	20041227				
US 6225284	B1	20010501	US	1997-981426		19971229
HK 1014964	A1	20050408	HK	1999-100124		19990111
PRIORITY APPLN. INFO.:			GB	1995-13224	Α	19950629
			GB	1996-429	Α	19960110
			JΡ	1996-536834	А3	19960628
			WO	1996-EP2840	W	19960628

OTHER SOURCE(S): MARPAT 126:171905

- Somatostatin analogs comprising the amino acid sequence -(D/L)Trp-Lys-X1-X2- [X1 = NHCH(CHMeOCH2R1)CO (R1 = optionally substituted phenyl) or NHCH(CH2R2)CO [R2 = ZCH2R1 (X = 0, S), CH2CO2CH2R1, C6H4OCH2R1-p, C6H3(CH2R1)OH-3,4]; X2 is an α -amino acid having an aromatic residue on the $C\alpha$ side chain or an amino acid unit selected from Dab, Dpr, Dpm, His, (Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala, and tert-Bu-Ala] or their pharmaceutically acceptable salts or complexes with a detectable element were prepared. The Lys residue Lys of the sequence corresponds to the Lys9 residue of native somatostatin-14. Thus, cyclo[HyPro-Phe-DTrp-Lys-Tyr(Bzl)-Phe] (I) was prepared by the solid phase method, starting from Fmoc-Phe-SASRIN Resin. IC50 data for binding of I to somatostatin receptor subtypes are tabulated.
- IC ICM C07K014-655 ICS A61K038-31
- CC 34-3 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 1
- ST somatostatin peptide prepn pharmacol property; receptor binding somatostatin peptide; gastric acid secretion somatostatin peptide; antitumor somatostatin peptide; angiogenesis somatostatin peptide; allograft somatostatin peptide; angioplasty somatostatin peptide
- IT Angiogenesis

Antitumor agents

- (preparation and pharmacol. properties of somatostatin peptides) IT 50-99-7, D-Glucose, reactions 141-46-8, Hydroxyacetaldehyde 15186-48-8, 2,3-O-Isopropylidene-D-glyceraldehyde 35661-40-6D, resin-bound 57260-73-8 69645-57-4 122350-59-8 134751-65-8 150629-67-7 187223-07-0
 - RL: RCT (Reactant); RACT (Reactant or reagent)
- (preparation and pharmacol. properties of somatostatin peptides) IT 187223-07-0
 - RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and pharmacol. properties of somatostatin peptides)

- RN 187223-07-0 ZCAPLUS
- CN Cyclo[L-lysyl-O-(phenylmethyl)-L-seryl-L-phenylalanyl-(4R)-4-[[[[2-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]amino]carbonyl]oxy]-L-prolyl-L-phenylalanyl-D-tryptophyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-C

CO2H

L80 ANSWER 32 OF 32 ZCAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 1996:254285 ZCAPLUS Full-text

DOCUMENT NUMBER: 124:311363

TITLE: Hydrophilic polymer and radioactive metal complexes as

INVENTOR(S):

locally administered radio-therapeutic agents for

treatment of cancer and inflammatory diseases Seki, Ikuya; Sato, Toku; Seri, Shigemi; Washino,

Hiroaki

PATENT ASSIGNEE(S): Nihon Mediphysics Co Ltd, Japan SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.


CODEN: JKXXAF

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08012597	А	19960116	JP 1993-290080	19931026
JP 3727074	В2	20051214		
PRIORITY APPLN. INFO.:			JP 1993-290080	19931026
GT				



- AB Biodegradable hydrophilic polymers (polysaccharides and their derivs. containing 1-4 hydrophilic monomer I, with average mol. weight 1 x 103-1 x 106; R1, R2 = H, amino, or hydroxy group; R3 = H, glycol, or carboxymethyl group; R4, R5 = H or hydroxy group) and complex with 1 or >1 radioactive metals are claimed as locally administered radio-therapeutic agents for treatment of cancer and inflammatory diseases. Thus, I were prepared and their pharmacokinetics and antitumer and antiinflammatory effects were studied in mice and rats and discussed with their clin. effectiveness.
- IC ICM A61K051-00
- CC 8-9 (Radiation Biochemistry)
 Section cross-reference(s): 29
- ST hydrophilic polymer radioactive metal complex antitumor;
- antiinflammatory hydrophilic polysaccharide radioactive metal complex IT 175783-37-6P 175783-38-7P 175892-38-3DP, complex with
- indium-111 175892-39-4P 175892-40-7P 176199-54-5P

RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(hydrophilic polymer and radioactive metal complexes as locally administered radio-therapeutic agents for treatment of cancer and inflammatory diseases)

- IT 67-43-6, Diethylenetriamine penta-acetic acid 1398-61-4, Chitin 9012-76-4, Chitosan 10361-82-7, Samarium chloride (SmCl3) 10361-92-9, Yttrium chloride (YCl3) 39271-65-3, Yttrium chloride (90YCl3) 39280-86-9, Glycol chitosan 58259-86-2 149979-17-9, DO 3MA
 - RL: RCT (Reactant); RACT (Reactant or reagent)

(hydrophilic polymer and radioactive metal complexes as locally administered radio-therapeutic agents for treatment of cancer and inflammatory diseases)

IT 175783-40-1P 175783-41-2P 175892-38-3P 175892-42-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(hydrophilic polymer and radioactive metal complexes as locally administered radio-therapeutic agents for treatment of cancer and inflammatory diseases)

IT 175892-38-3DP, complex with indium-111

RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(hydrophilic polymer and radioactive metal complexes as locally administered radio-therapeutic agents for treatment of cancer and inflammatory diseases)

RN 175892-38-3 ZCAPLUS

CN Chitosan, 2-hydroxyethyl ether, polymer with $10-[2-[(2-aminoethyl)amino]-2-oxoethyl]-\alpha,\alpha',\alpha''-trimethyl-1,4,7,10-$

tetraazacyclododecane-1,4,7-tricarboxylic acid (9CI) (CA INDEX NAME)

CM 1

CRN 149979-17-9 CMF C21 H40 N6 O7

CM 2

CRN 39280-86-9

CMF $\mbox{C2}$ H6 $\mbox{O2}$. \mbox{x} Unspecified

CM 3

CRN 9012-76-4

CMF Unspecified

CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 4

CRN 107-21-1 CMF C2 H6 O2

HO-CH2-CH2-OH

IT 175892-38-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(hydrophilic polymer and radioactive metal complexes as locally administered radio-therapeutic agents for treatment of cancer and inflammatory diseases)

RN 175892-38-3 ZCAPLUS

CN Chitosan, 2-hydroxyethyl ether, polymer with $10-[2-[(2-aminoethyl)amino]-2-oxoethyl]-\alpha,\alpha',\alpha''-trimethyl-1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylic acid (9CI) (CA INDEX NAME)$

CM 1

CRN 149979-17-9 CMF C21 H40 N6 O7

HO — CH2 — CH2 — OH

```
CRN 39280-86-9
CMF C2 H6 O2 . x Unspecified

CM 3

CRN 9012-76-4
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 4

CRN 107-21-1
CMF C2 H6 O2
```

L1

=> d his full

(FILE 'HOME' ENTERED AT 08:46:48 ON 21 FEB 2008)

FILE 'ZCAPLUS' ENTERED AT 08:47:31 ON 21 FEB 2008 E US2006-573938/APPS 1 SEA ABB=ON PLU=ON US2006-573938/AP

D SCA SEL RN

FILE 'REGISTRY' ENTERED AT 08:53:08 ON 21 FEB 2008

65 SEA ABB=ON PLU=ON (118726-52-6/BI OR 17137-11-0/BI OR L2294-90-6/BI OR 507475-91-4/BI OR 5292-43-3/BI OR 7429-91-6/BI OR 7439-91-0/BI OR 7439-94-3/BI OR 7440-00-8/BI OR 7440-10-0/BI OR 7440-12-2/BI OR 7440-19-9/BI OR 7440-20-2/BI OR 7440-27-9/B I OR 7440-30-4/BI OR 7440-45-1/BI OR 7440-52-0/BI OR 7440-53-1/ BI OR 7440-54-2/BI OR 7440-60-0/BI OR 7440-64-4/BI OR 7440-65-5 /BI OR 849610-60-2/BI OR 849610-61-3/BI OR 849610-62-4/BI OR 849610-63-5/BI OR 849610-64-6/BI OR 849610-65-7/BI OR 849610-66 -8/BI OR 849610-67-9/BI OR 849610-68-0/BI OR 849610-69-1/BI OR 849610-70-4/BI OR 849610-71-5/BI OR 849610-72-6/BI OR 849610-73 -7/BI OR 849610-74-8/BI OR 849610-75-9/BI OR 849610-76-0/BI OR 849610-77-1/BI OR 849610-78-2/BI OR 849610-79-3/BI OR 849610-80 -6/BI OR 849610-81-7/BI OR 849610-82-8/BI OR 849610-83-9/BI OR 849610-84-0/BI OR 849610-85-1/BI OR 849610-86-2/BI OR 849610-87 -3/BI OR 849610-88-4/BI OR 849610-89-5/BI OR 849610-90-8/BI OR 849610-91-9/BI OR 849610-92-0/BI OR 849610-93-1/BI OR 849610-94 -2/BI OR 849610-95-3/BI OR 849610-96-4/BI OR 849610-97-5/BI OR 849610-98-6/BI OR 849610-99-7/BI OR 849611-00-3/BI OR 849680-88 -2/BI OR 95196-95-5/BI) D SCA

L3 1 SEA ABB=ON PLU=ON L2 AND NRRS>3 D SCA

FILE 'ZCAPLUS' ENTERED AT 09:01:09 ON 21 FEB 2008 1 SEA ABB=ON PLU=ON L3 L4

FILE 'STNGUIDE' ENTERED AT 09:01:27 ON 21 FEB 2008

FILE 'ZCAPLUS' ENTERED AT 09:03:31 ON 21 FEB 2008 L5 11144 SEA ABB=ON PLU=ON L2 (L) PREP/RL L6 1 SEA ABB=ON PLU=ON L5 AND L1 D SCA SEL HIT RN

FILE 'REGISTRY' ENTERED AT 09:04:56 ON 21 FEB 2008

L746 SEA ABB=ON PLU=ON (118726-52-6/BI OR 17137-11-0/BI OR 507475-91-4/BI OR 849610-60-2/BI OR 849610-61-3/BI OR 849610-62 -4/BI OR 849610-63-5/BI OR 849610-64-6/BI OR 849610-65-7/BI OR 849610-66-8/BI OR 849610-67-9/BI OR 849610-68-0/BI OR 849610-69 -1/BI OR 849610-70-4/BI OR 849610-71-5/BI OR 849610-72-6/BI OR 849610-73-7/BI OR 849610-74-8/BI OR 849610-75-9/BI OR 849610-76 -0/BI OR 849610-77-1/BI OR 849610-78-2/BI OR 849610-79-3/BI OR 849610-80-6/BI OR 849610-81-7/BI OR 849610-82-8/BI OR 849610-83 -9/BI OR 849610-84-0/BI OR 849610-85-1/BI OR 849610-86-2/BI OR 849610-87-3/BI OR 849610-88-4/BI OR 849610-89-5/BI OR 849610-90 -8/BI OR 849610-91-9/BI OR 849610-92-0/BI OR 849610-93-1/BI OR 849610-94-2/BI OR 849610-95-3/BI OR 849610-96-4/BI OR 849610-97

10/573938 -5/BI OR 849610-98-6/BI OR 849610-99-7/BI OR 849611-00-3/BI OR 849680-88-2/BI OR 95196-95-5/BI) FILE 'ZCAPLUS' ENTERED AT 09:05:08 ON 21 FEB 2008 76 SEA ABB=ON PLU=ON L7 L8 ANALYZE PLU=ON L8 1- RN HIT: 46 TERMS L9 FILE 'REGISTRY' ENTERED AT 09:05:33 ON 21 FEB 2008 1 SEA ABB=ON PLU=ON 17137-11-0 L10 D SCA 45 SEA ABB=ON PLU=ON L7 NOT L10 L11 FILE 'ZCAPLUS' ENTERED AT 09:05:59 ON 21 FEB 2008 6 SEA ABB=ON PLU=ON L11 L12 D SCA FILE 'REGISTRY' ENTERED AT 09:06:41 ON 21 FEB 2008 0 SEA ABB=ON PLU=ON 507475-91-4P 1 SEA ABB=ON PLU=ON 507475-91-4 L14D SCA 0 SEA ABB=ON PLU=ON 95196-95-5P L15 1 SEA ABB=ON PLU=ON 95196-95-5 L16 D SCA 43 SEA ABB=ON PLU=ON L11 NOT (L14 OR L15 OR L16) L17 FILE 'ZCAPLUS' ENTERED AT 09:07:26 ON 21 FEB 2008 2 SEA ABB=ON PLU=ON L17 L18 D SCA FILE 'REGISTRY' ENTERED AT 09:16:14 ON 21 FEB 2008 L19 STRUCTURE UPLOADED D SCA L17 L20 STRUCTURE UPLOADED L21 STRUCTURE UPLOADED L22 50 SEA SSS SAM L21 D SCA STRUCTURE UPLOADED L23 L24 17 SEA SSS SAM L23 L25 STRUCTURE UPLOADED 50 SEA SSS SAM L25 L26 L27 STRUCTURE UPLOADED L28 4 SEA SSS SAM L27 D SCA D STAT OUE L28 D STAT QUE L26 D STAT QUE L26 L29 2020 SEA SSS FUL L25 SAVE TEMP L29 PAG938STR25L/A L30 4 SEA SUB=L29 SSS SAM L27 L31 62 SEA SUB=L29 SSS FUL L27 SAVE TEMP L31 PAG938STR27L/A FILE 'ZCAPLUS' ENTERED AT 09:46:30 ON 21 FEB 2008

L32 9 SEA ABB=ON PLU=ON L31

FILE 'REGISTRY' ENTERED AT 09:47:04 ON 21 FEB 2008
L33 47 SEA ABB=ON PLU=ON L31 NOT L17
L34 STRUCTURE UPLOADED
L35 0 SEA SUB=L29 SSS SAM L34

```
L36
            12 SEA SUB=L29 SSS FUL L34
               D SCA
    FILE 'ZCAPLUS' ENTERED AT 09:53:57 ON 21 FEB 2008
L37
             1 SEA ABB=ON PLU=ON L36
             9 SEA ABB=ON PLU=ON L37 OR L32
L38
L39
             1 SEA ABB=ON PLU=ON L38 AND L1
               SEL RN L38
    FILE 'REGISTRY' ENTERED AT 09:54:59 ON 21 FEB 2008
           273 SEA ABB=ON PLU=ON (934183-16-1/BI OR 111119-28-9/BI OR
L40
               137076-54-1/BI OR 14265-75-9/BI OR 15750-15-9/BI OR 15757-14-9/
               BI OR 317809-26-0/BI OR 33507-63-0/BI OR 705283-66-5/BI OR
               901439-51-8/BI OR 901439-89-2/BI OR 901442-07-7/BI OR 901443-47
               -8/BI OR 91037-65-9/BI OR 934183-14-9/BI OR 934183-15-0/BI OR
               934350-78-4/BI OR 934350-82-0/BI OR 934350-86-4/BI OR 934350-87
               -5/BI OR 10098-91-6/BI OR 110880-55-2/BI OR 110880-57-4/BI OR
               111844-19-0/BI OR 112188-16-6/BI OR 115608-61-2/BI OR 118726-52
                -6/BI OR 128009-23-4/BI OR 135702-31-7/BI OR 137184-55-5/BI OR
                137813-35-5/BI OR 13967-64-1/BI OR 13967-65-2/BI OR 13981-25-4/
               BI OR 13981-56-1/BI OR 14119-08-5/BI OR 14119-09-6/BI OR
               14133-76-7/BI OR 141743-95-5/BI OR 14191-64-1/BI OR 14265-85-1/
               BI OR 14687-25-3/BI OR 14809-53-1/BI OR 14834-85-6/BI OR
               14885-78-0/BI OR 148893-10-1/BI OR 14913-49-6/BI OR 14981-79-4/
               BI OR 15065-93-7/BI OR 15757-86-5/BI OR 15765-31-8/BI OR
               15776-20-2/BI OR 161552-03-0/BI OR 17137-11-0/BI OR 174267-75-5
                /BI OR 188982-12-9/BI OR 22541-18-0/BI OR 22541-19-1/BI OR
               267410-13-9/BI OR 29022-11-5/BI OR 294-90-6/BI OR 36849-05-5/BI
                OR 41444-88-6/BI OR 415706-07-9/BI OR 507475-91-4/BI OR
               5292-43-3/BI OR 585531-74-4/BI OR 6066-82-6/BI OR 623575-85-9/B
               I OR 676544-84-6/BI OR 676544-85-7/BI OR 676553-18-7/BI OR
               676553-19-8/BI OR 7087-68-5/BI OR 713520-27-5/BI OR 728914-72-5
                /BI OR 728914-74-7/BI OR 7429-91-6/BI OR 7439-91-0/BI OR
                7439-94-3/BI OR 7440-00-8/BI OR 7440-10-0/BI OR 7440-12-2/BI
               OR 7440-19-9/BI OR 7440-20-2/BI OR 7440-27-9/BI OR 7440-30-4/BI
                OR 7440-45-1/BI OR 7440-52-0/BI OR 7440-53-1/BI OR 7440-54-2/B
               I OR 7440-60-0/BI OR 7440-64-4/BI OR 7440-65-5/BI OR 766529-14-
               0/BI OR 766529-15-1/BI OR 766529-16-2/BI OR 766529-18-4/BI OR
               766529-19-5/BI OR 766529-20-8/BI OR 766529-22-0/BI OR 766529-24
                -2/BI OR 766529-25-3/BI OR 76652
            65 SEA ABB=ON PLU=ON L40 AND L2
L41
L42
            75 SEA ABB=ON PLU=ON L40 AND M/ELS
L43
            57 SEA ABB=ON PLU=ON L42 NOT L41
L44
            38 SEA ABB=ON PLU=ON L43 NOT (L31 OR L36)
               D SCA
    FILE 'ZCAPLUS' ENTERED AT 09:59:32 ON 21 FEB 2008
L45
             8 SEA ABB=ON PLU=ON (L41 OR L42) AND L38
     FILE 'REGISTRY' ENTERED AT 10:00:17 ON 21 FEB 2008
L46
           105 SEA ABB=ON PLU=ON L29 AND Y/ELS
L47
               STRUCTURE UPLOADED
             9 SEA SUB=L29 SSS SAM L47
L48
L49
           345 SEA SUB=L29 SSS FUL L47
L50
           142 SEA ABB=ON PLU=ON L49 AND M/ELS
L51
           203 SEA ABB=ON PLU=ON L49 NOT L50
    FILE 'REGISTRY' ENTERED AT 10:06:58 ON 21 FEB 2008
     FILE 'ZCAPLUS' ENTERED AT 10:07:02 ON 21 FEB 2008
```

10/573938 L52 86 SEA ABB=ON PLU=ON L51 ANALYZE PLU=ON L52 1- RN HIT: 196 TERMS L53 FILE 'REGISTRY' ENTERED AT 10:07:38 ON 21 FEB 2008 L54 9 SEA ABB=ON PLU=ON L50 AND Y/ELS D SCA FILE 'ZCAPLUS' ENTERED AT 10:08:22 ON 21 FEB 2008 10 SEA ABB=ON PLU=ON L54 L55 FILE 'REGISTRY' ENTERED AT 10:08:44 ON 21 FEB 2008 L56 112 SEA ABB=ON PLU=ON L50 AND LNTH/PG D SCA L2 FILE 'ZCAPLUS' ENTERED AT 10:11:54 ON 21 FEB 2008 36 SEA ABB=ON PLU=ON L56 L57 18 SEA ABB=ON PLU=ON L32 OR L37 OR L45 OR L55 L58 50 SEA ABB=ON PLU=ON L32 OR L37 OR L45 OR L55 OR L57 641196 SEA ABB=ON PLU=ON ?TUMOUR?/BI OR ?TUMOR?/BI 39 SEA ABB=ON PLU=ON L52 AND L60 L59 L60 L61 25232 SEA ABB=ON PLU=ON ?SCAFFOLD?/BI L62 2 SEA ABB=ON PLU=ON L49 AND L62 L63 D SCA L64 2 SEA ABB=ON PLU=ON (L51 OR L56) AND L62 40 SEA ABB=ON PLU=ON (L51 OR L56) AND L60 50 SEA ABB=ON PLU=ON L58 OR L64 OR L65 L65 L66 L67 8 SEA ABB=ON PLU=ON (L64 OR L65) AND L58 96 SEA ABB=ON PLU=ON GARLICH J?/AU L68 49 SEA ABB=ON PLU=ON SUHR R?/AU 710 SEA ABB=ON PLU=ON PATTERSON M?/AU L70 5 SEA ABB=ON PLU=ON L68 AND (L69 OR L70) L71 4 SEA ABB=ON PLU=ON L69 AND L70 5 SEA ABB=ON PLU=ON (L71 OR L72) L72 L73 L74 1 SEA ABB=ON PLU=ON L29 AND (L68 OR L69 OR L70) FILE 'REGISTRY' ENTERED AT 10:20:26 ON 21 FEB 2008 FILE 'ZCAPLUS' ENTERED AT 10:20:39 ON 21 FEB 2008 D STAT QUE L32 FILE 'REGISTRY' ENTERED AT 10:20:59 ON 21 FEB 2008 FILE 'ZCAPLUS' ENTERED AT 10:21:01 ON 21 FEB 2008 D STAT QUE L73 D STAT QUE L74 L75 5 SEA ABB=ON PLU=ON (L73 OR L74) FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 10:21:26 ON 21 FEB 2008 L76 1 SEA ABB=ON PLU=ON L73 FILE 'WPIX' ENTERED AT 10:21:40 ON 21 FEB 2008

FILE 'STNGUIDE' ENTERED AT 10:21:48 ON 21 FEB 2008

FILE 'ZCAPLUS, EMBASE, WPIX' ENTERED AT 10:22:04 ON 21 FEB 2008

5 DUP REM L75 L76 L77 (3 DUPLICATES REMOVED)

ANSWERS '1-5' FROM FILE ZCAPLUS

D IBIB ABS HITIND HITSTR L78 1-5

2 SEA ABB=ON PLU=ON (L71 OR L72)

L77

FILE 'REGISTRY' ENTERED AT 10:22:51 ON 21 FEB 2008

FILE 'ZCAPLUS' ENTERED AT 10:22:54 ON 21 FEB 2008

D STAT QUE L32

D STAT QUE L37

D STAT QUE L45

D STAT QUE L55

D STAT QUE L67

L79 17 SEA ABB=ON PLU=ON (L32 OR L37 OR L45 OR L55 OR L67) NOT (L73 OR L74)

D IBIB ABS HITIND HITSTR L79 1-17

FILE 'REGISTRY' ENTERED AT 10:26:43 ON 21 FEB 2008

FILE 'ZCAPLUS' ENTERED AT 10:26:46 ON 21 FEB 2008

D STAT QUE L64

D STAT QUE L65

L80 32 SEA ABB=ON PLU=ON (L64 OR L65) NOT (L79 OR L73 OR L74)
D IBIB ABS HITIND HITSTR L80 1-32

FILE HOME

FILE ZCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 21 Feb 2008 VOL 148 ISS 8 FILE LAST UPDATED: 20 Feb 2008 (20080220/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9 DICTIONARY FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of

experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 15, 2008 (20080215/UP).

FILE MEDLINE

FILE LAST UPDATED: 20 Feb 2008 (20080220/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE

FILE COVERS 1974 TO 20 Feb 2008 (20080220/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

FILE BIOSIS

FILE COVERS 1926 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 20 February 2008 (20080220/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

FILE WPIX

FILE LAST UPDATED: 20 FEB 2008 <20080220/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200812 <200812/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> IPC Reform backfile reclassification has been loaded to the end of
November 2007. No update date (UP) has been created for the
reclassified documents, but they can be identified by
20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC and
20071130/UPIC. <<<</pre>

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://scientific.thomson.com/support/patents/coverage/latestupdates/

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0: http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0710.p

- >>> XML document distribution format now available See HELP XMLDOC <<<
- >>> ECLA Codes and Current US National Classifications have been added see NEWS and HELP CHANGE <<<
- >>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

=>